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Zusammenfassung 
Zahlreiche pathogene „missense“-Mutation führen dazu, dass Proteine nicht 
korrekt gefaltet werden können und dadurch ihre Funktionalität verlieren. Diese 
Mutationen finden sich häufig im hydrophoben Kern oder in geordneten Regionen 
von Proteinen. Eine andere Klasse von krankheitsrelevanten Mutationen befindet 
sich jedoch in ungeordneten Proteinregionen und beeinflusst somit wahrscheinlich 
nur begrenzt die Funktionalität, zum Beispiel durch Veränderungen kurzer linearer 
Sequenzmotive, die Protein-Protein Interaktionen vermitteln. In dieser Arbeit wird 
ein peptidbasierter Interaktionsscreen präsentiert mit dem sich Veränderungen im 
Interaktom identifizieren lassen. Die vorliegende Arbeit konzentriert sich dabei auf 
neurologische Krankheiten. Synthetische Peptide von wild-typ und zugehörigen 
mutierten Proteinregionen, die auf Zellulosemembran gespottet wurden, 
ermöglichen die gleichzeitige Untersuchung von mehr als hundert Mutationen 
mittels Massenspektrometrie. SILAC-basierte Quantifizierung ermöglicht den 
Vergleich von Interaktionspartnern von wild-typ und mutierten Peptiden. Mehr als 
ein Drittel aller getesteten Mutationen hatten veränderte Interaktionen zur Folge. 
Darunter befanden sich auch drei Prolin zu Leucin Mutationen in zytosolischen 
Regionen von Transmembranproteinen, die zusammen mit dem benachbarten 
Leucin einem Dileucinmotiv ergeben und dadurch verstärkt mit Clathrin 
interagieren. Verschiedenste Proteine mit Dileucinemotiven wurden bereits mit 
Clathrin-vermittelter Endozytose in Verbindung gebracht. Diese hinzugewonnene 
Endozytose könnte Krankheitsmechanismen erklären, da die Mislokalisation der 
betroffenen Transmembranproteine zum effektiven Verlust derer Funktion führen 
würde. Diese Hypothese wurde hier von verschiedenen in vitro und in vivo 
Experimenten bezüglich der P485L Mutation im Glukose Transporter-1 (GLUT1), 
die das GLUT1-Defizit-Syndrom hervorruft, bestätigt. Weitere Evidenz wurde 
außerdem für die Funktionalität anderer mutationsbedingter Dileucinmotive 
gewonnen und die systematische Analyse von pathogenen Mutationen hat gezeigt, 
dass Dileucinmotive signifikant und spezifisch in ungeordneten zytosolischen 
Regionen von Transmembranproteinen überrepräsentiert sind. Dieser 
Peptidescreen macht das Potenzial unvoreingenommener Analysen zur Aufklärung 
von Krankheitsmechanismen deutlich, die von Veränderungen in Protein-Protein 
Interaktionen hervorgerufen werden. 
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Summary 
Many disease-associated missense mutations prevent proteins from folding 
correctly and lead to a complete loss-of-function. These mutations are often 
found in the hydrophobic core or in ordered regions of proteins. Another class 
of disease-related missense mutations, however, can be found in disordered 
regions. They are thought to impair only specific parts of a protein’s functions. 
Those mutations could, for example, modify short linear motifs that mediate 
protein-protein interactions. Here, we designed a peptide-based interaction 
screen to identify interactions that are affected by disease-associated mutations 
in disordered regions. We used synthetic peptides corresponding to the 
wild-type and mutated protein regions surrounding the disease mutation 
spotted on cellulose membrane to pull-down interaction partners. This setup 
allows for the screening of more than hundred disease-associated mutations at 
a time via mass spectrometry. In this thesis, we focused on neurological 
diseases. SILAC-based quantification allowed us to compare the interaction 
partners of wild-type peptides and their mutated variants. More than one-third 
of tested variant pairs show differential interactions. Interestingly, three 
disease-related proline to leucine mutations in cytosolic tails of transmembrane 
proteins lead to gain of a dileucine sequence. Several dileucine-containing 
peptide motifs are involved in clathrin-mediated endocytosis. In line with this, 
the newly created motifs seem to mediate interaction with the clathrin-mediated 
endocytosis machinery, also in the presented screen. The gain of endocytosis 
could explain the disease mechanisms since mislocalization of the affected 
transmembrane proteins would lead to their loss of function. This hypothesis 
has been corroborated by several in vitro and in vivo experiments for glucose 
transporter-1 (GLUT1) P485L, a mutation causing GLUT1 deficiency syndrome. 
We were able to provide functional evidence for a set of additional gained 
dileucine motifs and a systematic analysis of pathogenic mutations revealed 
dileucine motifs to be significantly and specifically overrepresented in 
structurally disordered cytosolic regions of transmembrane proteins.  
The data gained with the peptide screen highlights the power of differential 
interactome mapping as a generic approach to unravel disease mechanisms 
caused by changes in protein-protein interactions. 
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Introduction 
Mankind has, since its existence, suffered through diseases caused by bacteria, 
virus, fungi, parasites, toxic substances, malnutrition, or biologically based 
dysfunctions. For the longest time of human existence, however, the reasons for 
disease have remained elusive. Evil spirits, bad charms, and angry gods have 
been thought to be the causes and were tried to be fought in the most creative 
ways. Only after antibiotics had been discovered and the possibility to treat 
infectious diseases became available in the late nineteenth century, people 
realized that there must be another cause of disease. Also because 
unexplainably some diseases used to “run in families”. By the 20th century, 
mysterious family maladies were beginning to be understood as genetic 
disorders. The first idea of human genetic diseases, in 1908 by Archibald Garrod, 
was that they were caused by faulty “ferments” (enzymes). Actually, his idea 
that enzymes, which would soon be identified as proteins, could be the active 
cause of genetic diseases led to the idea that genetic information could be in 
some way responsible for the production of proteins (Pasternak 2005). By the 
time that James D. Watson (b. 1928) and Francis H. C. Crick (1916-2004) 
discovered the double helical structure of DNA in 1953, researchers established 
that the information units in the DNA somehow encode information for the 
synthesis of enzymes - the “one gene - one enzyme” hypothesis. How much 
these enzymes needed to be changed to cause human genetic disease, though, 
was still completely elusive. In 1957, the first example to show that the change 
of a single amino acid could cause disease was hemoglobin where mutation of 
glutamic acid in position six to a valine would cause sickle cell anemia, a red 
blood cell deforming disease (Ingram 1957). A quarter of a century passed 
before researchers became able to sequence DNA and determine the genetic 
changes underlying disease. The most significant recent advance in human 
molecular genetics was the publication of the draft version of the human genome 
sequence in 2001 (Venter 2001). 
The human genome can be changed and scrambled in many different ways. 
Whole blocks of DNA can be inserted or deleted, which, for chunks of more than 
1,000 nucleotides, is called a copy number variation. The more common form 
of variation, however, are differences in the nucleotide composition at a single 
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position. Small insertions or deletions (indels) can have a big effect on the 
following protein sequence even if only one or two base pairs are inserted 
because they lead to frameshifts. Understanding the genetic code also made 
clear that mutations of single nucleotides in the protein coding regions can have 
different outcomes. They can either leave the resulting protein sequence intact, 
i.e. synonymous or silent mutations, or change the codons in a way that 
different amino acids are integrated, i.e. nonsynonymous or missense 
mutations. This is because the genetic code is degenerate which means that 
many amino acids are encoded by multiple codons. 
The first platform in which disease-causing variants of the genome have been 
cataloged is the now called Online Mendelian Inheritance in Man (OMIM). It has 
been first established in 1966 by Victor McKusick (1921-2008), by then 
containing a mere 1,500 entries compared to the information about all known 
Mendelian diseases, and over 15,000 genes nowadays. This information has 
been partially integrated into the Humsavar database storing disease-causing 
genetic missense mutations in human UniProtKB/Swiss-Prot Entries (Famiglietti 
et al. 2014). 
In many cases, it is not known whether newly discovered variants cause disease, 
and even when associations have been established, untangling the molecular 
mechanisms is often not a straightforward task (Cooper and Shendure 2011). 
Hence, disease mechanisms are well characterized only for very few of these 
entries, which leaves over 100,000 disease-associated variants without known 
functional annotation (Sahni et al. 2015). 
Disease mutations in order and disorder 
On a protein-structure centric point of view, missense mutations can fall into 
two different protein regions: Either into ordered/globular structured regions of 
proteins or into natively unstructured segments, so-called intrinsically 
disordered regions (IDRs). In the first case, pathogenic mutations likely cause 
disease due to loss of function of the protein by disrupting three-dimensional 
folding. In fact, most disease-causing missense mutations affect evolutionarily 
conserved amino acids within structured regions of proteins and destabilize their 
structure (Subramanian and Kumar 2006; Yue, Li, and Moult 2005). However, 
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22% of human disease mutations occur in IDRs (Uyar et al. 2014; Vacic and 
Iakoucheva 2012). Since mutations in IDRs probably do not alter the protein 
structure, explaining how mutations in disordered regions can cause disease is 
less straightforward. 
The role of intrinsically disordered protein regions 
Traditionally, the function of a protein has been thought to depend on a well-
defined and folded three-dimensional structure of the polypeptide chain. This 
so-called structure-function paradigm is still prevalent in basic biology and 
biochemistry textbooks, and the abundance and functional significance of 
protein disorder in eukaryotes were largely unrecognized before the mid-1990s 
(Wright and Dyson 2015). Intrinsically disordered portions of proteins are often 
just thought to be passive, connective strings that hold the functional domains 
together. On the contrary to this common belief, it is nowadays well established 
that IDRs actively participate in different functions of proteins (Tompa 2011). 
While some proteins are predicted to be entirely disordered others might contain 
only some IDRs. Taken together they are usually referred to as intrinsically 
disordered proteins (IDPs). Almost one-third of the human proteome contains 
an IDR of at least 30 amino acids (van der Lee et al. 2014). Many IDPs have 
been collected into the DisProt database which provides the largest collection of 
proteins with disordered regions (Sickmeier et al. 2007).  
However, protein disorder is a property that is mainly predicted from the protein 
sequence. This possibility has been first discovered by the group of Keith Dunker. 
They noted from a handful of examples that disordered protein regions were 
generally enriched in polar and charged amino acids and depleted in 
hydrophobic amino acids (Xie et al. 1998). Since then, more than 50 different 
disorder prediction methods have been developed by various research groups 
(He et al. 2009; Dosztanyi, Meszaros, and Simon 2009). One popular method is 
IUPred, which provides a prediction of protein disorder based on an energy 
estimation approach (Dosztányi et al. 2005; Dosztányi 2018).  
IDPs are particularly associated with hubs in protein-interaction networks and 
play important roles in transcription, translation, signaling, and the cell cycle, 
all cellular processes that need flexible and fast adaptation (Tompa 2002; Wright 
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and Dyson 2015). Although there are exceptions to the rule: In a recent study, 
two IDPs have been found to interact with surprisingly strong affinity and 
without the formation of any transient secondary structure. The linker histone 
H1 and its nuclear chaperone prothymosin-alpha acquire this strong interaction 
via long-range electrostatic interactions that lead to rapid interconversion 
between different combinations of oppositely charged residues (Borgia et al. 
2018). 
Disorder shows a sharp increase associated with the transition from prokaryotic 
to eukaryotic cells. This suggests that the increased disorder content in 
eukaryotic proteomes might be used by nature to deal with the increased cell 
complexity due to the appearance of the various cellular compartments (Xue, 
Dunker, and Uversky 2012). 
More and more IDPs are being revealed to play important functions in 
unexpected areas of life: they save tardigrades from desiccation (Boothby et al. 
2017) or they assemble into a 3D extracellular organic matrix to form tooth 
enamel from first tetrapods to man (Wald et al. 2017). 
The importance of disordered proteins is also underlined by the tight control on 
their transcriptional and translational levels. Altered abundances of IDPs are in 
fact connected to several diseases. Disordered regions are prone to make 
promiscuous molecular interactions when their concentration is increased, and 
it has been shown that this is the likely cause of pathology when genes are 
overexpressed (Vavouri et al. 2009; Babu et al. 2011). Fidelity in signaling may 
require that most IDPs are available in appropriate amounts and not present 
longer than needed (Gsponer et al. 2008). 
IDPs are characterized by their biased amino acid composition, favoring charged 
and hydrophilic amino acids over bulky hydrophobic ones, and a general low 
sequence complexity (Wright and Dyson 2015). This makes them unable to form 
a well-organized hydrophobic core which is needed to form a structured domain 
(Uversky, Gillespie, and Fink 2000; Romero et al. 2001). It is the physical 
characteristics of IDPs that lead to their important roles in cellular signaling 
processes: A degree of flexibility, which enables them to interact promiscuously 
with different targets on different occasions and accessible sites for post-
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translational modification (Wright and Dyson 2015). In fact, they are frequently 
modified by post-translational modifications (PTMs) (Iakoucheva et al. 2004; 
Collins et al. 2008). However, the one most important feature that gives IDPs 
the possibility to interact with other proteins is the presence of small recognition 
elements. 
Intrinsically disordered regions can harbor interaction 
motifs 
Disordered regions of signaling and regulatory proteins frequently contain 
multiple conserved sequence motifs that interact with nucleic acids or globular 
domains in other proteins (Dyson and Wright 2005, 2002). These so-called short 
linear motifs (SLiMs) are usually of about 3-11 amino acids in length (Diella et 
al. 2008; Davey et al. 2012; Dinkel et al. 2014). The average binding motif is 
6–7 amino acids in length, with only 3–4 core positions conferring the majority 
of the interaction specificity (Tompa et al. 2014) and there are more than 200 
domains known to interact with SLiMs (Stein, Mosca, and Aloy 2011). 
Some of the earliest SLiMs to be defined have their function in cell cycle 
regulation. The original definition of linear motifs was provided by Tim Hunt 
(Hunt 1990): 
“These motifs are linear, in the sense that three-dimensional organization is not 
required to bring distant segments of the molecule together to make the 
recognizable unit. The conservation of these motifs varies: some are highly 
conserved while others allow substitutions that retain only a certain pattern of 
charge across the motif.” 
Eukaryotic versions of these SLiMs are stored, for example, in the eukaryotic 
linear motif database (ELM) (Dinkel et al. 2016). The ELM resource was 
established in 2003 with the mission to collect, annotate, classify and detect 
short linear motifs (Puntervoll 2003). SLiM databases still only scratch the 
surface of existing SLiMs. The majority still waits to be discovered. Even if 
constantly growing, taken together the three most important linear motif 
databases: ELM, Linear Motif Mediated Protein-protein Interaction (Sarkar, Jana, 
and Saha 2015) and Minimotif Miner (Lyon et al. 2018), they contain less than 
4,000 validated instances (as of September 2017, (Seo and Kim 2018)). This is 
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only a fraction of probably more than 100,000 SLiMs located within IDRs of the 
human proteome (Tompa et al. 2014). 
SLiMs are also functionally diverse. They can, for example, be involved in 
facilitating protein localization, e.g. nuclear localization signal, (Kelly and Owen 
2011; Fabbro and Henderson 2003), regulate protein degradation, e.g. 
polyubiquitination degrons KEN box or phosphodependent non canonical DSG 
degron (Davey et al. 2012; Castro et al. 2005; Fuchs, Spiegelman, and Kumar 
2004) or directly regulate enzymatic activity, e.g. phosphodependent 14-3-3 
motifs (Tompa et al. 2014). The same motif can be used in different contexts 
and in response to different signals to turn different signaling pathways on or 
off and cause different cellular responses (Wright and Dyson 2015). This is 
usually controlled at different stages: Pre-translational addition or removal of 
SLiM-containing exons, post-translational modification SLiM-containing 
peptides, allosteric SLiM inhibition or activation, and SLiM binding site 
competition (Dinkel et al. 2014). Peptide motifs are enriched in non-constitutive, 
alternatively spliced exons, tuning the regulatory potential of a protein by 
adding or removing peptide motifs (Buljan et al. 2012; Romero et al. 2006; 
Weatheritt and Gibson 2012) and also facilitating the rewiring of the interactome 
in different tissues. On a higher regulatory level, SLiMs often exhibit complex 
switching behavior for example by overlapping interfaces. In this way, they can 
cooperate with each other. Post-translational modifications can facilitate 
switching between different functional states of a protein, and thus, SLiMs 
function as key regulatory modules that allow for robust signaling networks (Van 
Roey, Dinkel, et al. 2013; Van Roey, Orchard, et al. 2013; Van Roey, Gibson, 
and Davey 2012; Davey et al. 2012). 
SLiMs form one of the three major classes of interaction interfaces that IDRs 
can be split into: large serpentine disordered domains, multi-partite disordered 
interfaces, and compact monopartite, short linear motifs (SLiMs) (Davey et al. 
2012). The majority of unstructured interfaces adapt to a template and 
secondary structures form after binding (Boehr, Nussinov, and Wright 2009). 
SLiMs differ from the other two large induced fit classes in two important 
attributes (Davey et al. 2012): Firstly, SLiMs are bound with lower affinity, 
usually between 1 and 150 micromolar (Seet and Pawson 2004; Neduva et al. 
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2005), for comparison, domains interact with relatively strong affinities even in 
the nanomolar range (Fuxreiter, Tompa, and Simon 2007). This allows SLiMs to 
engage in reversible and transient interactions (Wright and Jane Dyson 2009). 
It makes them crucial for many dynamic networks where large multi-protein 
complexes rapidly assemble and disassemble, but it also makes them inherently 
difficult to study. 
Secondly, because of their short length, it takes only one or a few mutations to 
generate a new motif. SLiMs are evolutionary dynamic and their short and easy 
pattern lets them appear and disappear independently in different proteins, as 
evidenced by their ubiquitous presence in higher eukaryotes (Gould et al. 2010). 
The plasticity and adaptability this provides to the interactome, however, also 
has its downside. Existing and necessary SLiMs can be disrupted or novel, but 
malfunctioning SLiMs can be created by a single point mutation (Figure 1). A 
proteome-wide comparison of the distribution of missense mutations from 
disease and non-disease mutation datasets revealed that, in IDRs, disease 
mutations are more likely to occur within SLiMs than neutral missense mutations 
(Uyar et al. 2014). If mutations disrupt binding peptides and/or PTM sites, they 
may result in disease outcomes, such as Noonan syndrome, Usher syndrome, 
cherubism, and aberrant signaling in cancer (Guettler et al. 2011; Pajkos et al. 
2012; Reimand and Bader 2013; Vacic et al. 2012). 
Even viruses have discovered how important and powerful SLiMs are. They 
commonly take advantage of the intrinsic evolutionary plasticity of SLiMs by 
mimicking host motifs to hijack host pathways (Kadaveru, Vyas, and Schiller 
2008; Davey, Travé, and Gibson 2011; Becerra, Bucheli, and Moreno 2017). 
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Figure 1 Mutations in disordered regions can impact protein-protein interactions. 
Changes in protein-protein interactions in disease 
Since the advent of molecular biology, we have learned that proteins do rarely 
act alone but interact with other proteins to fulfill their function. In the wealth 
of protein-protein interactions (PPIs), maps of proteins and their interactions 
can help to keep an overview. In PPI network graphs, nodes represent proteins 
while the lines connecting them represent their interactions. Zhong and 
colleagues have found that a set of disease-causing missense mutations can 
perturb a network by either complete loss of a gene product (node removal) or 
change in interaction (edgetic alterations). Node removal was likely to be caused 
by mutations affecting buried residues of the protein (comparable to ordered 
regions) and edgetic alterations were more often caused by mutations on the 
protein surface (comparable to disordered regions) (Zhong et al. 2009). In line 
with this finding, missense mutations were found to be enriched on the 
interaction interfaces of proteins associated with corresponding disorders (Wang 
et al. 2012). This loss of a distinct function compared to the loss of all 
functionality can also explain why different mutations in the same gene can 
cause different diseases. On the other hand, the analysis of protein interaction 
networks can also illustrate why mutations in different genes can lead to the 
same phenotype (Gandhi et al. 2006). The important role of PPIs mediated by 
IDRs leads to the conclusion that disruption of signaling- and regulatory 
 9 
 
 
networks via interaction-specific defects is the most plausible mechanism for 
diseases that involve mutations in IDRs. Several human diseases involve 
abnormal protein-protein interactions (Schuster-Böckler and Bateman 2008; 
Marc Vidal, Cusick, and Barabási 2011; Sahni et al. 2015; Hosp et al. 2015). 
Diverse studies have shown that changes in PPIs play an especially important 
role in neurological disorders. 
Intrinsic disorder and protein-protein interactions in 
neurological diseases 
Hosp and colleagues have quantitatively shown that changes in PPIs play a role 
in several neurodegenerative diseases, such as Alzheimer’s disease, 
Huntington’s disease, Parkinson’s disease, and spinocerebellar ataxia type 1 
(Hosp et al. 2015). A few years later, Malty and colleagues have shown that 
disruption of mitochondrial PPIs can lead to neurodegenerative diseases. They 
were able to show that several mutations at the protein interaction interface of 
SOD1 prevent its interaction with PRDX5, hence impairing their role in redox 
homeostasis, which in turn leads to the generation of reactive oxygen species 
(Malty et al. 2017). Also, mutations in either PARKIN or PINK disrupt the NF-κB 
complex which leads to its ectopic activation. 
Neurodegenerative diseases are often complex multifactorial disorders 
characterized by the interplay of many dysregulated physiological processes 
(Keane et al. 2015). However, de novo mutations, and hence a monogenic basis 
of neurological disease, might play a bigger role than previously anticipated 
(Veltman and Brunner 2012).  
In many of these monogenic cases, IDPs seem to play an important role. When 
individual proteins are involved in the pathogenesis of human 
neurodegenerative diseases, it appears that they are often either completely 
disordered or contained long disordered regions. These neurodegeneration-
related IDPs are also characterized by high binding promiscuity, as they are able 
to interact with a large number of unrelated partners (Uversky 2015). 
Taken together, this makes studying changes in PPIs as a potential cause of 
neurological diseases an especially appealing task. 
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Analyzing protein-protein interactions 
Understanding PPIs is of crucial importance not only to help to unravel disease 
mechanisms but also to understand the basic functions of proteins. Several 
methods exist to study PPIs. X-ray crystallography and NMR provide detailed 
spatial information on interaction interfaces. Surface plasmon resonance (SPR), 
isothermal titration calorimetry (ITC) (Pierce, Raman, and Nall 1999), and 
Förster resonance energy transfer (FRET) (Kenworthy 2001) are some examples 
for methods that provide binding affinities and kinetics. All of these methods 
have in common that a priori knowledge about interaction partners is needed 
and they hardly allow for de novo interaction discovery. Higher throughput 
techniques that are available come with their own drawbacks: microarrays, 
phage display and the yeast two-hybrid system (Fields and Song 1989) rely on 
in vitro assays or heterologous biological systems. The currently most unbiased 
approach to study PPIs in a high-throughput manner is affinity purification 
followed by mass spectrometry (AP-MS). This technique allows analyzing 
interactions in their physiological context and in relevant organisms (Gingras et 
al. 2007). One important step in defining PPIs is setting apart specific from 
unspecific binders (background). One early idea was to get rid of background 
binders by stringent washes. In tandem affinity purification (TAP; (Puig et al. 
2001)) the protein of interest is expressed with two affinity tags which allow two 
consecutive purifications to get rid of non-specific contaminants. Especially in 
the early times of AP-MS, this proved very useful because almost everything 
was yet to discover. Due to its extensive and stringent workflow, however, this 
method only allows for the identification of very stable complexes. Also, the 
sensitivity of modern mass spectrometers has become so high that they still 
identify even low abundant background binders. Comparable to the pigeons in 
Cinderella, quantitative AP-MS (q-AP-MS) came to the rescue and puts “the good 
ones into the pot, the bad ones into the crop”.  
Mass spectrometry identifies proteins by assigning mass over charge ratios to 
peptides and, since these are not necessarily connected to abundance, it is not 
inherently a quantitative method. Several approaches have been developed to 
make proteomics become quantitative (Gstaiger and Aebersold 2009; Cox and 
Mann 2011; Bantscheff et al. 2012). One important advancement was the 
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metabolic incorporation of stable heavy isotopes in proteins in cell culture 
(SILAC). It permits different cellular populations to be mixed and analyzed 
together since the incorporated mass shifts make it possible to distinguish their 
proteomes. This allows for quantitative measurements. In the case that SILAC 
approaches are not feasible, there are also label-free methods to compare 
protein levels in different samples. Label-free quantification (LFQ) is a 
computational method to compare protein abundances between samples. It has 
to be borne in mind, though, that stable isotope-based methods can detect even 
minor changes while label-free methods usually require at least a twofold 
change (Cox et al. 2014). Stable isotope-based methods are generally more 
precise than label-free approaches since samples can be combined in an earlier 
step during sample preparation and they can be analyzed together (Sury, Chen, 
and Selbach 2010; Lau et al. 2014). With these approaches at hand, proteins 
that co-purify with a protein of interest can be compared to a negative control 
(Vermeulen, Hubner, and Mann 2008; Paul, Hosp, and Selbach 2011). 
Conveniently, the possibility to quantitatively compare samples not only allows 
to distinguish specific binders from the background, but it provides the unique 
possibility to even study dynamic changes in interaction due to perturbations of 
the system. This can, for instance, be used to study modification-dependent 
interactions, for example by studying binding to post-translationally modified 
immobilized peptides and their unmodified counterparts (Selbach et al. 2009; 
Bartke et al. 2010; Francavilla et al. 2013). Very importantly it also allows 
studying differences between the interactomes of wild-type and mutant proteins 
(Hosp et al. 2015). As stated before, the most interesting changes in interaction 
could concern weak and transient interactions. In standard AP-MS, the dilution 
step of producing cell lysate followed by washes might lead to the loss of exactly 
these weak or transient interactions. One way to deal with this is in vivo cross-
linking (Kaake et al. 2014). Since the cross-linking reagents add a mass to an 
unknown position on the proteins and interconnect peptides, the search space 
is vastly increased and it might be due to these possible problems in 
identification that cross-linking is generally not the method of choice. A few 
years ago, another type of method was introduced that is able to identify protein 
connections in vivo. In these approaches, the protein of interest is equipped 
with a biotin ligase which enables the addition of a chemical handle (biotin) to 
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near-neighbors, including proximal and interacting proteins in their native 
cellular environment. These methods are called engineered ascorbate 
peroxidase (APEX) or proximity-dependent biotin identification (BioID) and, 
respectively, allow for different spatial or temporal resolution (Roux et al. 2012; 
Rhee et al. 2013). In a recent publication, AP-MS and BioID have been combined 
in a single construct to benefit from the advantages of both strategies and to 
even obtain interaction distances within a protein complex (Liu et al. 2018) 
One class of PPIs that request to dig very deep in the mass spectrometry bag 
of tricks are PPIs mediated by SLiMs since their interaction sites are often used 
transiently. Indeed, high-throughput approaches such as affinity purification 
coupled to mass spectrometry (AP-MS) and yeast two-hybrid (Y2H) assays fail 
to capture these weak interactions, with only ~1% of Y2H associations relying 
on SLiMs (Neduva and Russell 2006). PPIs mediated by SLiMs have some 
technical advantages, though: 
Peptide motifs are often sufficient to mediate interaction. They provide a 
compact and functionally autonomous module that does not interfere much with 
the structural and functional rest of the protein and hence can be studied even 
without the context of the whole protein (Tompa et al. 2014). This allows for the 
study of PPIs involving SLiMs by testing peptide-protein interactions. Schulze 
and Mann (2004) have shown that this feasible even for low-affinity interactions. 
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Approach in this thesis: A relatively high-throughput 
mass spectrometry-based screen for disease-causing 
changes in protein-protein interactions 
“Identifying peptide motifs through sequence similarity searches is generally 
subject to high levels of statistical uncertainty, and they are elusive to identify 
experimentally. However, to gain a better and more complete description of the 
complex physiological and pathological processes of the cell, much more focus 
should be placed not only on identifying them, but also establishing their 
functionality through a combination of high- and low-throughput studies.” 
Tompa et al. 2014 
In this thesis, we have decided to concentrate on missense mutations in IDRs 
implicated in neurological disease. By focusing on pathogenic mutations, we 
know that the affected IDR plays an important role in the protein’s function. The 
pathogenicity reveals that changing the peptide sequence in this region has a 
broad impact. Since mutations in IDRs probably do not alter the protein 
structure, it is unlikely that this is based on the protein losing all its functionality. 
We make use of the autonomous properties of IDRs and use synthetic peptides 
of 15 amino acid length surrounding the position of a disease mutation to pull 
down interaction partners from cell lysate. For the sake of cost-effectiveness 
and higher throughput, we employ peptide synthesis on a cellular membrane 
(Hilpert, Winkler, and Hancock 2007; Frank 1992). This approach is often used 
for identification of antibody binding sites with a far western set-up, but here 
single spots are excised and analyzed by mass spectrometry (Okada et al. 2012; 
Dittmar et al. 2017) to detect specific and differential interactors of IDRs and 
their disease variants. Such peptide pull-downs can maintain specificity even in 
the setting of low-affinity interactions (Schulze and Mann 2004). An increasing 
number of diseases have been connected to genomic mutations, thanks to 
extensive sequencing efforts. The disease mechanisms, however, are in most 
cases not known. This thesis will try to narrow the gap between genotype and 
phenotype by establishing a novel peptide-based interaction screen for disease-
related mutations and proving its validity by following up on chosen candidates. 
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Materials and Methods 
With some additions and some parts explained in greater detail, this section is 
mainly taken from Meyer et al. 2018. 
Peptide-protein interaction screen 
Candidate selection 
Disease mutations in humans were taken from UniProt annotations (UniProt 
Consortium 2012) of Online Mendelian Inheritance in Man, OMIM®, McKusick-
Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, 
MD), (https://omim.org/). 
This dataset consists of experimentally validated missense mutations that 
contribute to inherited diseases. Inherited disease mutations were 
downloaded from UniProt (http://www.uniprot.org/docs/humsavar.txt, 
release: 2015_07 of 24-Jun-2015, (Famiglietti et al. 2014)). Only mutations 
that were associated to ‘Disease’ were kept. ‘Unclassified’ mutations or 
‘Polymorphisms’ were excluded. The 26,649 disease mutations were further 
filtered by applying a disorder cut-off. Disorder tendencies of 15 amino acids 
(AAs) long peptides, with the AA mutated in disease, if possible, located at 
position eight, were predicted using IUPred (Dosztányi et al. 2005) using the 
‘SHORT’ (Famiglietti et al. 2014) profile considering the sequential 
neighborhood of 25 residues. IUPred disorder scores above 0.5 denote 
regions of the proteins that have 95% likelihood to be disordered. For 
filtering, the mean disorder score for all 15 AAs as well as the mutation 
position were required to be >0.5. This resulted in 1,878 disease mutations 
in disordered regions. Next, we assigned disease classes to 3,119 different 
diseases included in the Humsavar database by combining a manual approach 
(together with Marieluise Kirchner) with automatic annotation with the 
Human Phenotype Ontology database, HPO (Köhler et al. 2017). We selected 
305 mutations causing neurological diseases. After manual inspection 
(together with Marieluise Kirchner), we remained with 128 mutations causing 
124 distinct neurological diseases that were used for the peptide-protein 
interaction screen (Table 4). 
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Experimental setup 
Peptides of 15 AAs, in total 128 wild-type peptide and 128 related peptides 
containing the disease-causing mutation (256 peptides) plus one control peptide 
pair were synthesized in situ on cellulose membrane using PepTrack™ 
techniques (JPT Peptide Technologies, Berlin, Germany) (Frank 2002). Peptides 
were bound to cellulose membrane with β-alanines performing as a linker. 
Control peptide: VPPPVPPRRR amino acids 1150-1158 of SOS1 contains classical 
polyproline type II motif PXPhiXR for SH3 domain recognition and binds GRB2 
with an affinity of about 4 µM (Schulze and Mann 2004). To obtain control baits 
prolines were replaced with alanines to prevent proline-directed folding. 
Two peptide filters were moistened in cell lysis buffer [50 mM HEPES pH 7.6 at 
4°C, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 10% Glycerol, 0.5% Nonidet P-40, 
0.05% SDS and 0.25% sodium deoxycholate, supplemented with protease 
inhibitor (Roche) and benzonase (Merck)]. In order to reduce nonspecific 
binding, the membrane was incubated with 1 mg/ml yeast t-RNA (Invitrogen) 
for 10 min and then washed twice with wash buffer. The entire peptide libraries 
were incubated with 15 ml of light or heavy SILAC labeled cell lysate (5 mg/ml) 
from SH-SY5Y cells for 2 h (details about cell culture and production of cell lysate 
see further down). Membranes were washed three times with wash buffer and 
air dried. 
Cell culture 
SH-SY5Y (for peptide array) and HEK T-REx™-293 (for follow-up studies) cells 
were cultured under standard cell culture conditions. In brief, cells were cultured 
in DMEM (Life Technologies) complemented with 10% fetal calf serum (Pan-
Biotech) at 37°C and 5%CO2. 
Cells used for SILAC based experiments were cultured in SILAC DMEM (Life 
Technologies) complemented with glutamine (Glutamax, Life Technologies), 
Pyruvate (Life Technologies), non-essential amino acids (Life Technologies) and 
10% dialyzed fetal calf serum (Pan-Biotech). The SILAC DMEM was 
supplemented with standard L-arginine (Arg0, Sigma-Aldrich) and L-lysine 
(Lys0, Sigma-Aldrich) (“light”) as in (Schwanhäusser et al. 2011). Alternatively, 
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Arg6 and Lys4 (“medium-heavy”) or Arg10 and Lys8 (“heavy”) were added in 
place of their light counterparts. 
SILAC amino acids were prepared in PBS to stock solutions at the concentrations 
listed in Table 1. 
Table 1 SILAC amino acids 
Amino acid Mol weight (average) Stock conc [g/L] 
Arg0 210.6619 84 
Arg6 216.6178 86 
Arg10 220.5915 88 
Lys0 182.6485 146 
Lys4 223.1341 178 
Lys8 190.5912 152 
Amino acids were diluted 1:2000 in medium. All components were added to a 
vacuum filter system and sterile filtered. 
Cell lysate for peptide array 
Cell pellet from SH-SY5Y cells grown in 50x 15 cm dishes for each SILAC label 
were lysed in lysis buffer [50 mM HEPES pH 7.6 at 4°C, 150 mM NaCl, 
1 mM EGTA, 1 mM MgCl2, 20% Glycerol, 1% Nonidet P-40, 0.1% SDS and 
0.5% sodium deoxycholate, supplemented with protease inhibitor (Roche) and 
benzonase (Merck)] after 15 total passages and 7 passages in SILAC medium. 
Volume of lysis buffer and cell pellet was almost 1:1. Cells were lysed 30 min 
on ice and then passed 5x through 20G needle and 1x through 26G needle. 
Lysate was centrifuged for 25 min at 4,600 x g at 4°C to get rid of cell debris. 
This resulted in ~7 ml lysate per SILAC label. Cell lysate was diluted 1:1 with 
wash buffer to yield a final concentration of 5mg/ml and to dilute detergent 
concentration that could inhibit peptide-protein interactions. 
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Sample preparation for mass spectrometric analysis 
We got advice on the method from Daniel Perez Hernandez (MDC). Most 
importantly he introduced us to membrane blocking with yeast t-RNA. 
Single spots were punched out from cellulose membrane with a 2 mm diameter 
ear punch (Carl Roth) and SILAC pairs were placed together in a 96-well plate 
(Thermo Scientific) prepared with 30 µl of denaturation buffer [6 M urea 
(Sigma-Aldrich), 2 M thiourea (Sigma-Aldrich), 10 mM HEPES, pH 8]. Samples 
were reduced by incubating with 10 µl of 3.3 mM DTT (Sigma-Aldrich) in 
50 mM ammonium bicarbonate (ABC) buffer for 30 min at RT, followed by an 
alkylation step using 10 µl of 18.3 mM iodoacetamide (IAA) (Sigma-Aldrich) in 
50 mM ABC for 60 min at RT. The samples were first digested using 1 µg 
endopeptidase LysC (Wako, Osaka, Japan) for 4 h. The samples were diluted by 
adding 100 µl of 50 mM ABC (pH = 8.5), and finally digested with 1 µg trypsin 
(Promega) for 16 h. The digestion was stopped by acidifying each sample to pH 
< 2.5 by adding 10% trifluoroacetic acid solution. The peptide extracts were 
purified and stored on stage tips according to (Rappsilber, Ishihama, and Mann 
2003). Using a stage tip adaptor for high throughput stage tipping in a 
centrifuge (Kind gift from Nils Kulak, Max Planck Institute of Biochemistry). 
LC-MS/MS analysis 
Peptides were eluted using Buffer B (80% Acetonitrile and 0.1% formic acid) and 
organic solvent was evaporated using a speedvac (Eppendorf). Samples were 
diluted in Buffer A (5% acetonitrile and 0.1% formic acid). Peptides were separated 
on a reversed-phase column with 45 min gradient with a 250 nl/min flow rate of 
increasing Buffer B concentration on a High Performance Liquid Chromatography 
(HPLC) system (ThermoScientific). Peptides were ionized using an electrospray 
ionization (ESI) source (ThermoScientific) and analyzed on a Q-exactive plus 
Orbitrap instrument (ThermoScientific). Dynamic exclusion for selected precursor 
ions was 30 s. The mass spectrometer was run in data dependent mode selecting 
the top 10 most intense ions in the MS full scans, selecting ions from 300 to 
1700 m/z (Orbitrap resolution: 70,000; target value: 1,000,000 ions; maximum 
injection time of 120 ms). The resulting MS/MS spectra from the Orbitrap had a 
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resolution of 17,500 after a maximum ion collection time of 60 ms with a target of 
reaching 100,000 ions. 
Data analysis 
The resulting raw files were analyzed using MaxQuant software version 1.5.2.8 
(Cox and Mann 2008). Default settings were kept except that ‘match between 
runs’ and ‘re-quantify’ was turned on. Lys8 and Arg10 were set as labels and 
oxidation of methionines and N-terminal acetylation were defined as variable 
modifications. Carbamidomethylation of cysteines was set as fixed modification. 
The in silico digests of the human Uniprot database (2015-12), a fasta file 
containing all peptides used for pull-down and a database containing common 
contaminants were done with Trypsin/P. The false discovery rate was set to 1% 
at both the peptide and protein level and was assessed by in parallel searching 
a database containing the reversed sequences from the Uniprot database. 
Following statistics and figures were done using R (R version 3.2.1, RStudio 
Version 1.0.143). The resulting text files from MaxQuant analysis were filtered 
to exclude reverse database hits, potential contaminants, and proteins only 
identified by site. We imputed missing LFQ-intensity values with random noise 
simulating the detection limit of the mass spectrometer (Keilhauer, Hein, and 
Mann 2015). To this end, imputed values were taken from a log normal 
distribution with 0.25× the standard deviation of the measured, logarithmized 
values, down-shifted by 1.8 standard deviations. In this way, we obtained a 
distribution of quantitative values for each protein across samples. For 
determination of specific interactions, two replicated pull-downs for the same 
peptide were tested against all other pull-downs, excluding the corresponding 
variant peptide, by the nonparametric Mann–Whitney U test. Resulting p-values 
(-log10) and fold-changes (log2 space) have been plotted as volcano plots to 
determine cut-offs. We used an approach that uses a graphical formula to 
combine fold-change and p-value cut-off (Keilhauer, Hein, and Mann 2015): 
െ𝑙𝑜𝑔10ሺ𝑝ሻ  ൒ ௖|௫|ି௫బ with x: enrichment factor of a protein, p: p-value of the Mann–
Whitney U test calculated from replicates, x0: fixed minimum enrichment, 
c: curvature parameter. The curvature parameter c determines the maximum 
acceptable p-value for a given enrichment x. 
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The parameters c and x0 can be optimized based on prior knowledge of known 
true and false positives (Keilhauer, Hein, and Mann 2015). Here, cut-offs were 
chosen according to known interaction partners of the SOS1 control peptide 
(Schulze and Mann 2004). This resulted in x0=0, c=8. 
This cut-off was applied to all other pull-downs to separate specific binders from 
background. SILAC ratios were normalized by subtracting the median SILAC 
ratio of every experiment from all SILAC ratios in that experiment. To define 
interaction partners that bind differentially to wild-type and mutant peptide, a 
SILAC cut-off was defined. For wild-type specific interaction partners, the mean 
log2 SILAC ratio of the two replicates needed to be >1 and none of the two 
ratios <0 (mutant specific mean log2 SILAC ratio < -1 and none of the two ratios 
>0). Resulting figures were modified in Inkscape (0.91). 
PRM on adaptor proteins that bind dileucine peptides 
Experimental procedure was identical to general peptide-protein interaction 
screen. Only peptide variants from GLUT1_P485L, ITPR1_P1059L, 
CACNA1H_P648L and CACNA1H_A748V (control peptide) were used for 
experiment. 
LC-MS/MS analysis 
Peptides were separated by reverse phase chromatography on an effective 150 
min gradient (0, 2, 100, 30, 15, 1 and 5 min with 2, 4, 20, 30, 60, 90 and 90% 
of buffer B with 90% acetonitrile) and analyzed on a Q-Exactive HFx (Thermo 
Fisher Scientific). The PRM settings were: 30,000 resolution; 5e5 AGC target; 
1.6 m/z isolation window; 60 ms max ion injection time. The inclusion list for 
the PRM method was generated using Picky (Zauber, Kirchner, and Selbach 
2018) with SILAC option enabled and a retention time window of 30 min. 
Predicted retention-times were calibrated in Picky with a complex sample of 
100 ng Pierce HeLa Protein standard (Thermo Fisher Scientific) immediately 
before the PRM measurements. 
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Analysis of PRM data 
By Henrik Zauber: Traces of all fragments from precursors in the spectral library 
(as exported from picky) were extracted from all rawfiles using the Thermo 
MSFileReader and the MSFileReader.py bindings written by François Allen. For 
each light or heavy scan the normalized spectral contrast angle (SCN) was 
calculated (Toprak et al. 2014). Peaks were manually selected and required a 
SCN > 0.4 and Fragment Matches > 4 in the light or heavy channel. Further 
peaks needed to be within a similar retention time range across all different 
measurements. Ratios for each fragment using the maximum intensity of each 
peak were calculated. The median log2 transformed ratio (log2FC) for each 
peptide in each raw-file was calculated from selected fragment ratios: The five 
highest abundant fragments were selected from the peak with the highest 
detected SCN. Peptide log2FC were plotted as boxplot distributions in a protein 
centric manner across the different experiments (Figure 9) (Analysis by Henrik 
Zauber). 
Far western validation of peptide-protein interactions 
Peptide Spot Array was stained with Ponceau solution (2% Ponceau in 30% TCA) 
for 2 min. The membrane was subsequently activated with MeOH for 5 min. The 
following steps were conducted at 4°C. Membrane was washed 3x 3 min with wash 
buffer [50 mM HEPES pH 7.6 at 4°C, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl2] 
(same as for peptide array experiment followed by mass spectrometry). Membrane 
was blocked with 1 mg/ml yeast t-RNA (Invitrogen) for 10 min and then washed 
twice with wash buffer. The entire peptide library was incubated with 14 ml of light 
SILAC labeled cell lysate (5 mg/ml) from SH-SY5Y cells for 2 h (recovered from 
peptide experiment followed by mass spectrometry). Membranes were washed 
three times shortly with wash buffer. Subsequent steps were again conducted at 
room temperature. The membrane was washed and blocked in 3% BSA in wash 
buffer for 10 min, followed by 1 h incubation in primary antibody (anti-CHC, 1:1500 
(4 µl in 6 ml), rabbit, abcam, ab21679) in a sealed plastic bag and on a rotor. 
Following washing steps were kept short to minimize the time for peptide-protein 
interactions to resolve. Membrane was rinsed once and washed twice for 5 min 
with wash buffer. This was followed by incubation for 1 h with secondary antibody 
(anti-rabbit HRP, GE Healthcare) 1:10.000 (1 µl in 10 ml) again in a sealed plastic 
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bag on rotor. The membrane was washed like before. Proteins were detected with 
chemiluminescence substrate (Perkin Elmer) on a ChemiDoc MP Imaging System 
(Bio-Rad) and Image Lab 5.2.1 Software (Experiment with Teresa Melder). 
Follow-up on GLUT1 
Generation of stable cell line 
We purchased SLC2A1 (GLUT1) from Harvard Plasmid repository 
(HsCD00378964). Q5® Site-Directed Mutagenesis Kit (NEB) was used for 
adding a stop codon and subsequent P485L mutation. The stop codon has been 
added to the gene with the following primers 
Fw:TCCCAAGTGTAATTGCCAACTTTCTTGTACAAAGTTG, 
Rev:ATCAGCCCCCAGGGGATG. 
PCR CYCLING CONDITIONS: 
STEP TEMP TIME 
Initial Denaturation 98°C 30 s 
25 Cycles 98°C 
67°C 
72°C 
10 s 
20 s 
1 min 45 s 
Final Extension 72°C 2 min 
Hold 8°C   
The P485L Mutation was introduced by changing c.1454 C>T (Slaughter, 
Vartzelis, and Arthur 2009) with Fw:CTGTTCCATCtCCTGGGGGCT, 
Rev:CTCCTCGGGTGTCTTGTCAC. 
PCR CYCLING CONDITIONS: 
STEP TEMP TIME 
Initial Denaturation 98°C 30 s 
25 Cycles 98°C 
68°C 
72°C 
10 s 
20 s 
1 min 45 s 
Final Extension 72°C 2 min 
Hold 8°C   
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SLC2A1 and SLC2A1 mutant have been further cloned into a destination vector 
with an N-terminal BirA-FLAG Tag (pDEST-pcDNA5-BirA-FLAG N-term (Couzens 
et al. 2013)) with Gateway cloning strategy (Thermo Fisher Scientific). HEK 293 
Flp-In T-Rex cells (Invitrogen) that exhibit tetracycline-inducible expression of 
BirA-FLAG-GLUT1 or BirA-FLAG-GLUT1_P485L were generated using the Flp-In 
system developed by Life Technologies according to the manufacturer’s protocol 
(Kindly generated for us by the Markus Landthaler lab, MDC Berlin). The Flp-In 
approach allows streamlined generation of stable mammalian cell lines by taking 
advantage of a Saccharomyces cerevisiae-derived DNA recombination system. 
This system uses a recombinase (Flp) and site-specific recombination (Craig 
1988; Sauer 1994) to facilitate integration of the gene of interest into a specific 
site (FRT site) in the genome of mammalian cells. 
BioID 
BioID employs a promiscuous biotin ligase to biotinylate proteins based on 
proximity labeling (Roux et al. 2018). It is a powerful method to identify 
interacting and proximal proteins even for transient interactions. 
Medium-heavy and heavy labelled HEK T-REx™-293 cells were induced for 24 h 
with 0.1 µg/ml doxycycline to induce expression of GLUT1 (wild-type, wt) or 
GLUT1_P485L (mutant, mut). Light labelled cell lines from both GLUT1 and 
GLUT1_P485L were left uninduced and served as a control for background 
binding. SILAC labeling allowed for quantitative comparison of proteins that 
were proximity labelled by the expressed GLUT1 constructs 
(Forward experiment: Light - Control, Medium-heavy - wt, Heavy - mut; Label 
swap experiment: Light - Control, Medium-heavy - mut, Heavy - wt). During 
the induction period all cell lines were incubated for 24 h in cell culture medium 
containing 50 µM biotin. BioID experiment was performed essentially as in 
(Couzens et al. 2013), with minor adaptations. 
Mass spectrometry setup and analysis was done similarly as to samples from 
peptide pull-downs, but on bead digested peptides were separated on a 
2,000 mm monolithic column with a 100 µm inner diameter filled with C18 
material that was kindly provided by Yasushi Ishihama (Kyoto University) using 
a 4 h linear gradient with a 300 nl/min flow rate of increasing Buffer B 
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concentration on a High Performance Liquid Chromatography (HPLC) system 
(Thermo Scientific). The resulting raw files were analyzed using MaxQuant 
software version 1.5.2.8 (Cox and Mann 2008). Default settings were kept 
except that ‘match between runs’ and ‘re-quantify’ was turned on. Lys4 and 
Arg6 or Lys8 and Arg10 were set as labels and oxidation of methionines and 
N-terminal acetylation were defined as variable modifications. 
Carbamidomethylation of cysteines was set as fixed modification. The in silico 
digests of the human Uniprot database (2015-12), a fasta file containing the 
sequence of BirA-FLAG-GLUT1 and a database containing common 
contaminants were done with Trypsin/P. The false discovery rate was set to 1% 
at both the peptide and protein level and was assessed by in parallel searching 
a database containing the reversed sequences from the Uniprot database. 
Biotinylated proteins with a wild-type to mutant enrichment ratio (log2FC) >1 
or <-1 in both replicates were considered as significant. These proteins were 
analyzed for gene ontology enrichment of cellular components with 
http://metascape.org (Tripathi et al. 2015). 
FLAG-GLUT1 localization 
HEK 293 Flp-In T-Rex cells with BirA-FLAG-GLUT1 or BirA-FLAG-GLUT1_P485L 
were seeded on coverslips coated with poly-L-lysine (Sigma-Aldrich). After 
induction for 24 h in doxycycline (0.1 µg/ml) containing media, cells were fixed 
with 4% PFA (paraformaldehyde). Standard procedures were used for 
immunostaining. Cells were stained against FLAG 1:200 (F1804, Sigma). 
Nucleus was stained with DAPI (Sigma). Costainings were performed by 
Jing-Yuan Cheng: FLAG staining was accompanied by staining to one of the 
following endosomal markers and with the following dilutions: anti-EEA1 (Cell 
Signaling Technology, 1:100); anti-Rab4 (Cell Signaling Technology, 1:100); 
anti-Rab9 (Cell Signaling Technology, 1:100); anti-LAMP1 (Cell Signaling 
Technology, 1:100). Mouse anti-FLAG staining was substituted by rabbit anti-
GLUT1 (Merck Millipore, 1:500) to costain mouse monoclonal antibodies: anti-
VTI1A (BD Biosciences, 1:100); anti-VTI1B (BD Biosciences, 1:100). Secondary 
antibodies all come from Invitrogen. For colocalization analysis three z stacks of 
5-10 cells each were quantified for each marker with Imaris v8.4.1. For details 
see “Fluorescence microscopy from cell culture”, “Colocalization analysis”. 
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FLAG-GLUT1 motif mutants 
GLUT1_P485A mutant was generated with help of 
http://nebasechanger.neb.com/ from pENTRY_GLUT1 vector. Entry vectors 
containing GLUT1_wt, _P485L or _P485A were further cloned into a destination 
vector harboring an N-terminal FLAG-tag, via gateway cloning technology. 
HEK 293 were seeded on coverslips coated with poly-L-lysine (Sigma-Aldrich). 
After 12 h, they were transfected with either of the three plasmids with Jetprime 
(Polyplus-Transfection). After 24h, cells were fixed with 4% PFA. Standard 
procedures were used for immunostaining. Cells were stained against FLAG 
1:200 (F1804, Sigma-Aldrich). Nucleus was stained with DAPI (Sigma-Aldrich). 
Samples were imaged on an upright epifluorescence microscope (Leica DM5000 
B) and Leica DFC365 FX camera. 
Transferrin uptake 
Essentially as in “FLAG-GLUT1 localization”. Additionally, after 24 h cells were 
serum-starved for 1 h and used for Transferrin (Tf) uptake. For Tf uptake, cells 
were incubated with 10 μg ml−1 Tf-Alexa568 (Life Technologies) for 10 min at 
37°C. Three z stacks of more than 15 cells each have been quantified with Imaris 
v8.4.1. For details see “Fluorescence microscopy from cell culture”, 
“Colocalization analysis”. 
FLAG-GLUT1 localization under AP-2 µ knock-down 
To rescue the GLUT1_P485L phenotype, clathrin-mediated endocytosis (CME) 
was inhibited by knocking down AP-2 µ and hence the adaptor complex 
responsible for recognition of cargo for CME. AP-2 is a stable protein complex 
and hence two subsequent rounds of knock-down are needed (Motley et al. 
2003). 
On day 1 cells were seeded in 6-well plates. On day 2, cells were transfected 
with 25 nM final siRNA concentration (AP-2 µ: ON-TARGETplus Human AP2M1 
(Dharmacon) and non-target: ON-TARGETplus Non-targeting Pool 
(Dharmacon)) according to DharmaFECT (Dharmacon) transfection protocol. 
24 h after transfection, medium was replaced with complete medium to reduce 
cytotoxicity and incubated for another 24 h. On day 4, cells were transfected 
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again as on day 2. On day 5, cells were seeded in a 24-well plate onto coverslips 
coated with poly-L-lysine (Sigma-Aldrich) for microscopy and into a 6-well plate 
for western blot analysis. Doxycycline (0.1 µg/ml) was added to the medium to 
induce expression of the GLUT1 constructs. After induction for 48 h, cells in 24-
well plates were fixed with 4% PFA. Standard procedures were used for 
immunostaining. Cells were stained with rabbit polyclonal GLUT-1 antibody 
1:200 (Merck Millipore) and co-stained with mouse monoclonal anti-alpha 
adaptin antibody [AP6] 1:200 (Abcam). Secondary antibodies with Alexa 
fluorophores were all purchased from Invitrogen. Nucleus was stained with DAPI 
(Sigma). 
Lysate from cells in 6-well plates was used for western blotting, α and μ2 
subunits of AP-2 were detected using mouse monoclonal antibodies from 
Thermo Fisher Scientific and BD transduction, respectively. Profilin 1 was stained 
as a loading control with polyclonal rabbit antibody from CST. Horseradish 
peroxidase coupled secondary antibodies were purchased from GE Healthcare. 
Proteins were detected with chemiluminescence substrate (Perkin Elmer) on a 
ChemiDoc MP Imaging System (Bio-Rad) and quantified with Image Lab 5.2.1. 
Fluorescence microscopy from cell culture 
Images from FLAG-GLUT1 localization were acquired by Leica DMI6600 confocal 
laser scanning microscope with an HCX PL APO 63.0/1.40 oil objective. 
Transferrin uptake, GLUT1-localisation under AP-2 µ knock down, antibody 
feeding assay and GLUT1 in iPSCs were acquired by a Zeiss LSM 700 confocal 
laser scanning microscope with an EC Plan-Neofluar/NA1.3 40x oil objective or 
a EC Plan-Apochromat/NA1.4 63x oil objective. Images were further processed 
with Fiji (Schindelin et al. 2012). 
Colocalization analysis 
Imaris v8.4.1 was used for quantitative colocalization analysis. The original 
z-stack images were adjusted by adding an adequate mask on the respective 
red channel to subtract background noise (Costes et al. 2004). The threshold 
for the mask was uniformly adjusted in each staining experiment. Automatic 
thresholding was used to define the area where a colocalization would be 
determined and the statistics was calculated for each colocalization channel 
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(Costes et al. 2004). For the images whose observed correlation was not 
statistically significant in comparison to randomized images, the colocalization 
channel was built without additional thresholding on the masked dataset. The 
resulting thresholded Pearson’s coefficients were exported. The number of 
images and cells in the analyses is stated in the respective Method sections. 
Radioactive glucose uptake under AP-2 µ knock-down 
AP-2 knock down was performed essentially as described before (FLAG-GLUT1 
localization under AP-2 µ knock-down). In detail, here, initially, 500,000 cells 
were seeded in a 6-well plate and subsequently 200,000 cells were seeded in 
triplicates in a 24-well plate without coverslips. 1 µg/ml doxycycline was used 
to induce GLUT1 expression. Radioactive glucose uptake was performed mainly 
as in (Shi and Kandror 2008). Radioactive glucose cocktail was prepared by 
adding 10 μL of 3H-2-deoxy-D-glucose in ethanol:water solution (specific 
activity, 5–10 Ci (185–370 GBq)/mmol) (Perkin Elmer) to a 2.0-mL tube and 
left open for 5 min to evaporate ethanol. 1.6 mL of KRH(−) glucose buffer 
(121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4, 0.33 mM CaCl2, 12 mM HEPES, 
pH 7.4) and 16 μL of cold 2-DOG (100X) stock solution (100 mM 
2-deoxy-D-glucose in KRH (−) glucose) (Sigma-Aldrich) were added to the tube. 
Cells in each well were rinsed with DMEM (without serum, SFM) warmed to 37°C 
and SFM was added to cells slowly and carefully by the side of the well in order 
to avoid detachment of cells. Cells were incubated with 0.5 mL of SFM (in case 
of +dox containing 1µg/µl doxycycline) per well for 2 h at 37°C. Cells in each 
well were washed twice with 2 mL of KRH (−) glucose buffer at 37°C. 225µl of 
KRH (-) containing 25 µM final cytochalasin B (dissolved in DMSO) or 0.5% 
DMSO were added to each well. Immediately after, 25 μL of radioactive glucose 
cocktail was added to all wells. Samples were incubated at 37°C for 1 h and 
then transferred on ice. Radioactive glucose cocktail was aspirated, and ice-cold 
KRH (+) glucose (121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4 0.33 mM 
CaCl2:  12 mM HEPES, 25 mM D- (+)- Glucose, pH 7.4.) was added to terminate 
the reaction. Cells were washed once more with ice-cold KRH (+) glucose. Plate 
was transferred to room temperature, and 400 μL of 0.1% SDS in KRH (−) 
glucose were added to each well, incubated at room temperature for 10 min, 
and thoroughly resuspend to homogeneity. 100 µl of the lysate was kept to 
28 
 
 
measure protein concentration with DC protein assay kit I (BioRad). 300 μL of 
lysates were transferred in scintillation vials containing 4 mL of Rotiszint eco 
plus scintillation fluid (Carl Roth) and count in a Liquid Scintillation Analyzer (Tri-
Carb 2800TR, PerkinElmer) for 1 min per vial. These numbers represent “Counts 
in the samples”. In parallel, 10 μL of the radioactive glucose cocktail were mixed 
with 290 μL of 0.1% SDS in KRH (−) glucose and this mixture was measured 
under the same conditions. This number represents “Counts in the cocktail”. The 
amount of intracellular 2-deoxyglucose was calculated using the following 
formula: 
ቂ ሾ஼௢௨௡௧௦ ௜௡ ௧௛௘ ௦௔௠௣௟௘ሿൈଵ଴଴଴ሾ஼௢௨௡௧௦ ௜௡ ௧௛௘ ௖௢௖௞௧௔௜௟ሿൈ଴.଴ଷൈሾ஼ሿൈ௧ቃ  pmol/mg×min 
where [C] is protein concentration in mg/ml and t is the total time of incubation 
with radioactive glucose in min. All resulting values were divided by the overall 
mean value from all wild-type GLUT1 (+ doxycycline, - cytochalasin B) and 
multiplied by 100 to receive relative values for glucose uptake (%). For test of 
statistical significance, the mean values of three technical replicates were 
calculated from three biological replicates and determined by one-tailed t-test. 
Depicted values are mean values over all replicates and error bars show 
standard error of mean (SEM) over all replicates. 
GST pulldown assay 
GLUT1 cytoplasmic C-terminal tail was amplified from 
pDEST_pcDNA5_FLAG_BirA GLUT1 or GLUT1_P485L with 
Fw:tatatcGAATTCGTTCCTGAGACTAAAGGC, 
Rev:aacaatGCGGCCGCTTACACTTGGGAATCAGCC. This resulted in C-terminal tail 
amino acids 451-492 (UniProt P11166). Added EcoRI and NotI restriction sites 
were used to insert the PCR product into pGEX6P1 to generate GST-fusion 
chimera. Other cytoplasmic regions were ordered as gBlocks Gene Fragments 
(IDT) from the region ± 20AA of the mutation position, with an additional 
5’-EcoRV restriction site and 3’-stop codon-NotI restriction site. After restriction, 
the gene fragments were inserted into pGEX6P2. 
By Giulia Russo: Expression of GST-tagged proteins was induced for 5 h at 22°C 
by addition of isopropyl thio-β-d-galactoside (0.5 mM) to E.Coli BL21 in 2X YT 
medium (0.8 OD). To lyse the cells, bacterial pellets were resuspended in PBS 
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and left on ice for 15 min in presence of PMSF (1 mM), cyanase (4 U/µl) and 
lysozyme (1 mg/ml). Then, Triton X-100 was added to 0.5% and cells were 
sonicated for 2 min. Lysates were centrifuged for 15 min at 50,000 x g. 300 μl 
of glutathione-coupled beads were added to the supernatant and rotated end-
over-end for 2 h at 4°C. Beads were washed three times with PBS / 0.1% Triton 
X-100 and once with PBS. 
Pulldown experiments were performed using mouse brain extracts. Mouse brains 
were homogenized in 2.5 ml buffer (20 mM Hepes, 320 mM sucrose, pH 7.5) 
containing protease inhibitor cocktail (Sigma-Aldrich). The homogenate was 
centrifuged at 1000 x g for 10 min and the supernatant was supplemented with 
1% Triton X-100, 50 mM KCl and 2 mM MgCl2, and kept on ice for 10 min with 
occasional vortexing. The lysate was cleared by centrifugation at 17,000 x g for 
15 min and at 178,000 x g for 15 min. The supernatant was recovered and used 
at a concentration of 7.5 mg protein/ml. 
The pulldown experiment was performed using 85 μg of GST fusion proteins and 
0.6 ml protein extract by end-over-end rotation for 3 h. The samples were 
washed four times with buffer containing 20 mM Hepes, 50 mM KCl, 2 mM MgCl2, 
Triton X-100 (1%) and once in the same buffer without detergent. Proteins were 
eluted from the beads twice with Laemmli buffer and analysed by Western 
blotting. The following antibodies and dilutions were used: mouse anti-talin 
1:1000 (Sigma-Aldrich), mouse anti-γ1 adaptin of AP-1 1:500 
(BD Transduction), mouse anti α-adaptin of AP-2 1:200 (BD Transduction), 
horseradish peroxidase-conjugated goat anti-mouse 1:2000 (Jackson labs). 
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GLUT1 in patient-derived iPSCs 
Generation of patient-derived iPSCs 
By Juan M. Pascual: Fibroblasts were obtained from a GLUT1 deficient patient 
with the P485L mutation. The voluntary informed consent process was 
documented in writing as approved in advance by the University of Texas 
Southwestern Medical Center Institutional Review Board. This included 
information regarding the de-identification of the sample and the adherence to 
HIPAA regulations. 
A 4 mm single-use, sterile skin punch was applied to the lateral surface of the 
left shoulder after the skin had been cleansed with iodine solution in aseptic 
fashion followed by injection of 0.5 ml of 1% unbuffered lidocaine with a 
vasoconstrictor. Prilocaine and lidocaine cream had been previously applied to 
the area. The punch was advanced by rotation under pressure and the explant 
was severed from its base and harvested in culture medium containing complete 
DMEM plus 20% FBS and placed on ice until the explant was divided for culture 
the same day. The explant was divided into 12-15 evenly sized pieces and each 
piece maintained in a 10 cm dish at 37°C until fibroblast confluence was 
reached. The cells were then treated with trypsin and passaged into a T-25 flask 
for further expansion. Fibroblasts were grown to approximately 50% confluence 
in the T-25 flask. They were then suspended with trypsin and frozen over dry 
ice in complete DMEM medium with 10% DMSO at a density of 106 cells/ml per 
vial prior to storage and shipment on dry ice. 
By Sebastian Diecke: The patient fibroblast were reprogrammed using the 
mRNA reprogramming kit ReproRNA™-OKSGM from Stem Cell Technologies 
according to the instructions (by Sebastian Diecke lab, MDC/BIH). In brief, 1x105 
fibroblast cells were plated on Geltrex coated 6-well plate using regular DMEM 
media with 10% FBS. The day after the cells were transfected with the 
ReproRNA- OKSGM construct using the ReproRNA transfection reagents and 
growth Media with B18R. The next 5 days the growth media was changed every 
day and supplemented with B18R and 0.8 µg/ml puromycin. After 8 days the 
growth media was exchanged by ReproTeSR and first colonies appeared after 
14 days. In total 5 clones were picked and established using mTESR-1 media. 
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As a control for the experiments the following fibroblasts (NHDF-Ad-Der 
Fibroblasts, C-2511, LONZA) were reprogrammed using the Epi5™ Episomal 
iPSC Reprogramming Kit from Thermo Fisher Scientific following the vendor's 
instructions. The established lines and clones were registered and named using 
the Human pluripotent stem cell registry (https://hpscreg.eu/): BIHi037-(A-E). 
The iPSCs used for the experiments were characterized using the PSC 4-Marker 
immunocytochemistry kit from Thermo Fisher SCIENTIFIC following the 
instructions of the protocol. In addition to the 4 markers (OCT4, SOX2, TRA-1-
60 and SSEA4) included in the kit, the expression of another pluripotency 
marker NANOG (Nanog PA1-097, Thermo Fisher Scientific) was analyzed. 
iPSC culturing 
By Ina-Maria Rudolph: Human iPSC cultures were maintained on plates coated 
with hESC-Qualified Matrigel™ (Corning) in mTESR-1 medium (Stem Cell 
Technologies) following the manufacturer's instruction. All cells were cultured at 
37°C in humidified atmosphere containing 5% O2 and 5% CO2. Cells were 
passaged using StemPro Accutase (Thermo Fisher) and replated in mTESR1 
medium with the addition of 10 μM ROCK inhibitor Y-27632 (LC Laboratories) 
(culturing and preparation of cells for experiments by Ina-Maria Rudolph). 
GLUT1 localization in iPSCs 
Human iPSCs were seeded on coverslips coated with hESC-Qualified Matrigel™ 
(Corning). Cells were fixed with 4% PFA, stained with rabbit polyclonal GLUT1 
antibody 1:200 (Merck Millipore) and costained with mouse monoclonal VTI1A 
antibody 1:100 (BD Transduction). Secondary antibodies with Alexa 
fluorophores have all been purchased from Invitrogen. 
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GLUT1_P485L in a mouse model 
By Ralf Kühn: GLUT1 P485L mice were produced by microinjection of C57BL/6N 
zygotes with Cas9 protein (IDT), synthetic guide RNA (IDT) 
(5’GAGGAGCTCTTCCACCCTCT3’) and a mutagenic single stranded 
deoxyoligonucleotide (IDT) 
(5’TAGCTGCCTGTGCTCCAGAGAGATCCTTGGGCTGCAGGGAGCAGGCCGGGCTGG
GTGTGGGGCTCCTCACACTTGGGAGTCCGCCCCCAacaaGTGGAAGAGCTCCTCGGG
TGTCTTGTCACTTTGG3’) as recombination template, as described (Wefers et al. 
2017). Reagents were diluted in microinjection buffer (10 mM Tris, 
0.1 mM EDTA, pH 7.2), filtered through a centrifugal filter (Millipore, 
UFC30LG25) and stored in single use aliquots at -80°C. For microinjections, 
zygotes were obtained by mating of C57BL/6N males with superovulated 
C57BL/6N females (Charles River, Sulzbach, Germany). Zygotes were injected 
into one pronucleus following standard procedures (Ittner and Götz 2007). 
Injected zygotes were transferred into pseudo-pregnant NMRI female mice to 
obtain live pups. All mice showed normal development and appeared healthy. 
Mice were handled according to institutional guidelines under experimentation 
license no. G0162/12 approved by the Landesamt für Gesundheit und Soziales 
(Berlin, Germany) and housed in standard cages in a specific pathogen-free 
facility on a 12 h light/dark cycle with ad libitum access to food and water. 
Immunofluorescence in mouse tissue 
Mouse keeping and experiments by Carmen Birchmeier lab (MDC) and especially 
Luis R. Hernandez-Miranda with help from Sven Buchert. E14-E15.5 embryos 
were obtained by Caesarian section from pregnant dam on day 14-15.5 post-
coitus. Whole-mount embryos were dissected in ice-cold phosphate buffer and 
fixed for 2 h with a solution of 4% PFA in ice-cold phosphate buffer and 
cryoprotected overnight in 30% sucrose in phosphate buffer at 4°C. Whole 
embryo heads were sectioned in a horizontal plane using a cryostat to obtain 
12-16 μm sections. 
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Sample preparation for confocal microscopy 
Essentially as in Hernández-Miranda et al. 2011. Brain sections were incubated 
in blocking buffer 1 (5% horse serum and 0.1% Triton™-X 100 made in PBS) 
for 1 h at room temperature. Then, sections were incubated overnight in 
blocking buffer 1 containing the following antibodies: rabbit anti-Glut1 (1:200; 
Merck Millipore #07-1401), rat anti-ICAM2 (1:100; BD Biosciences #553326) 
and Isolectin GS-IB4 Alexa Fluor 488 conjugate (1:100, Thermo Fisher Scientific 
#I21411) at 4°C. Next, sections were washed three times in ice-cold PBS and 
incubated for 3 h in blocking buffer 1 containing Cy3 horse anti-rabbit (1:500; 
Jackson Lab), Cy5 horse anti-rat (1:500; Jackson Lab) and DAPI at room 
temperature. Fluorescence was imaged on a Zeiss LSM 700 (Jena, Germany) 
confocal microscope in a non-blind manner. 
Sample preparation for STED microscopy 
Sample staining and STED microscopy by Anna Szymborska (MDC). Sections 
were washed twice for 5 minutes with PBS to remove the embedding resin and 
incubated in 0.2% Triton X-100 in blocking buffer 2 (1% bovine serum albumin, 
1% fetal calf serum in PBS) for 1 h at room temperature. Samples were 
incubated with primary antibodies anti-Glut1 (rabbit anti-human, Merck 
Millipore #07-1401) and anti-ICAM2 (rat anti-mouse CD102, BD Biosciences 
#553326) at 1:100 dilution in blocking buffer 2 overnight at 4°C. Next, samples 
were washed three times for 5 minutes in PBS and incubated with STAR Red 
goat anti-rabbit antibody (Abberior, #2-0012-011-9), Alexa Fluor 594 donkey 
anti-rat antibody (Thermo Fisher Scientific #A21209), and Isolectin GS-IB4 
Alexa Fluor 488 conjugate (Thermo Fisher Scientific #I21411), all diluted at 
1:500 in blocking buffer 2. Subsequently, samples were washed three times for 
5 min in PBS and mounted in Abberior Mount Solid Antifade mounting reagent 
(Abberior, #4-0100-007-4) under #1.5 coverslips (22x50 mm, VWR #631-
0138) and allowed to cure overnight at room temperature. 
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STED imaging and image analysis 
IB4 and ICAM2 signals were used to assess the positions of luminal (IB4 and ICAM2 
positive) and abluminal (IB4 positive, ICAM2 negative) vessel membranes. Cross-
sections of vessels (10-20 per animal) were selected for imaging in areas where 
luminal and abluminal membranes were clearly distinguishable, typically in the 
vicinity of the endothelial cell nucleus. 
STED images were acquired using Abberior STED microscope equipped with 640 nm, 
561 nm and 485 nm pulsed excitation lasers, 775 nm and 595 nm pulsed depletion 
lasers, UPlanSApo 100x/1.40 Oil objective (Olympus), 509/22 (GFP), 605/50 (Cy3) 
and 685/70 (Cy5) bandpass emission filters and spatial light modulators for STED 
beam shaping and alignment. Emitted light was collected with avalanche photodiode 
detectors using 8 ns-wide detection time gates. 120 µs total pixel dwell time per 
channel was used. Cy3 and Cy5 channels were acquired by line switching followed 
by the acquisition of the GFP channel.  
STED images in 488 nm and 640 nm channels were aligned using reference images 
of fluorescent beads (Tetraspeck, 100 nm, ThermoFisher Scientific #T7280). Centers 
of beads were determined by centroid fit and resulting positions were used as control 
points to calculate an affine transformation between the 488 nm and 640 nm 
channels.  
To quantify the average amount of membrane-localized Glut1 per vessel, a 
measurement area containing all pixels within 300 nm of manually segmented 
abluminal membrane was created. Luminal membranes were not included in the 
analysis due to frequent collapse of vessels during sample preparation. The ratio 
between mean Glut1 and mean IB4 signal was used as a measure of Glut1 to account 
for the amount of membrane in the measurement area, imaging depth and antibody 
penetration differences between samples. The ratio of Glut1 to IB4 was further 
corrected using images of Tetraspeck beads for relative intensity fluctuations 
between Cy5 and GFP detection channels between imaging sessions. Statistical 
significance was assessed using unpaired Student’s t-tests of log2 transformed data. 
The analysis was performed using ImageJ and Matlab 2015 (Mathworks, Inc). 
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Analysis of human missense variants and short linear 
motifs (SLiMs) 
By Bora Uyar: 
SLiM regular expression patterns 
262 annotated SLiM class definitions (regular expression patterns) were 
downloaded from the Eukaryotic Linear Motif (ELM) database (Dinkel et al. 
2016). In order to analyze dileucine motifs, an additional motif ‘.LL.’ was added 
to this compilation and named ‘LIG_diLeu_1’ in order to conserve the naming 
convention followed by the ELM database. The general formula for the dileucine 
motif is [DERQ]…L[LVI] as in http://elm.eu.org/elms/TRG_LysEnd_APsAcLL_1. 
Importantly, however, Kozik et al. 2010 have shown that even a “dileucine on 
its own can act as a weak internalization signal”. In fact, the CACNA1H peptide 
does not carry a strict dileucine motif, but it still recruits clathrin in our hands. 
Literature and our finding convinced us to continue our follow-ups with LL as the 
only requirement for the motif. 
Pathogenic and non-pathogenic missense variants 
Humsavar dataset: For the analysis of the missense variants that lead to de 
novo SLiM instances in protein sequences Uniprot Humsavar dataset (version 
12-Apr-2017) (Famiglietti et al. 2014) was downloaded and filtered for missense 
variants. Variants that are classified as ‘Disease’ or ‘Polymorphism’ in this 
dataset were selected. 
ClinVar dataset: Clinically relevant genomic variation data annotated in the 
ClinVar database (Landrum et al. 2016) was downloaded from the ftp server 
(ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/variant_summary.txt.gz) in 
tab-delimited format (latest update on 25th of March, 2017). The downloaded 
table was filtered for assembly version GRCh38, and variants of type ‘single 
nucleotide variant’ were kept. In order to integrate the ClinVar annotations with 
other kinds of annotations available from the Uniprot database, these nucleotide 
variants were translated to the Uniprot protein sequences to obtain single 
amino-acid substitutions using the Ensembl Variant Effect Predictor (version 82) 
(VEP) (McLaren et al. 2016). The output of VEP tool was filtered to only keep 
missense variants such that the translated amino-acid substitution occurs at 
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exactly the same amino acid at the same position of the Uniprot sequence with 
the same gene name as those of the annotation in the ClinVar dataset (‘Name’ 
field). Thus, 98,219 unique single amino-acid substitutions (missense variants) 
from 4,298 Uniprot sequences were obtained. Variants primarily annotated with 
clinical significance levels ‘Pathogenic’, ‘Pathogenic/Likely pathogenic’, or 
‘Likely pathogenic’ were grouped as ‘Disease’ variants, while variants annotated 
with ‘Benign’, ‘Benign/Likely benign’, or ‘Likely benign’ were grouped into the 
‘Polymorphism’ variants. 
Analysis of gain of SLiMs via missense variants in disordered 
regions 
For each reviewed human protein from Uniprot (20,191 proteins), the disorder 
scores of each residue were calculated using IUPred (using the ‘short’ setting). 
Using an IUPred disorder score cut-off of 0.4, the missense variants in 
disordered regions were selected. The missense variants that overlap PFAM 
domains were further filtered out based on the PFAM domain annotations found 
in the protein feature files downloaded from Uniprot in GFF format (e.g. the link 
to the GFF file for GLUT1 is http://www.uniprot.org/uniprot/P11166.gff). These 
protein feature files were also used to detect the transmembrane proteins and 
their cytoplasmic/extracellular regions. The missense variants in disordered 
regions and not overlapping any PFAM domains were further classified as 
variants from 1) the whole proteome, 2) the transmembrane proteins (only 
those that have annotation of at least one cytoplasmic domain or an 
extracellular domain, in total 3,836 proteins), 3) the cytoplasmic domains of 
transmembrane proteins, and 4) extracellular domains of transmembrane 
proteins. For each of these classes, the number of disease-causing variants and 
the number of polymorphisms that lead to a gain of SLiMs was counted and a 
two-sided Fisher’s Exact Test was applied to see if there is a statistically 
significant difference for the likelihood of a given class of SLiMs to be gained via 
disease-causing variant compared to that of polymorphisms. 
Peptide-protein interaction network analysis 
180 peptide-protein interactions that passed the LFQ filter and showed 
significant differential SILAC ratios between wild-type and mutant forms of the 
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peptides were used to compose a peptide-protein interaction network. The 
network was visualized using Cytoscape 3.5.1 (Shannon et al. 2003). Enriched 
GO terms for each sub-graph were calculated using the topGO R package (Alexa 
and Rahnenfuhrer, 2016). 
A functional gain of dileucine motifs 
Antibody feeding assay 
An antibody feeding assay was used to study the gain of endocytosis by gain of 
dileucine motifs. For antibody internalization assay, genes and cytoplasmic 
regions were chosen according to the following criteria: All 11 disease mutations 
from Humsavar and Clinvar (‘Pathogenic’ or ‘Conflicting interpretations of 
pathogenicity’, in case ‘pathogenic’ or likely pathogenic was included in the 
different interpretations) that lead to a gain of a dileucine motif were considered. 
All regions +/-7 AAs of the mutation were analyzed according to Eukaryotic 
Linear Motif (ELM) database (Dinkel et al. 2016). CACNA1H_P618L and 
RET_P1039L were not considered for the assay since wild-type variants of the 
peptides already harbor trafficking motifs. For GLUT1_P485L the whole 
cytoplasmic C-terminus was amplified via PCR adding EcoRV 5’ and NotI 3’. All 
other seven constructs were generated by inserting the region surrounding the 
mutation position with Q5® Site-Directed Mutagenesis Kit (NEB) resulting in a 
15 AA insert (we were not able to generate a construct for CACNA1H_P648L) 
(practical help with cloning by Martha Hergeselle). For primers see Table 2. 
Chimeras consisting of the respective cytoplasmic region and the human TAC 
antigen (interleukin-2 receptor α chain, CD25) were constructed based on a TAC 
construct (Diril et al. 2009). HeLa cells were transiently transfected with the TAC 
chimera constructs using jetPRIME (Polyplus-transfection). Two days after 
transfection, cells were labeled with anti-TAC IgG (Santa Cruz Biotechnology) 
(1:1000 diluted in Opti-MEM; Invitrogen) for 30 min at 4°C. After one change 
of medium (to Opti-MEM at 37 °C), plasma membrane antigens were allowed to 
internalize for 30 min at 37°C. The cells were then fixed with 4% PFA (Sigma-
Aldrich) for 10 min on ice, and surface-bound TAC antibody was blocked using 
goat anti-mouse serum [goat anti-mouse IgG (Thermo Fisher Scientific at a 1:5 
dilution in goat serum dilution buffer, consisting of 30% normal goat serum 
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(Sigma-Aldrich), 450 mm NaCl in 20 mM sodium phosphate buffer pH 7.4] for 
2 h at room temperature. Cells were permeabilized and blocked with goat serum 
dilution buffer containing 0.2% saponin for 10 min. For detection of internalized 
TAC antibody, a goat anti-mouse Alexa Fluor 488-conjugated IgG (Invitrogen) 
was added for 1 h. Cells were then washed three times for 10 min each with 
sodium phosphate buffer containing 0.02% saponin. For total TAC staining, the 
specimens were incubated for 1 h with TAC antibody diluted 1:1000. As 
secondary antibody, an Alexa Fluor 594-conjugated goat anti-mouse IgG 
(Invitrogen) was added for 30 min, and nuclei were stained using DAPI (Sigma-
Aldrich). Cells were washed, and coverslips were mounted in ProLong® Gold 
antifade reagent (Invitrogen). For imaging, cells with positive signal in the 594 
channel were chosen. All cells shown are positive for total TAC staining (594). 
We have seen that the level of internalized TAC chimera (488) does not correlate 
with the amount of total TAC staining (594), between samples and in the same 
sample, and hence we have decided to exclude this channel from visualization. 
Table 2 Primers used for generation of TAC-chimera proteins. 
Primer Name Sequence 
CACNA1H_P648_fw TTGAGCTTGAACAGCCCTGATTAGGATATCCAGCACAGTGGC 
CACNA1H_P648wt_rev CGGGCCGTGCCCCCCGGTGCCTGGGATTGTTCTTCTACTCTTCCTC 
CACN1H_P648L_rev CAGGCCGTGCCCCCCGGTGCCTGGGATTGTTCTTCTACTCTTCCTC 
ITPR1_P1059_fw  CTGGACTTGGATGACCACGGCTAGGATATCCAGCACAGTGGC 
ITPR1_P1059wt_rev  TGGGGTGTTCTCCTCACTTCCTCCGATTGTTCTTCTACTCTTCCTC 
ITPR1_P1059L_rev TAGGGTGTTCTCCTCACTTCCTCCGATTGTTCTTCTACTCTTCCTC 
L1CAM_S1194_fw CTCAACGGGGACATCAAGCCCTAGGATATCCAGCACAGTGGC 
L1CAM_S1194wt_rev CGATGGCTGGCTGCTGCCAAAGGCGATTGTTCTTCTACTCTTCCTC 
L1CAM_S1194L_rev CAATGGCTGGCTGCTGCCAAAGGCGATTGTTCTTCTACTCTTCCTC 
RHBDF2_P189_fw CTGGCCCGGGGCCGGGCCTTCTAGGATATCCAGCACAGTGGC 
RHBDF2_P189wt_rev CGGATCCACAATCTTGGGCATCTTGATTGTTCTTCTACTCTTCCTC 
RHBDF2_P189L_rev CAGATCCACAATCTTGGGCATCTTGATTGTTCTTCTACTCTTCCTC 
CFTR_P5_fw GCCAGCGTTGTCTCCAAACTTTAGGATATCCAGCACAGTGGC 
CFTR_P5wt_rev CTTTTCCAGAGGCGACCTCTGCATGATTGTTCTTCTACTCTTCCTC 
CFTR_P5L_rev CTTTTCCAGAAGCGACCTCTGCATGATTGTTCTTCTACTCTTCCTC 
CFTR_P750_fw CGCATCAGCGTGATCAGCACTTAGGATATCCAGCACAGTGGC 
CFTR_P750wt_rev AGGCAGTATCGCCTCTCCCTGCTCGATTGTTCTTCTACTCTTCCTC 
CFTR_P750L_rev AAGCAGTATCGCCTCTCCCTGCTCGATTGTTCTTCTACTCTTCCTC 
KCNQ1_R452_fw CTGGACCACTTCTCTGTCGACTAGGATATCCAGCACAGTGGC 
KCNQ1_R452wt_rev CCGCCGCTCTTCTGGGGGGTCGCAGATTGTTCTTCTACTCTTCCTC 
KCNQ1_R452L_rev CAGCCGCTCTTCTGGGGGGTCGCAGATTGTTCTTCTACTCTTCCTC 
KCNQ1_R591_fw CTGAACCGAGTAGAAGACAAGTAGGATATCCAGCACAGTGGC 
KCNQ1_R591wt_rev GCGGGCGCCGATCGTGTTGCTGCCGATTGTTCTTCTACTCTTCCTC 
KCNQ1_R591L_rev GAGGGCGCCGATCGTGTTGCTGCCGATTGTTCTTCTACTCTTCCTC 
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Results 
A peptide-based interaction screen on disease-related 
mutations 
We set out to develop a high-throughput screen to study the changes in protein-
protein interactions (PPIs) provoked by disease-causing missense mutations. 
We were especially interested in mutations located in intrinsically disordered 
regions (IDRs), since their likelihood to impact isolated protein functionalities, 
like PPIs, is increased. Short peptide sequences, SLiMs, in IDRs are often 
sufficient to mediate PPIs. This means that they can maintain functionality even 
when isolated from the context of the whole protein. This made us reason that 
quantitative interaction proteomics with immobilized synthesized peptides 
should enable us to study the impact of disease-causing missense mutations in 
IDRs. 
Detecting specific and differential peptide-protein interactions  
As the first step, we assembled a list of promising candidates to include in our 
peptide-based interaction screen (together with Marieluise Kirchner) (Figure 2). 
We turned to Uniprot’s Humsavar disease database as a reliable source of 
disease-causing mutations (Uyar et al. 2014). We predicted disordered regions 
with the IUPred web tool (Dosztányi et al. 2005). This allowed us to filter for 
missense mutations that lye in IDRs. Additionally, we decided to concentrate on 
mutations that cause neurological diseases (for details see Methods). We ended 
up with more than 100 peptide pairs of 15 AAs in length that correspond to the 
IDRs in both wild-type and mutant variant. All final candidates were synthesized 
on cellulose membrane (by JPT peptide technologies, Berlin, Germany) and used 
to pull down interaction partners from cell lysate (Figure 3). To identify 
interacting proteins, each peptide-spot then had to be excised and the 
associated proteins were identified and quantified with shotgun mass 
spectrometry. 
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Figure 2 Candidate selection for peptide-protein interaction screen on neurological 
disease-causing mutations. Candidates were selected from missense mutations in the 
Humsavar database (Uniprot) by selecting mutations in disordered regions that cause neurological 
diseases (Disease classification and manual selection together with Marieluise Kirchner). 
One important question that follows such a measurement is: which proteins 
truly interact with the peptide and which are promiscuous binders that interact 
non-specifically (i.e. background binders). 
To address this point we applied two levels of filtering. First, we compared the 
normalized intensities (label-free quantification - LFQ) (Cox et al. 2014) coming 
from two replicate peptide spots (light and heavy SILAC replicate) with the 
associated proteins that had been identified for all other peptide spots. Specific 
interaction partners are thought to be significantly enriched for a limited number 
of peptides. 
Second, we applied SILAC-based quantification (Mann 2006) to detect proteins 
binding differentially to wild-type and mutant peptide variants. To this end, two 
identical membranes were incubated with cell lysate from either light- or heavy-
metabolically labeled cells. After excision, wild-type and mutant variant from 
forward (wt-light and mut-heavy) or reverse (mut-light and wt-heavy) 
experiment were combined in the same tube. To validate the general 
functionality of the screen and to provide significance thresholds for all other 
candidates, we included a control peptide from the literature. 
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Figure 3 Quantitative interaction
screen with disease-associated
disordered regions. Cellulose
membranes with synthetic wild-type
(circles) and mutated (stars) peptides are
incubated with lysate from light (light
blue) or heavy (dark blue) SILAC-labeled
cells to pull-down interacting proteins.
Spots are excised, corresponding
wild-type/mutant pairs are combined and
analyzed by quantitative shotgun
proteomics (represented by an Orbitrap).
Middle: label-free quantification (LFQ)
identifies specific interactors by
comparing both replicates to all other
pull-downs. Volcano plots depict protein
enrichment in the two replicate pull-
downs of a given peptide over all other
peptide pull-downs, separately for the
wild-type (left) and mutant peptide
(right). The threshold (red lines) was
derived from the benchmark experiment
with the SOS1 peptide. LFQ-specific
interactors are depicted in red. SILAC-
based quantification identifies differential
binders by directly comparing
corresponding wild-type and mutant
pairs. Differential binders of the wild-type
and mutant peptide appear in the upper-
right and lower-left quadrants,
respectively. 
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PxxP motif-containing peptide recruits proteins with 
SH3-domains 
To test the applicability of our screen we had to choose a benchmark to answer 
the following questions: (i) Can the peptide-based interaction screen capture 
known protein-protein or even known peptide-protein interactions and (ii) can 
it detect differential binding to wild-type and mutated peptides? 
 
Figure 4 Proof of concept, on SH3-domain binding peptide, results in known specific 
and differential interaction partners. A, SOS1 derived peptide with an SH3 domain-binding 
PxxP motif. Prolines are substituted by alanines to disrupt binding motif. B, Volcano plot from LFQ 
data for wild-type SOS1 peptide. Specific binders are shown as red dots. Four out of five known 
binders (red gene names) are detected. C, Differential binders of the wild-type and mutant SOS1 
peptide. Proteins with SH3 domains are shown with black outlines. 
To this end, we included a peptide stemming from SOS1 (son of sevenless 
homolog 1) (Schulze and Mann 2004). This peptide represents amino acids 
1150–1158 of SOS1 (SGSGVPPPVPPRRR) (Figure 4 A). It contains a proline-rich 
motif that is known to interact with SH3 (Src Homology 3) domain-containing 
proteins. Of its known interaction partners: GRB2, CD2AP, PACSIN3, SNX9 and 
SNX18 (Schulze and Mann 2004), only the latter could not be identified in our 
set-up and we identified five additional interactors. Strikingly, when comparing 
the wild-type to the mutated peptide in which all prolines were exchanged with 
alanines, all remaining significant and differential interaction partners in our 
setup contain SH3 domains. The SOS1 peptide is known to bind GRB2 with an 
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affinity of about 4 µM (Vidal et al. 1998). This made us confident that we would 
be able to identify other relevant low-affinity SLiM-domain interactions in our 
screen. 
Peptide-protein interaction screen reveals possible disease 
mechanisms 
Approximately, 400 interacting proteins were identified on average to be 
associated with every single peptide spot. If all of those would be considered 
specific interaction partners this would result in ~100,000 interactions for the 
whole array (Figure 5 A). One strength of shotgun proteomics, however, is that 
promiscuous background binders are not a problem, but can be used to 
normalize data and, when treated in the right way, can be distinguished from 
specific interactions (Keilhauer, Hein, and Mann 2015). Applying our filter criteria 
(LFQ filter) reduced the interactions to 618 that are considered to be specific 
(Figure 5 A). These were distributed over about half of the peptide candidates 
(120 out of 256) (Figure 5 B). The others did not show specific interactions when 
compared to the background. However, not all of these specific interactions were 
differential when comparing wild-type and mutant peptide (Figure 5 A). In 180 
cases the interaction was affected by the mutation. 111 of these interactions 
are lost through mutations in the peptide, while 69 are gained. Of note, since 
pull-downs can also capture indirect binders, not all of these interactions are 
necessarily direct. This means that more than half of peptide-variant pairs that 
have significant interactors also show differential interaction of at least one of 
the specific interaction partners (44 out of 76) (Figure 5 B). 
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Figure 5 Specific and differential interactors of wild-type and mutant IDRs. 
A, Quantitative filter to select specific and differential interactors. Only a minor fraction of all 
detected interactions are specific (LFQ filter). Moreover, only a fraction of specific interactors is 
differential (SILAC filter), i.e. shows preferential binding to the wild-type or mutant form of a 
peptide. Mutation-induced interaction losses are more frequent than mutation-induced gains. 
B, Impact of the two filters on peptide candidates. After applying the LFQ filter on all interactions, 
about half of the 256 peptides (128 variant pairs) show at least one specific binder (left pie chart). 
These 120 peptides relate to 76 peptide pairs with specific interactions of wild-type and/or mutant 
peptide. More than half of these 76 peptide pairs show differential interactions (SILAC filter). 
To illustrate all differential interactions in a compact manner, they are here 
displayed in a network (Figure 6). Some peptides share differential interactors, 
which might suggest similar disease mechanisms. It is, for example, interesting 
to note that in three cases the conversion of arginine to tryptophan leads to the 
loss of HSP90b interactions. None of these proteins, however, was known to 
interact with HSP90b before and so the significance of this finding is unclear. 
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It is also interesting to see that interactions of FLOT1 and FLOT2 are lost when 
arginine is converted to cysteine (GJB1_R264C), but gained when arginine is 
added through mutation (DKC1_G402R). 
 
Figure 6 Differential interactions of wild-type and mutant IDRs. A network of all differential 
interactions. Peptides (rectangles) and interacting proteins (ovals) are represented as nodes. The 
edges indicate preferential binding to the wild-type (blue) or mutant (red) form of a peptide 
(edge-darkness indicates SILAC ratios). Highlighted subnetworks are enriched in splicing 
regulators and clathrin-coated vesicle proteins, respectively. 
New insights into the role of FUS_R521C in amyotrophic 
lateral sclerosis (ALS) 
One particularly interesting finding is the loss of interactions of the fused in 
sarcoma (FUS) R521C mutant (insert in Figure 6). FUS is an RNA-binding protein 
implicated in amyotrophic lateral sclerosis (ALS) (Deng, Gao, and Jankovic 
2014). ALS is a fatal neurological disorder characterized primarily by the rapid 
degeneration of motor neurons (Sharma et al. 2016). There are over 50 
mutations in FUS in ALS families (Deng, Gao, and Jankovic 2014). Most of these 
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mutations are dominant missense mutations that cluster in and around the C-
terminal nuclear localization signal (Zakaryan and Gehring 2006). One of these 
mutations is R521C. In our screen, however, we found significant interaction of 
several splicing factors with the wild-type peptide stemming from the amino 
acids 512-526 of FUS. These interactions were decreased due to the R521C 
mutation. R521C has been shown to lead only to a mild cytosolic mislocalization 
(Dormann et al. 2010) and hence it is tempting to believe that there might be 
two disease mechanisms that add up to each other. This assumption is also 
corroborated by the fact that FUS is known to be involved in RNA splicing and 
to interact with SRSF10. Even more strikingly, this interaction has been mapped 
to the region of concern, since it is known that it is lost in truncated forms of 
FUS that lack the C-terminus (Yang et al. 1998). 
Gain of dileucine motifs as a recurrent cause of disease 
Another cluster stands out even more: Three peptides seem to gain interactions 
with clathrin when they carry a specific disease mutation (Figure 6 and Figure 7 
A, B). Clathrin is a major player in intracellular trafficking, which leads to the 
assumption that erroneous protein trafficking might be the underlying disease 
mechanism. This would be particularly reasonable in the case of transmembrane 
proteins, and in fact, all three peptides stem from membrane spanning 
transporters: a calcium channel CACNA1H (calcium channel, voltage-
dependent, T type, alpha 1H subunit) or Cav3.2, ITPR1 (inositol 
1,4,5-trisphosphate receptor type 1) and SLC2A1 (solute carrier family 2, 
facilitated glucose transporter member 1) also known as GLUT1 (glucose 
transporter 1) (Figure 7 C). The disease mutations have something else in 
common: In all three cases, a proline had been mutated to a leucine, changing 
the sequence to two consecutive leucines (a simplified version of the dileucine 
motif, (D/E)…LL) (Figure 7 D). Dileucine motifs are known to be recognized by 
proteins involved in intracellular clathrin-mediated trafficking (Pandey 2009). To 
make the motif accessible to the trafficking machinery it has to face the cytosol. 
All three dileucine motifs are harbored in a cytosolic domain of the respective 
transporter. The idea suggests itself that, in all cases presented, a 
mislocalization of the transmembrane proteins mimics the loss of one copy of 
the gene, responsible for a haploinsufficient disease. 
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Figure 7 Recruitment of clathrin by recurrent gains of dileucine motifs. A, Volcano plots 
for pull-downs with mutated peptides derived from CACNA1H, GLUT1, and ITPR1. Specific binders 
(relative to all other pull-downs) are highlighted in red. All three peptides specifically interact with 
clathrin. B, Corresponding SILAC plots show that clathrin and related proteins preferentially bind 
to the mutated form of the peptides (relative to the wild-type). C, Graphical representation of the 
mutation sites. All three mutations affect cytosolic regions of transmembrane proteins. CACNA1H 
and GLUT1 are located mainly in the plasma membrane and ITPR1 mainly in the ER. D, Alignment 
of the three peptide sequences reveals a common gain of a dileucine motif. 
Only the mutations in GLUT1 and ITPR1 actually lead to the creation of a 
textbook dileucine motif ((D/E)…LL) (ELM entry). CACNA1H_P648L does not 
create a classical trafficking motif. The P1059L mutation in ITPR1, however, also 
creates a so-called clathrin box (LLDLD). Even if the created motifs are not 
perfect, it has been shown repeatedly that variations are common and that 
dileucine can even act on its own (Staudt, Puissant, and Boonen 2016; Traub 
2009; Kozik et al. 2010; Pandey 2009). 
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Mutations in the three transporters lead to different neurological diseases. 
CACNA1H_P648L is involved in childhood absence epilepsy (Chen et al. 2003). 
This disease manifests as loss of consciousness with sudden on- and offset. The 
causality of the mutation is under debate, but Chen and colleagues report that 
the P648L mutation in one copy of the gene leads to this specific form of 
epilepsy. 
ITPR1_P1059L leads to spinocerebellar ataxia type 15/16 (SCA15/16) (Hara et 
al. 2008). SCA15/16 is characterized by pure cerebellar ataxia, very slow 
progression, and marked cerebellar atrophy (Gardner et al. 2005; Storey et al. 
2001). Most SCA15/16 patients have heterozygous deletions at the 5’ end of 
the ITPR1 gene which lead to a dramatic decrease in ITPR1 expression levels 
(Yamazaki et al. 2011). ITPR1_P1059L was found to have indistinguishable 
channel characteristics from that of the wild-type protein. Anyways, 
heterozygous deletions and the P1059L mutation of ITPR1 exhibit similar clinical 
features in affected patients (Hara et al. 2008). The domain in which P1059 is 
localized is known to be highly regulated through splicing, phosphorylation, ATP 
binding but also interaction with regulatory proteins. Hence, it is accessible to 
protein-protein interaction. 
The GLUT1_P485L mutation causes GLUT1 deficiency syndrome (G1DS), a 
disorder characterized by seizures and intellectual disability with onset in early 
infancy (Leen et al. 2010; Pascual et al. 2008; De Vivo et al. 1991). GLUT1 is a 
glucose transporter localized in the endothelial cells of the blood-brain barrier 
and in astrocytes and is mainly responsible for glucose transport into the brain 
and hence its energy supply. Also in the case of G1DS, loss of a single copy of 
GLUT1 is known to cause the disease (Seidner et al. 1998). 
All three mutations lead to diseases that are known to be caused by 
haploinsufficiency of one gene. This is in good agreement with our theory that 
mislocalization leads to functional knock-out of one copy. 
Peptide-protein interactions can be confirmed by far-western 
blotting approach 
As an orthogonal method, a far-western blotting approach can be used to 
validate peptide-protein interactions (Figure 8). To verify interaction of clathrin 
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to dileucine containing peptides, we employed, in principle, the same 
experimental setup as before, but instead of cutting out single peptide spots to 
prepare them for mass spectrometry, we labeled the membrane with an 
antibody against clathrin, thereby making it possible to visualize clathrin 
interacting peptides. In agreement with our high-throughput data, we detect 
stronger signal at dileucine containing peptides when compared to most other 
peptides (specific) and also when comparing the mutant peptides to their wild-
type counterparts (differential) (with Teresa Melder). 
 
Figure 8 Recruitment of clathrin by dileucine motif-containing peptides can be 
confirmed by the far-western blotting approach. Whole peptide array was incubated with 
cell lysate and consequently probed with clathrin antibody. Dileucine motif-containing peptides 
show much stronger signal than all other peptides and mutant peptides are enriched compared 
to their wild-type counterparts (Experiment with Teresa Melder). 
Adaptor proteins bind preferentially to dileucine 
containing peptides 
I tiny flaw in the logic, however, is that dileucine motifs are generally not 
recognized by clathrin directly, but bind adaptor proteins that then recruit 
clathrin and lead to clathrin-mediated trafficking. 
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Figure 9 Adaptor proteins bind preferentially to mutant variant peptides carrying a 
dileucine. A highly sensitive, targeted mass spectrometry technique (parallel reaction 
monitoring, PRM) reveals that adaptor proteins (AP-1, AP-2, AP-3) bind preferentially to peptides 
carrying a dileucine when compared to their wild-type counterparts (Set-up with Henrik Zauber, 
analysis and figure by Henrik Zauber). 
In mass spectrometry absence of evidence is not necessarily evidence of 
absence. Some peptides, and hence proteins, might escape identification 
because of their low abundance or the peptide`s characteristics. To increase the 
likelihood to detect adaptor proteins, in case they actually bind to the dileucine 
peptides, we made use of a more sensitive targeted mass spectrometry assay 
against peptides from several APs based on their known fragmentation spectra 
(Zauber, Kirchner, and Selbach 2018). Repeating the peptide pull-downs for 
GLUT1, CACNA1H and ITPR1 with targeted proteomics as read-out, confirmed 
that several APs preferentially interact with the mutated peptides (Figure 9). 
(Design with Henrik Zauber, Analysis by Henrik Zauber) 
A dileucine-motif gain causes mislocalization of 
glucose transporter GLUT1 
To confirm the expected mislocalization of GLUT1_P485L when compared to the 
wild-type, we generated a stable cell line (Kindly generated by Markus 
Landthaler’s lab, MDC Berlin). Here, HEK cells equipped with an Flp-In site carry 
one copy of BirA-FLAG-tagged GLUT1 in the genome. Immunofluorescence 
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staining followed by confocal microscopy revealed that wild-type GLUT1 localizes 
mainly to the plasma membrane while GLUT1_P485L accumulates in 
intracellular vesicles (Figure 10).  
 
Figure 10 Mutation-induced dileucine motif gain causes mislocalization of the glucose 
transporter GLUT1 in stable HEK cells. A, Confocal images of GLUT1 localization in HEK cells 
stably expressing FLAG-GLUT1, reveal that the wild-type is localized mainly at the cell membrane 
while the P485L mutant is mislocalized to intracellular compartments (green, FLAG-GLUT1; blue, 
DAPI). Scale bars: 10 µm B, Colocalization analysis shows extensive colocalization of mutant, but 
not wild-type GLUT1 with markers of several endocytic compartments. Pearson’s correlation 
coefficients (as implemented in the Imaris software) were determined for GLUT1 variants with 
the indicated marker proteins. Data represented as mean ± SD (Data obtained by Jing-Yuan 
Cheng). 
To figure out more about the intracellular localization of the GLUT1 mutant and, 
potentially unravel trafficking proteins involved in the mislocalization, we applied 
a proximity labeling technique, BioID (Roux et al. 2012). When comparing 
GLUT1 wild-type and mutant, the biotin ligase (BirA) coupled to GLUT1 wild-
type, biotinylated mainly proteins known to localize at the plasma membrane. 
The mutant-specific proteins, on the other hand, were significantly enriched in 
terms related to intracellular trafficking (Figure 11). Interestingly, subunits of 
three different adaptor proteins (APs) were also enriched by GLUT1_P485L 
(Figure 11 D). 
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Figure 11 GLUT1_P485L mislocalizes to endocytic compartments. A, Comparison of 
proteins colocalizing with wild-type and mutant GLUT1 by proximity labelling (BioID). SILAC 
log2 fold changes (Log2FC) from two replicate experiments with swapped isotope labels. Blue and 
red labeled proteins are enriched by wild-type GLUT1 or mutant GLUT1, respectively. B, The ten 
most significant cellular component GO-terms reveal that mutated GLUT1 is involved in clathrin-
dependent processes and endosomal trafficking. In contrast, wild-type GLUT1 colocalizes with 
plasma membrane-associated proteins. C, Coloured according to the top three enriched GO-terms 
and shows the variants’ typical subcellular compartments. Figure adapted from (Raiborg and 
Stenmark 2009). D, Adaptor protein complexes AP-1, AP-2, and AP-3 show increased 
colocalization with GLUT1 due to P485L mutation in replicates of BioID experiment from (A). 
Identified subunits of APs are shown in red. 
  
 53 
 
 
Binding of adaptor proteins causes mislocalization of 
GLUT1_P485L 
Adaptor proteins are the connecting elements that recognize trafficking motifs 
on cargo proteins and recruit clathrin, so vesicles containing the cargo can be 
released from the membrane of origin (Traub and Bonifacino 2013). AP-1, AP-
2, and AP-3 have been detected, each responsible for a different step in 
intracellular trafficking. AP-2 localizes to the plasma membrane and is 
responsible for the uptake of a wide range of cargo proteins via clathrin-
mediated endocytosis. AP-1 plays a role in protein sorting in the trans-Golgi 
network (TGN) and endosomes (Bonifacino and Rojas 2006; Hirst et al. 2012). 
Also, AP-3 localizes to the TGN and endosomes, but to different endosomal buds 
(Peden et al. 2004; Theos et al. 2005). Here, it mediates cargo transport from 
tubular endosomes to late endosomes and is involved in the biogenesis of 
lysosome-related organelles (Park and Guo 2014). 
Following up on this finding, we wanted to prove that APs can interact with the 
C-terminal cytoplasmic tail of GLUT1. To this end, we performed pull-downs of 
a GST fusion protein with the wild-type or P485L mutant cytoplasmic tail. In this 
in vitro set-up, the mutant but not the wild-type tail showed interaction with AP-
1 and AP-2, further strengthening our disease hypothesis (Figure 12; Pull-down 
by Giulia Russo). 
To test if GLUT1_P485L, in fact, reaches the plasma membrane and is then taken 
up again via endocytosis, we incubated cells expressing one of the GLUT1 
variants with fluorescently labeled transferrin. Transferrin binds the transferrin 
receptor which is a well-known cargo for clathrin-dependent endocytosis (CDE). 
GLUT1_P485L but not GLUT1 wild-type showed extensive colocalization with 
endocytosed transferrin (Figure 13). This indicates that only GLUT1_P485L is 
involved in major trafficking by CDE from the plasma membrane. 
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Figure 12 GST-pull down corroborates that GLUT1_P485L interacts with AP-1 and AP-2. 
P485L mutant but not wild-type GLUT1 C-terminal tail interacts with AP-1 and AP-2. Tails were 
tagged with GST to pull-down interaction partners from mouse brain lysate. Talin is shown as a 
negative control and is not pulled down from either of the two variants (Experiment by 
Giulia Russo). 
 
Since AP-2 is responsible for endocytosis from the plasma membrane, we 
hypothesized that an AP-2 knock-down should result in a reconstitution of 
GLUT1_P485L levels at the plasma membrane and hence a rescue of the disease 
phenotype. To test this idea, we knocked down AP-2 expression levels via siRNA 
targeting the µ-subunit (see Methods). Consistently with our prediction, AP-2 
knock-down restored GLUT1_P485L localization at the plasma membrane 
(Figure 14). 
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Figure 13 GLUT1_P485L colocalizes with endocytosed transferrin. Mutant but not 
wild-type GLUT1 extensively colocalizes with endocytosed transferrin. HEK cells stably expressing 
FLAG-GLUT1 were incubated with fluorescently labeled transferrin for 10 min before fixation. Scale 
bar: 10 µm. Quantification is represented as mean ± SD. 
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Figure 14 GLUT1_P485L mislocalization can be rescued by knockdown of AP-2. Western 
blot against AP-2 α- and µ-subunits shows downregulation after two rounds of siRNA transfection 
against AP-2 µ. AP-2 knockdown leads to relocalization of GLUT1_P485L to the plasma membrane 
and hence rescue of the mutation phenotype. Scale bar: 10 µm. 
GLUT1_P485L is functional for glucose uptake 
The next question posing itself is if GLUT1_P485L is indeed functional after its 
localization is restored to the plasma membrane. We decided to study this via a 
radioactive glucose uptake assay after knock-down of AP-2 (Figure 15). It is 
indeed possible to distinguish the additional amount of glucose that is taken up 
by the stable HEK cells via the additional copy of GLUT1 from their basal glucose 
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uptake (comparison of uptake -doxycycline with +doxycycline). In both cases, 
glucose uptake also ranges significantly over background measurements 
(comparison to values obtained after use of glucose uptake inhibitor, 
cytochalasin B). While glucose uptake in wild-type GLUT1 remained constant 
after knock-down of AP-2, it leads to a significant increase of glucose uptake in 
the P485L mutant. Since expression levels of GLUT1 variants in the two stable 
cell lines are not necessarily the same, this setup does not allow to draw 
conclusions about the comparison of wild-type and mutant levels. However, the 
findings make us confident, that mislocalization of an, at least partially, 
functional GLUT1 is the cause for the disease. 
 
Figure 15 Glucose uptake of cells expressing GLUT1_P458L increases after AP-2 
knockdown. GLUT1 expression of stable HEK cells was induced by doxycycline, cytochalasin B 
inhibition was used as a control. % glucose uptake is relative to GLUT1 wild-type, +doxycycline, 
-cytochalasin B. Mean values of technical triplicates from three independent experiments are 
shown. We only compare glucose uptake within and not between cell lines to account for possible 
differences between clones. Error bars: SEM. ** p-value < 0.01 from a paired, one-sided t-test. 
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GLUT1_P485L mutation leads to gain of function 
In theory, it is still possible that mutation of proline 485 indirectly leads to 
mistrafficking by disrupting some existing SLiM. To test this, we exchanged the 
proline not by leucine but by alanine. In this way, we did not create a dileucine 
motif but made sure that a proline dependent motif would be disrupted. As 
expected, the alanine mutant mostly resembled the wild-type localization, 
providing additional evidence that the gain of dileucine motif is indeed causative 
for the mislocalization of GLUT1_P485L (Figure 16; Experiment together with 
Jing-Yuan Cheng). 
 
Figure 16 GLUT1_P485L is a gain of function mutation. Mutating proline 485 of GLUT1 to 
alanine instead of leucine maintains the wild-type phenotype in transiently transfected HEK 293 
cells. Scale bar: 10 µm. 
GLUT1 mislocalizes in patient-derived induced 
pluripotent stem cells (iPSCs) 
All findings presented so far were either obtained in vitro or using stable cell 
lines that overexpress a tagged version of GLUT1. We were wondering if the 
same phenotype would be obtained also in a more physiological context. For 
this aim, we decided to turn to induced pluripotent stem cells from a patient 
carrying the GLUT1 P485L mutation. Patient fibroblasts were obtained via a skin 
punch from a GLUT1 deficient patient harboring the P485L mutation and were 
kindly obtained for us by her attending doctor (Juan M. Pascual, UT 
Southwestern Medical Center). Fibroblasts were then reprogrammed into iPSCs 
by RNA-based transfer of pluripotency markers (Sebastian Diecke, Core Facility 
Stem Cells, MDC) (Figure 17 A). Immunofluorescent staining of GLUT1 in control 
iPSCs showed predominant localization at the plasma membrane. Patient cells 
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additionally revealed characteristic intracellular GLUT1 accumulations (Figure 
17 B). This shows that also untagged GLUT1_P485L at physiological levels is 
differently localized when compared to the wild-type variant. Patient cells still 
show partial staining of the plasma membrane, which is in agreement with the 
fact that the patient carries a heterozygous GLUT1 mutation (Leen et al. 2010; 
Pascual et al. 2008; Slaughter, Vartzelis, and Arthur 2009) and the cells are 
most likely populated with wild-type as well as GLUT1_P485L variants. 
  
Figure 17 GLUT1_P485L shows intracellular mislocalization in iPSCs derived from a 
patient suffering from GLUT1 deficiency syndrome. A, A skin sample was taken from a 
GLUT1 deficiency patient with a heterozygous GLUT1_P485L mutation. Fibroblasts were grown 
and reprogrammed to iPSCs (Skin biopsy by Juan M. Pascual, generation of iPSCs by Sebastian 
Diecke). B, Heterozygous GLUT1_P485L mutation leads to partial mislocalization of GLUT1 in 
patient-derived iPSCs. Scale bars: 10µm. C and D, GLUT1_P485L colocalizes with the post-Golgi 
SNARE VTI1A. Scale bar: 10µm (C). Data represented as mean ± SD (D). 
Intracellular GLUT1_P485L colocalizes with VTI1A, a post-Golgi-SNARE that 
functions throughout the endocytic pathway. This is consistent with data from 
60 
 
 
stable HEK cells and shows that GLUT1_P485L mislocalizes to endocytic 
compartments. 
GLUT1 is not endocytosed from the plasma 
membrane in iPSCs 
However, while in HEK cells colocalization with almost all endocytic trafficking 
compartments can be detected (data from Jing-Yuan Cheng), in patient iPSCs 
GLUT1 is concentrated in a pattern resembling the trans-Golgi network (TGN). 
There also is no colocalization of GLUT1_P485L with fluorescently labeled 
transferrin (data not shown). This indicates that GLUT1_P485L in steady state 
is not actively involved in endocytic trafficking from the plasma membrane. In 
agreement with these findings, AP-2 knockdown did not have the same effect 
on GLUT1_P485L localization in iPSCs as in HEK cells (data not shown). On the 
contrary, it did not seem to affect the mutant’s localization at all. There could 
be different reasons for this (see Discussion). 
GLUT1_P485L localization at the blood-brain barrier is 
perturbed in vivo 
To show that GLUT1_P485L mislocalizes in its physiological environment and in 
a more physiological context of GLUT1 deficiency syndrome, we sought to study 
this mutant in endothelial cells of the blood-brain barrier in mice. To this end, 
we generated a mutant mouse harboring the GLUT1 P485L mutation via 
CRISPR/Cas9 technology (Figure 18 A; Mouse generated by Ralf Kuehn, 
Transgenic Core facility, MDC/BIH). Only heterozygous mice carrying the P485L 
mutation could be generated. These mice, however, appeared viable, fertile and 
did not display any obvious phenotype. We did not obtain any homozygous mice 
from six heterozygous crossings (genotyping with Martha Hergeselle). A more 
detailed inspection revealed that homozygous mutant pups come to term but 
are removed from the litter by the dams. To be able to compare the localization 
of GLUT1 in endothelial cells of the blood-brain barrier of wild-type, 
heterozygous and homozygous mutant mice, we carried out 
immunofluorescence stainings of the cerebral cortex in embryos of (E) 14.5-
15.5 days (staining by Luis R. Hernandez-Miranda). These stainings reveal an 
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apparent decrease in GLUT1 levels from wt to homozygous mutants. Vessel 
morphology and length appears normal, as shown by anti-ICAM2 staining to 
label the luminal plasma membrane and isolectin B4 (IB4) staining to label the 
entire endothelial plasma membrane (Figure 18 B). Anyhow, endothelial cells 
only have very narrow space in between the luminal and abluminal membranes, 
which is in fact too narrow to be resolved with standard confocal microscopy 
(Wong et al. 2013; Cox and Sheppard 2004). We employed super-resolution, 
stimulated emission depletion (STED) microscopy, which is able to resolve the 
distance between the two membrane layers (Figure 18 C; STED imaging and 
analysis by Anna Szymborzka). Quantification revealed that GLUT1 levels seem 
to drop slightly in heterozygous mice and are significantly reduced in 
homozygous mutants (Figure 18 D). 
This indicates that GLUT1 is removed from the plasma membrane in vivo and it 
disproves the possibility that GLUT1_P485L remains on the membrane causing 
disease because of its incapability to transport glucose. 
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Figure 18 GLUT1_P485L in endothelial cells of the blood-brain barrier in mice. A, A mouse 
carrying the GLUT1 P485L mutation was created by CRISPR/Cas9-targeted method. PAM 
sequence and gRNA are marked in the targeted region of Slc2a1 (GLUT1 gene). Sanger 
sequencing confirmed insertion of mutation (chromatogram A = green, T = red, C = blue, G = 
black) (Mouse generated by Ralf Kühn). B, Immunohistological analyses of cortical slices of wild-
type, heterozygous, and homozygous GLUT1 mutant mice using antibodies against GLUT1 (red) 
and DAPI (blue) as counterstain (left panels); a higher magnification of a vessel stained by 
antibodies against GLUT1 (red), IB4 (green), and ICAM2 (blue) is shown in the right panels. Scale 
bar: 100 µm (By Luis R. Hernandez-Miranda). C, Representative STED images of transverse cross-
sections through brain vessels of wild-type (+/+), heterozygous (+/P485L) and homozygous 
(P485L/P485L) mutant mice stained with isolectin B4 and antibodies against GLUT1 and ICAM2. 
Insets show a fragment of the abluminal membrane (IB4 positive, ICAM2 negative) indicated with 
a black box. Scale bars: 2 µm (main panels); 0.25 µm (insets). D, Quantification of GLUT1 signal 
relative to IB4 signal in vessel membranes (n, number of vessels per genotype; N, number of 
animals per genotype). Boxplot central line indicates the median, the bottom and top edges of 
the box indicate the 25th and 75th percentiles, respectively (STED imaging and analysis by Anna 
Szymborzka). 
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How common are dileucine gains in disease? 
Since we found three mutation-based dileucine gains in cytoplasmic tails of 
transmembrane proteins in our rather limited interaction screen, we were 
curious to see how many more potential “dileucineopathies” could be found in 
disease databases. We screened the Humsavar and Clinvar database for 
additional dileucine creating mutations in disordered cytosolic regions of 
transmembrane proteins. Taken together, we found eight additional mutations, 
four from Humsavar, and four from Clinvar (analysis by Bora Uyar). 
 
Figure 19 Dileucineopathies: dileucine motif gains in cytoplasmic regions of 
transmembrane proteins. A systematic bioinformatic search (in Humsvar and Clinvar 
databases) revealed a total of 11 pathogenic mutations in cytosolic segments of 8 different 
transmembrane proteins that create dileucine motifs (Analysis by Bora Uyar). See also: Table 5. 
These mutations affect a total of five additional proteins to the ones found in our 
screen (Figure 19; Table 5). Among these mutations are also two dileucine gains 
in the cytoplasmic domain of the cystic fibrosis transmembrane conductance 
regulator (CFTR) that lead to cystic fibrosis. Interestingly, an increased 
endocytosis rate of CFTR has already been reported to lead to cystic fibrosis (Silvis 
et al. 2003). In this study, the disease is caused by increased removal from the 
cell surface due to a novel tyrosine-based endocytic sequence within an 
intracellular loop in CFTR. One important question remaining is if the creation of 
a dileucine is actually disease causative or a mere irrelevant byproduct of disease 
mutations that are actually based on a different mechanism. If the latter were 
the case, we would expect an equal distribution of novel dileucine motifs in 
disease and in non-pathogenic polymorphism databases. In the case of functional 
dileucine motifs, on the other hand, we would expect them to be especially 
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enriched in their region of action, which are disordered regions of transmembrane 
proteins facing the cytoplasm. A global survey of all disordered regions of the 
entire proteome revealed that dileucine motif gains occurred at about the same 
rate in disease and non-pathogenic variants (OR = 0.81, p-value = 0.319, two-
sided Fisher’s Exact Test) (Figure 20 B). In the cytosolic tails of transmembrane 
proteins, however, we observed a 3.7-fold enrichment of dileucine motifs 
implicated in disease (OR = 3.7, p-value = 0.017, two-sided Fisher’s Exact Test, 
Figure 20 B). A comparison (disease-associated versus polymorphism) of all 
gained motifs in disordered regions of cytoplasmic tails of transmembrane 
proteins reveals the dileucine motif to have the most significant and specific 
enrichment (Figure 20 A). Interestingly, no double motif of any other amino acid 
is significantly enriched in the same kind of analysis (Table 3). 
 
Figure 20 Mutation-induced dileucine motifs are a significant cause of disease. 
A, Comparison of all gained motifs (disease-associated versus polymorphism) in disordered 
regions of cytoplasmic tails of transmembrane proteins reveals the dileucine motif to have the 
most significant and specific enrichment (Analysis based on Humsavar, by Bora Uyar). B, Relative 
frequency of dileucine motif gains in disease mutations and polymorphisms in different disordered 
regions (IUPred score >= 0.4) of the proteome. Dileucine motif gain is significantly enriched only 
in disordered regions of the cytoplasmic domains of transmembrane proteins (two-sided Fisher’s 
exact test; analysis by Bora Uyar). 
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Table 3 Enrichment of all amino acid duplicates in disease. Of all amino acids in cytoplasmic 
regions of transmembrane proteins, only double leucines are significantly enriched in disease 
(Analysis by Bora Uyar). 
SLiM Gain in disease 
All other 
disease 
mutations 
Gain in 
polymorphism 
All other 
polymorphisms p-value oddsRatio log2 oddsRatio 
diLeu 7 302 7 1121 0.0168 3.707 1.8903 
diArg 0 309 10 1118 0.1313 0.172 -2.5395 
diMet 1 308 0 1128 0.2150 10.974 3.4560 
diAsp 2 307 3 1125 0.2937 2.614 1.3863 
diGly 1 308 12 1116 0.3207 0.434 -1.2042 
diPro 1 308 12 1116 0.3207 0.434 -1.2042 
diSer 9 300 24 1104 0.3956 1.425 0.5110 
diLys 3 306 7 1121 0.4559 1.708 0.772 
diIle 0 309 5 1123 0.5911 0.33 -1.5995 
diVal 2 307 4 1124 0.6149 2.032 1.0229 
diAla 1 308 9 1119 0.6991 0.573 -0.803 
diThr 3 306 8 1120 0.7113 1.505 0.5898 
diGlu 4 305 12 1116 0.7597 1.316 0.3962 
diAsn 0 309 2 1126 1 0.728 -0.4580 
diCys 0 309 0 1128 1 1 0 
diGln 1 308 7 1121 1 0.727 -0.4600 
diHis 1 308 3 1125 1 1.564 0.6452 
diPhe 0 309 1 1127 1 1.214 0.2798 
diTrp 0 309 1 1127 1 1.214 0.2798 
diTyr 0 309 1 1127 1 1.214 0.2798 
Are dileucine mutations in other proteins functional? 
The question remains if these additional dileucine motif gains can cause 
mistrafficking similar to GLUT1_P485L. To show if the newly formed motifs are 
active in endocytosis, we performed antibody feeding experiments. To this end, 
we created chimeric constructs consisting of the IL-2 receptor alpha chain (TAC) 
fused to mutated and wild-type cytosolic regions of the respective disease 
protein (practical assistance for cloning from Martha Hergeselle). TAC protein is 
brought to the plasma membrane and the additional tail decides if the protein 
is subsequently internalized or if it stays at the plasma membrane. Cells 
expressing these proteins were incubated with antibodies against the 
extracellular region of TAC and, in case of an active endocytosis motif, allowed 
to endocytose the chimeric proteins together with bound antibodies. A specific 
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staining protocol was then used to exclusively detect internalized antibodies 
(Diril et al. 2009). We expect no uptake of the wild-type fusion proteins, but a 
visible staining pattern for the mutant versions. Of the eleven dileucine 
candidates, two motif gains had been excluded from the screen because they 
already contain a predicted endocytic motif in the wild-type sequence (according 
to prediction with ELM). Of the remaining nine, for one we could not obtain the 
correct construct. Of the remaining candidates, one was the fusion proteins for 
GLUT1 that served as a positive control plus seven additional dileucine motif 
gains. Four of the seven tested mutations resulted in increased internalization 
relative to the corresponding wild-type sequences (Figure 21). Three mutations, 
however, did not behave as expected. KCNQ1_R591, does not acquire 
endocytosis. This might indicate that a dileucine cannot be surrounded simply 
by any other amino acid to lead to a functional motif. ITPR1_P1059 and 
CFTR_P750, both already show endocytosis of the wild-type construct. In the 
case of CFTR_P750 this could be explained by the fact that the wt peptide 
contains a degenerate endocytosis motif EQGEAILPRISVIST. Kozik and 
colleagues have shown that in order to gain a functional motif the distance 
between acidic residue (E) and LL/IL can vary between two and four (Kozik et 
al. 2010). 
ITPR1_P1059L is a peptide stemming from the original peptide screen. It is a 
special case as is does not only contain a dileucine motif (E…LL) but also a so-
called clathrin box (L[IVLMF].[IVLMF][DE]). The wt peptide, however, does not 
even contain a degenerate version of the known motif. It is hence not clear why 
it shows endocytosis. However, both the original peptide screen and the PRM 
based analysis result in stronger recruitment of clathrin or APs by the mutant 
when compared to the wild-type. Even if the antibody uptake assay in its present 
form cannot be considered to be quantitative, it is intriguing to think that the 
mutant form seems to display a stronger staining pattern when compared to the 
wt. 
Collectively, these results indicate that several additional pathogenic dileucine 
motif gains cause protein mistrafficking. This makes us think that there might 
be a general concept of “dileucineopathies”. 
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Figure 21 Mutation-induced gains of dileucine motifs are a recurrent cause of disease. 
Antibody feeding indicates that four out of seven tested mutations with a gain of dileucine motif 
lead to a gain in endocytosis. Fluorescence signal comes from the internalized antibody. Surface-
exposed anti-TAC antigen was blocked prior to permeabilization. Scale bars: 10 µm. 
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Discussion 
The work presented here is, to the best of my knowledge, the first systematic 
experimental analysis of how mutations in disordered regions affect protein-
protein interactions. It includes a scalable proteomic screen that can (i) capture 
known interactions, (ii) detect how mutations in SLiMs affect binding of cognate 
domains and (iii) provide mechanistic insights into pathogenesis. 
Potentials and limitations of the peptide screen 
The two main advantages of the peptide-based interaction setup are its 
scalability, by using synthetic peptides, and specificity, by employing two 
quantitative filters. The importance of quantitative filters is illustrated by the 
control peptide. It is supposed to bind SH3 domain-containing proteins and 
application of the specificity filter got rid of non-SH3 containing proteins from 
otherwise SILAC differential interaction partners. The proteins that were 
discarded due to that threshold could be indirect interactors, at least they 
appear with low to medium confidence as interaction partners of remaining SH3 
domain-containing proteins in the STRING database (Szklarczyk et al. 2015). 
The approach presented here provides a powerful tool to study SLiM domain 
interactions that are typically weak or transient, for example, interactions 
between adaptors and sorting signals that have Kds in the micromolar range 
(Owen, Collins, and Evans 2004). It is also a helpful approach for cytosolic 
domains of large transmembrane proteins that are otherwise intrinsically 
difficult to study. The screen is able to capture interactions that are often 
overlooked in classical proteomics, where protein-protein interaction discovery 
is often based on tandem affinity purification tag (TAP-tag) or yeast two-hybrid 
(Y2H) experiments. Such methods are typically biased toward stable 
interactions (Diella et al. 2008; Landry et al. 2013; B. A. Liu, Engelmann, and 
Nash 2012; Neduva and Russell 2006; Tompa et al. 2014). In fact, 
GLUT1_P485L has been part of a large scale Y2H study (Sahni et al. 2015) and 
has not been found to gain interaction partners. Even if we did detect clathrin-
related proteins in our peptide-based interaction screen with shotgun analysis, 
we initially did not detect the APs responsible for the interaction. We were able 
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to detect them only with a more targeted approach. So the question remains 
how many other weak interactions we lost. 
Between gain and loss of function, the more prevalent concept in PPI studies in 
disease is arguably loss-of-function and loss-of-interaction studies. However, 
additional to the discovery of the loss of physiological protein-protein 
interactions, we have found a significant fraction of gains of interaction. Our 
approach is open to considering both directions of changes in PPIs. Reports of 
gain in interaction are so far rare in the literature.  
We made use of mutations stored in the OMIM database which contains many 
rare diseases. These are often understudied, but can in some way be considered 
“experiments of nature”. By studying changes in protein behavior, and especially 
protein-protein interactions, this thesis can help understanding disease 
mechanisms but potentially also basic functions of proteins. 
Even if the here employed peptide screen has many advantages, it is important 
to consider also the weaknesses of the approach. 
Every screen is only as good as its input. In the case presented here, the screen 
depends on the disease databases used to extract disease-causing mutations. 
Even though Humsavar is thought to be a gold standard in disease databases 
and to contain only disease-causing mutations, the picture might become more 
dispersed when diving into the literature. One of the dileucineopathy candidates 
in the original screen, CACNA1H_P648L, seems to be disease-causing, but then 
the authors of the original publication state that the patient inherited the 
mutation from one parent, but the parents show no symptoms. The authors 
provide a valid explanation for this, which, however, remains to be proven (Chen 
et al. 2003). Heron and colleagues even challenge the findings of Chen et al. 
(Heron et al. 2004). On the other hand, in support of the pathogenicity, another 
study found several mutations in CACNA1H responsible for epileptogenesis 
(Khosravani et al. 2004). 
In another incidence, L1CAM_S1194L has disappeared from the Humsavar 
variant database and is now listed as a natural variant in Uniprot, although still 
connected to disease and also linked to Clinvar, where it is categorized as 
pathogenic. 
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Inconsistencies like these highlight the difficulty of causal disease descriptions. 
However, the peptide array remains powerful in detecting changes in peptide-
protein interactions. If these changes can be tolerated by the cell or if they lead 
to disease remains to be shown for every single case by more in-depth follow-
up experiments. 
Additionally, the approach presented here is clearly an in vitro technique. The 
usage of cell lysate disperses spatial resolution and the local concentration of 
peptide or ligand is not necessarily physiological. Additionally, the chosen cell 
line might not contain all involved interaction partners or might bring together 
proteins that actually never meet in the cell. Also taking IDRs out of their protein 
context can in some cases change their behavior.  
Even if the screen harbors high potential for up-scalability a current bottleneck 
is the time needed for punching out single spots and the machine time needed 
to measure all samples in the mass spectrometer. A grid to punch out several 
spots at once could alleviate the first issue, while parallel injection could 
decrease run time up to 2-fold and TMT labeling would allow more samples to 
be analyzed in parallel, which could decrease measurement time up to 5-fold. 
Advances in machine performance will also decrease the runtime in the future. 
Very recently, it has been shown that 1000 proteins can be identified in a 5-
minute gradient (Meier et al. 2018), which would be sufficient for a low 
complexity pull-down sample and relates to an almost 10-fold decrease in 
measurement time. 
Potential applicability of the peptide screen 
SLiMs are relatively simple sequence patterns and may arise convergently and 
be lost rapidly in a short timescale (Davey, Travé, and Gibson 2011; Davey et 
al. 2012; Holt et al. 2009). This easy emergence might lead to ‘‘noisy’’ 
interactions without functional consequences (Landry et al. 2013; Levy, Landry, 
and Michnick 2009; Tompa et al. 2014), thus raising an important question: how 
many of the binding motifs, PTM sites, and interactions mediated by these 
modules are functionally relevant? Since the peptide screen presented here 
employs disease mutations it allows studying which motifs are functionally 
relevant. One point that was not considered in the current analysis, is that IDRs 
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and SLiMs often involve PTMs and mutations often affect modification sites 
(Radivojac et al. 2008; Narayan, Bader, and Reimand 2016). With the current 
set-up, PTMs on peptides could be studied in a controlled manner, circumventing 
the issue of modifications by endogenous proteins, which might occur in the 
case of overexpression studies. A triple SILAC approach could be used to 
compare interaction partners of wt-unmodified, wt-modified and mutated 
peptides. In this way, it could be studied how PTMs regulate dynamic 
interactions of the interactome by creating a new binding interface, modulate 
the affinity of existing binding surfaces either positively or negatively, and how 
mutations change either of those functions. With probably more than a million 
PTM instances in the human proteome (Tompa et al. 2014), this leaves a lot of 
room for further studies. 
Given that no interaction partner has been identified for ~75% of structural 
domain families there is a huge knowledge gap to be filled (Stein, Mosca, and 
Aloy 2011; Tompa et al. 2014). SLiMs are defined by such small information 
content that predicting them bioinformatically results in many false positives. 
Consequently, there are still rather few examples of bioinformatics discovery 
and subsequent experimental validation (Gibson et al. 2015). Large scale 
screens provide the opportunity to compare peptide sequences to protein 
domains in interacting proteins and hence the approach presented here could 
be used for motif discovery. A screen could be designed especially for that 
purpose and harbor many slight variations of the same sequence that could be 
tested for binding preferences. Here, TMT labeling could be of use again and 
provide the possibility to directly compare up to ten variations of similar 
sequences. 
In this project, the screen has been applied to neurological diseases but it is not 
restricted to that and can in the future be applied to other diseases or even non-
pathogenic polymorphisms. 
Is the choice of control peptides representative for the 
screen? 
Gibson and colleagues note that “protein-protein interactions they [SLiMs] 
mediate often depend on other factors, such as the PTM status of the motif and 
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the abundance of the interacting protein, both of which are not generally 
accounted for in experiments identifying interactions (Landry et al. 2013)” and 
that “this may not be an issue for certain protein domains, such as SH3 (Tonikian 
et al. 2009) and PDZ (Belotti et al. 2013), as the interactions they mediate are 
rather stable and are much better represented in HTSs [high-throughput 
studies]” (Tompa et al. 2014). This leads to the question if the choice of a poly-
proline containing peptide really reflects the whole spectrum of interaction. It 
undoubtedly shows that the peptide array can, in general, detect low-affinity 
interactions but more controls might be needed to study the applicability under 
different settings and under the range of different affinities. 
Open question on GLUT1_P485L 
Even if we were able to show that GLUT1_P485L mislocalized when compared 
to the wild-type form and the phenotype is partially rescued by AP-2 knockdown, 
the deeper we dig the more open questions come up. For example, 
GLUT1_P485L mislocalizes in HEK 293 cells and also in patient-derived iPSCs. 
The apparent localization, though, is slightly different and colocalization analysis 
shows that the mutant resides in different compartments. GLUT1_P485L also 
colocalizes with endocytosed transferrin in HEK 293 but not in iPSCs. 
Consistently, we were able to rescue GLUT1_P485L localization via AP-2 
knockdown in HEK 293 cells but not in iPSCs. It might be that due to different 
cellular conditions HEK and iPSC traffic wild-type GLUT1 differently. Since 
GLUT1_P485L carries only a single point mutation, it is likely that the 
characteristics of wt GLUT1 trafficking are maintained, while the newly gained 
dileucine motif adds clathrin-mediated trafficking. This would provide different 
access points for different APs at different locations in the cell. Wild-type GLUT1 
is trafficked in a clathrin-independent manner (Eyster et al. 2009; Maldonado-
Báez, Williamson, and Donaldson 2013). Although there is an exception when 
GLUT1 localization is controlled by thioredoxin-interacting protein (TXNIP). 
TXNIP itself contains a dileucine motif and binds to GLUT1 at the plasma 
membrane, where is recruits AP2 and clathrin to lead to endocytosis of GLUT1 
(Wu et al. 2013).  
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At this point, it is difficult to say which cellular system provides more valid 
information about the actual disease mechanism, since neither of the cell lines 
accurately reflects endothelial cells of the blood-brain barrier. To continue the 
study in a more physiological context, endothelial cells of the blood-brain barrier 
could be differentiated from iPSCs (Lippmann et al. 2012) and used to study 
GLUT1_P485L trafficking. The closest approach, however, to studies in patients 
are animal disease models. 
GLUT1_P485L in vivo 
Studies of GLUT1 at the blood-brain barrier (BBB) in vivo present their very own 
challenges. The endothelial cell thickness ranges from about 0.2 μm away from 
the nucleus to about 0.9 μm in the vicinity of the nucleus (in rat brain capillaries) 
(Wong et al. 2013), revealing that due to its resolution limit confocal microscopy 
is infeasible to study GLUT1 localization in this system (Cox and Sheppard 
2004). It is hence impossible to detect accumulations of GLUT1 in the cytosol 
or generally to distinguish the two different layers of the plasma membrane by 
confocal microscopy. We were, however, able to detect differences in GLUT1 
levels in brain sections of mouse embryos with a visible decrease from wild-type 
over heterozygous to homozygous mutants. We employed super-resolution 
STED microscopy to be able to differentiate between the membrane layers of 
endothelial cells of the BBB. STED analysis confirmed downregulation of GLUT1 
mutant levels, although it appeared to be significant only for the homozygous 
mutant. Anyways, we were not able to detect intracellular GLUT1. It might be 
that accumulations escaped our detection because of at least two different 
issues: (i) in comparison to cells in culture that grow flat on a surface and can 
easily be scanned entirely via z-stacks, endothelial cells in the brain span in 
different planes and it is much more challenging to image a cell in its entirety. 
Hence we might have been looking in the wrong planes. (ii) To detect a cell cut 
in the plane were accumulations might have formed, a microscopy technique 
that allows for scanning of the sample by eye is needed. This would be possible 
with confocal microscopy, which lacks sufficient resolution, and proved difficult 
with STED, where long wavelength emitting dyes are preferred that are not 
visible for the human eye. It is hence still possible that intracellular 
accumulations simply escaped our detection. 
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Interestingly, the apparent decrease in GLUT1 levels was not so apparent in 
adult mice, where there was no visible difference between wt and +/P485L mice 
with confocal and STED microscopy. P485L/P485L mice were not viable.  
In the future, it will be interesting to see if GLUT1 levels are decreased in the 
whole brain, for example by Western blot or mass spectrometry. If they are not 
decreased that could mean that accumulations are present in the cytoplasm, 
whereas a general decrease could mean that the P485L mutation ultimately 
leads to degradation of GLUT1. 
To validate the possibility to rescue the GLUT1_P485L phenotype. Mutant mice 
could be crossed with AP-2 deficient mice. The AP-2 knockout in mice is 
embryonically lethal (Mitsunari et al. 2005). However, a conditional AP-2 
knockout (Kononenko et al. 2014) could be used to knock out AP-2 selectively 
in endothelial cells of the BBB and potentially rescue the phenotype. This model 
could also be used to study potential differences in GLUT1 trafficking at different 
stages in development. 
Functionality of GLUT1 mutant 
One important factor for the potential treatment of GLUT1 deficiency syndrome 
by relocalization of GLUT1_P485L to the plasma membrane is the actual 
functionality of the mutant. In a different study, glucose uptake had been tested 
in erythrocytes of a GLUT1_P485L patient. The KM was found to be similar to the 
wild-type value but Vmax was at roughly half of the wild-type capacity (Pascual 
et al. 2008). Estimating changes in KM is raised difficult by factors such as 
subunit cooperativity arising from transporter polymerization (Coderre et al. 
1995). However, at this point, it is unclear if endocytosis might play a role in 
that system, too. To rule out any influence the mutant should be tested, for 
example, in Xenopus oocytes as for other mutants in (Pascual et al. 2008) or as 
in (E. E. Lee et al. 2015). 
In the study presented here, the rescue of GLUT1_P485L localization 
significantly increased the level of glucose uptake in a stable HEK 293 cell line. 
With the current set-up, however, no conclusions about the comparison of wild-
type and mutant GLUT1 can be made. The stable cell line expressed mutant 
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GLUT1 generally in lower amounts than the wild-type, which makes a 
comparison inadequate. 
Gain of dileucine motifs as a general disease 
mechanism 
The so-called dileucine motif [D/E]…L[L/I] in cytosolic tails of transmembrane 
proteins can recruit different adaptor proteins, depending on its previous cellular 
location. The motif is not very complex and can easily emerge by chance. 
Additionally, even a single LL can be functional (Kozik et al. 2010). 
In our peptide screen as well as in the bioinformatics analysis, dileucine motifs 
mostly emerged by mutation of proline to leucine. In our opinion this is due to 
two reasons. We were focusing on disordered regions and proline is the most 
disorder-promoting amino acid (Theillet et al. 2013). Also, proline codons can 
mutate into leucine codons by changes of a single nucleotide. Mutation of 
cytosine to uracil changes a proline CC[AUCG] to a leucine CU[AUGC]. 
Furthermore, the spontaneous deamination that converts cytosine to uracil or 
even worse 5-methylcytosine to thymine (Duncan and Miller 1980), is one of 
the most common DNA mutations. 
Gain of functional dileucine motifs can have different effects on proteins. Either, 
as in GLUT1_P485L, which is not normally involved in clathrin-mediated 
trafficking, it adds a completely new aspect to protein transport. In other cases, 
a trafficking motif can also emerge where other such motifs are already present 
and functional, and only disturb the finely balanced trafficking. As for example 
in CFTR, where a gain of a tyrosine-based endocytosis motif enhances trafficking 
kinetics and leads to cystic fibrosis (Silvis et al. 2003). 
Two of the proteins that we identified as candidates for dileucineopathies are 
mainly located at the ER. This raises the question about the functionality of the 
motif since the ER is not a target of clathrin-dependent trafficking. In general, 
trafficking of proteins is definitely not trivial and different variants (isoforms, 
modifications etc.) might be handled differently. The two proteins that mainly 
localize to the ER are RHBDF2 and ITPR1. Both of them, however, have been 
found also at other sites in the cell. RHBDF2 for example has also been shown 
to localize at the plasma membrane (Blaydon et al. 2012). ITPR1 was shown to 
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localize not only to the ER but also to the nuclear envelope, portions of the Golgi 
(Ross et al. 1989; Foskett, White, et al. 2007) and also to the plasma membrane 
(Tanimura, Tojyo, and Turner 2000; Dellis et al. 2006). The subcellular 
localization seems to be at least partially cell type dependent. The mutations 
might, therefore, affect the population of proteins that is not residing at the ER 
and thus cause disease. Of course, more detailed follow-up experiments are 
required to assess the impact of these mutations. Interestingly, a number of 
human neurodegenerative disorders such as Huntington’s disease, SCA2, and 
SCA3 have recently been related to dysregulated ITPR1 function due to 
abnormal protein interactions (Bezprozvanny 2011; Foskett, Kevin Foskett, et 
al. 2007; Higo et al. 2010; Schorge et al. 2010). Of note, even if a dileucine is 
gained in a cytosolic tail of a transmembrane protein, this does not automatically 
mean it will be a functional trafficking motif.  
There are several possibilities that might explain why we did not observe increased 
uptake for all dileucine candidates in the antibody feeding experiment. First, given 
the odds ratio of ~4 (Figure 20 B), it is not expected that all pathogenic dileucine 
motif gains cause disease by altering clathrin-dependent trafficking. Second, two 
of the mutation sites we tested (CFTR_P750, ITPR1_P1059) already showed uptake 
in the wild-type, which makes it difficult to assess the impact of the additionally 
gained dileucine motif. The CFTR_P750 peptide contains the sequence: E..E.IL, 
which closely resembles the dileucine motif and might explain endocytosis of the 
wild-type variant. In the disease context, these two mutations might still affect the 
kinetics of clathrin-dependent trafficking, as seen for a tyrosine-based 
internalization motif in CFTR (Silvis et al. 2003). A more quantitative method would 
be needed to assess differences in endocytosis rates. 
Understanding disease mechanisms makes diseases druggable. Especially in 
this case, where relocalization of potentially functional proteins might lead to 
full recovery of protein function. 
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Conclusion 
“It is becoming increasingly clear that we can often better understand the 
mechanistic impact of genomic variation on the functional proteome through 
using molecular interactions as a basic cellular functional unit, rather than 
functions of proteins as a whole.” Woodsmith and Stelzl 2017 
In this thesis, a screen on disease-causing mutations has revealed that the 
emergence of a leucine in cytoplasmic tails of transmembrane proteins can lead 
to the gain of a dileucine motif which can be recognized by the clathrin-mediated 
trafficking machinery and can lead to mislocalization of the protein. 
The broad applicability and potential of the peptide-based interaction screen will 
hopefully continue to help to unravel disease mechanisms also in the future. 
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Graphic novel 
  
  
For more than hundred 
thousand known, 
pathogenic mutations the 
actual disease mechanism 
is not known. 
Mutations in structured 
regions of proteins most 
likely lead to misfolding 
and loss of function... 
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...but what about 
mutations that fall into 
the disordered segments 
of the protein? 
Proteins interact to 
fulfill their tasks in the 
cells. Interactions can be 
mediated by disordered 
regions. 
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Mutations can lead to 
disruption of these 
interactions and might be 
an explanation for 
disease. 
There are so many 
proteins and interactions 
in the cell that we need a 
powerful method to study 
them. 
Mass spectrometry based 
proteomics is the perfect 
tool! 
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It helped us to find the 
needle in the haystack! 
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Some proteins function 
like gates to permit 
adequate supply of the 
cell with nutrients. 
In many diseases, gates 
are blocked, which leads 
to disease. 
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Mutations don’t always 
destroy; they can also 
create new things -- like 
tags that tell other 
proteins to transport the 
mutated protein to 
different places. 
If this happens to a gate, 
it might still be fully 
functional but sitting in 
the wrong place. This 
does not permit nutrient 
transport anymore! 
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Supplementary information 
Abbreviations 
AA Amino acid 
ABC Ammonium bicarbonate 
BBB Blood-brain barrier 
BirA Biotin-protein ligase 
CACNA1H Calcium Voltage-Gated Channel Subunit Alpha1 H 
CRISPR/Cas9 
Clustered regularly interspaced short palindromic repeats/CRISPR 
associated protein 9 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid) 
ER Endoplasmic reticulum 
FBS Fetal bovine serum 
FMP Leibniz-Forschungsinstitut für Molekulare Pharmakologie 
GLUT1 Glucose transporter 1 
HEK (293) Human embryonic kidney cells 293 
HRP Horseradish peroxidase 
IDP Intrinsically disordered protein 
IDR Intrinsically disordered region 
iPSC Inducible pluripotent stem cell 
ITPR1 Inositol 1,4,5-trisphosphate receptor type 1 
MDC 
Max Delbrück Center for Molecular Medicine in the Helmholtz 
Association 
mRNA Messenger RNA 
mut Mutant 
PCR Polymerase chain reaction 
PTM Post-translational modification 
SDS Sodium dodecyl sulfate 
siRNA Small (or short) interfering RNA 
SLC2A1 Solute carrier 2A1 
wt Wild-type 
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Supplementary tables 
Table 4 All peptide candidates included in the peptide-based interaction screen 
Disease name Gene name Peptide ID 
Peptidesequence 
(wt) 
Achalasia-addisonianism-alacrima syndrome 
(AAAS) [MIM:231550] 
AAAS Q9NRG9_Q15K PPPPPRGQVTLYEHN 
Aicardi-Goutieres syndrome 6 (AGS6) 
[MIM:615010] 
ADAR P55265_G1007R LRTKVENGEGTIPVE 
Aicardi-Goutieres syndrome 6 (AGS6) 
[MIM:615010] 
ADAR P55265_K999N FENPKQGKLRTKVEN 
Alternating hemiplegia of childhood 2 (AHC2) 
[MIM:614820] 
ATP1A3 P13637_D220N EPQTRSPDCTHDNPL 
Episodic ataxia 2 (EA2) [MIM:108500] CACNA1A O00555_R2135C VLGPKARRLDDYSLE 
Episodic ataxia 2 (EA2) [MIM:108500] CACNA1A O00555_P897R AELSREGPYGRESDH 
Epilepsy, childhood absence 6 (ECA6) 
[MIM:611942] 
CACNA1H O95180_A748V DPTRPPRATDTPGPG 
Epilepsy, childhood absence 6 (ECA6) 
[MIM:611942] 
CACNA1H O95180_P648L PGTGGHGPLSLNSPD 
Epilepsy, childhood absence 6 (ECA6) 
[MIM:611942] 
CACNA1H O95180_G499S PSAVQGQGPGHRQRR 
Mental retardation and microcephaly with 
pontine and cerebellar hypoplasia (MICPCH) 
[MIM:300749] 
CASK O14936_P396S KINTKSSPQIRNPPS 
Epilepsy, idiopathic generalized 8 (EIG8) 
[MIM:612899] 
CASR P41180_A988V EPQKNAMAHRNSTHQ 
Epilepsy, idiopathic generalized 8 (EIG8) 
[MIM:612899] 
CASR P41180_R898Q RSNVSRKRSSSLGGS 
Joubert syndrome 9 (JBTS9) [MIM:612285] CC2D2A Q9P2K1_P1122S TTAEGPNPSWNEELE 
Joubert syndrome 9 (JBTS9) [MIM:612285] CC2D2A Q9P2K1_T1114M FQRTVCHTTTAEGPN 
Epileptic encephalopathy, early infantile, 2 
(EIEE2) [MIM:300672] 
CDKL5 O76039_V718M RVGSFYRVPSPRPDN 
Epileptic encephalopathy, early infantile, 2 
(EIEE2) [MIM:300672] 
CDKL5 O76039_N399T STSKDLTNNNIPHLL 
Joubert syndrome 5 (JBTS5) [MIM:610188] CEP290 O15078_W7C MPPNINWKEIMKVDP 
Frontotemporal dementia and/or amyotrophic 
lateral sclerosis 2 (FTDALS2) [MIM:615911] 
CHCHD10 Q8WYQ3_P34S PPPSAAAPAPAPSGQ 
Amyotrophic lateral sclerosis 17 (ALS17) 
[MIM:614696] 
CHMP2B Q9UQN3_T104N KMAGAMSTTAKTMQA 
Amyotrophic lateral sclerosis 17 (ALS17) 
[MIM:614696] 
CHMP2B Q9UQN3_Q206H SDEEIERQLKALGVD 
Frontotemporal dementia, chromosome 3-
linked (FTD3) [MIM:600795] 
CHMP2B Q9UQN3_D148Y MINDTLDDIFDGSDD 
Ceroid lipofuscinosis, neuronal, 4A (CLN4A) 
[MIM:204300] 
CLN6 Q9NWW5_R6T MEATRRRQHLGATGG 
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Ceroid lipofuscinosis, neuronal, 8 (CLN8) 
[MIM:600143] 
CLN8 Q9UBY8_E269V DWNFAQPEAKSRPEG 
Hypomyelination with brainstem and spinal 
cord involvement and leg spasticity (HBSL) 
[MIM:615281] 
DARS P14868_R494G RQTSMFPRDPKRLTP 
Leukoencephalopathy with brainstem and 
spinal cord involvement and lactate elevation 
(LBSL) [MIM:611105] 
DARS2 Q6PI48_Y629C PPEELKPYHIRVSKP 
Epilepsy, familial focal, with variable foci 
(FFEVF) [MIM:604364] 
DEPDC5 O75140_S1073R SSAQSAESSSVAMTP 
Epilepsy, familial focal, with variable foci 
(FFEVF) [MIM:604364] 
DEPDC5 O75140_S1162G STNSSDSSSQQLVAS 
Epilepsy, familial focal, with variable foci 
(FFEVF) [MIM:604364] 
DEPDC5 O75140_A452V SPKESENALPIQVDY 
Dyskeratosis congenita, X-linked (DKCX) 
[MIM:305000] 
DKC1 O60832_G402R QGLLDKHGKPTDSTP 
Dyskeratosis congenita, X-linked (DKCX) 
[MIM:305000] 
DKC1 O60832_P409L GKPTDSTPATWKQEY 
Combined oxidative phosphorylation 
deficiency 12 (COXPD12) [MIM:614924] 
EARS2 Q5JPH6_E96K ENIEDMLEWAGIPPD 
Combined oxidative phosphorylation 
deficiency 12 (COXPD12) [MIM:614924] 
EARS2 Q5JPH6_R108W PPDESPRRGGPAGPY 
Combined oxidative phosphorylation 
deficiency 12 (COXPD12) [MIM:614924] 
EARS2 Q5JPH6_R168G PRYDNRCRNMSQEQV 
Neuropathy, congenital hypomyelinating or 
amyelinating (CHN) [MIM:605253] 
EGR2 P11161_I268N PLTPLSTIRNFTLGG 
Leukodystrophy with vanishing white matter 
(VWM) [MIM:603896] 
EIF2B5 Q13144_S447L NITLPEGSVISLHPP 
Parkinson disease 18 (PARK18) [MIM:614251] EIF4G1 Q04637_R1205H PSQPEGLRKAASLTE 
Xeroderma pigmentosum complementation 
group F (XP-F) [MIM:278760] 
ERCC4 Q92889_G513R EEGDVEEGYRREISS 
Cockayne syndrome B (CSB) [MIM:133540] ERCC6 Q03468_P1042L HLKRRIQPAFGADHD 
Pontocerebellar hypoplasia 1C (PCH1C) 
[MIM:616081] 
EXOSC8 Q96B26_S272T VKKLMDEVIKSMKPK 
Amyotrophic lateral sclerosis 6 (ALS6) 
[MIM:608030] 
FUS P35637_R521C DSRGEHRQDRRERPY 
Amyotrophic lateral sclerosis 6 (ALS6) 
[MIM:608030] 
FUS P35637_G507D GGDRGGFGPGKMDSR 
Tremor, hereditary essential 4 (ETM4) 
[MIM:614782] 
FUS P35637_R216C GQQDRGGRGRGGSGG 
Cerebral palsy, spastic quadriplegic 1 (CPSQ1) 
[MIM:603513] 
GAD1 Q99259_S12C TPSSSATSSNAGADP 
Leukodystrophy, globoid cell (GLD) 
[MIM:245200] 
GALC P54803_Y490N SQPFPSTYKDDFNVD 
Gaucher disease (GD) [MIM:230800] GBA P04062_R87W ESTRSGRRMELSMGP 
Glutaric aciduria 1 (GA1) [MIM:231670] GCDH Q92947_M191T SGSDPSSMETRAHYN 
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Dystonia, dopa-responsive (DRD) 
[MIM:128230] 
GCH1 P30793_P23L ARCSNGFPERDPPRP 
Dystonia, dopa-responsive (DRD) 
[MIM:128230] 
GCH1 P30793_R249S EDPKTREEFLTLIRS 
Parkinson disease 11 (PARK11) [MIM:607688] GIGYF2 Q6Y7W6_T112A TGRGGGGTVVGAPRG 
Parkinson disease 11 (PARK11) [MIM:607688] GIGYF2 Q6Y7W6_V1242I NHSTLHSVFQTNQSN 
Parkinson disease 11 (PARK11) [MIM:607688] GIGYF2 Q6Y7W6_D606E PPHMGELDQERLTRQ 
Charcot-Marie-Tooth disease, X-linked 
dominant, 1 (CMTX1) [MIM:302800] 
GJB1 P08034_R264C GSLKDILRRSPGTGA 
Charcot-Marie-Tooth disease, X-linked 
dominant, 1 (CMTX1) [MIM:302800] 
GJB1 P08034_C280G TGAGLAEKSDRCSAC 
Charcot-Marie-Tooth disease, X-linked 
dominant, 1 (CMTX1) [MIM:302800] 
GJB1 P08034_R230C RRSNPPSRKGSGFGH 
Epilepsy, focal, with speech disorder and with 
or without mental retardation (FESD) 
[MIM:245570] 
GRIN2A Q12879_D1251N NLYDIDEDQMLQETG 
Leukoencephalopathy, megalencephalic, with 
subcortical cysts, 2B (MLC2B) [MIM:613926] 
HEPACAM Q14CZ8_R288C YMDQNDDRLKPEADT 
Lesch-Nyhan syndrome (LNS) [MIM:300322] HPRT1 P00492_V8G MATRSPGVVISDDEP 
Charcot-Marie-Tooth disease 2F (CMT2F) 
[MIM:606595] 
HSPB1 P04792_T164A LSPEGTLTVEAPMPK 
Neuronopathy, distal hereditary motor, 2B 
(HMN2B) [MIM:608634] 
HSPB1 P04792_T151I LPPGVDPTQVSSSLS 
Short-rib thoracic dysplasia 9 with or without 
polydactyly (SRTD9) [MIM:266920] 
IFT140 Q96RY7_E664K EPRLFVCEAVQETPR 
Neuronopathy, distal hereditary motor, 6 
(HMN6) [MIM:604320] 
IGHMBP2 P38935_D974E AQLQRRLDKKLSELS 
Incontinentia pigmenti (IP) [MIM:308300] IKBKG Q9Y6K9_Q183H AASEQARQLESEREA 
Spinocerebellar ataxia 15 (SCA15) 
[MIM:606658] 
ITPR1 Q14643_P1059L GGSEENTPLDLDDHG 
Hypogonadotropic hypogonadism 1 with or 
without anosmia (HH1) [MIM:308700] 
KAL1 P23352_H672R LKHRHPHHYKPSPER 
Pallister-Hall syndrome (PHS) [MIM:146510] KIF7 Q2M1P5_P632L EEEEEEEPPRRTLHL 
Hydrocephalus due to stenosis of the 
aqueduct of Sylvius (HSAS) [MIM:307000] 
L1CAM P32004_S1194L AFGSSQPSLNGDIKP 
Charcot-Marie-Tooth disease 1C (CMT1C) 
[MIM:601098] 
LITAF Q99732_T49M GPTTGLVTGPDGKGM 
Frontotemporal dementia (FTD) 
[MIM:600274] 
MAPT P10636_L583V KIGSTENLKHQPGGG 
Frontotemporal dementia (FTD) 
[MIM:600274] 
MAPT P10636_V654M HKPGGGQVEVKSEKL 
Progressive supranuclear palsy 1 (PSNP1) 
[MIM:601104] 
MAPT P10636_R5L MAEPRQEFEVMEDHA 
Amyotrophic lateral sclerosis 21 (ALS21) 
[MIM:606070] 
MATR3 P43243_T622A SQKTESSTEGKEQEE 
Rett syndrome (RTT) [MIM:312750] MECP2 P51608_P225R GKLLVKMPFQTSPGG 
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Rett syndrome (RTT) [MIM:312750] MECP2 P51608_G161V DFDFTVTGRGSPSRR 
Rett syndrome (RTT) [MIM:312750] MECP2 P51608_E10Q AGMLGLREEKSEDQD 
Charcot-Marie-Tooth disease 2B2 (CMT2B2) 
[MIM:605589] 
MED25 Q71SY5_A335V LPPGPPGAPKPPPAS 
Dejerine-Sottas syndrome (DSS) 
[MIM:145900] 
MPZ P25189_A221T RQTPVLYAMLDHSRS 
Neurodegeneration with brain iron 
accumulation 1 (NBIA1) [MIM:234200] 
PANK2 Q9BZ23_E134G GRLGAPMERHGRASA 
Parkinson disease 2 (PARK2) [MIM:600116] PARK2 O60260_A82E RKGQEMNATGGDDPR 
Parkinson disease 2 (PARK2) [MIM:600116] PARK2 O60260_A92V GDDPRNAAGGCEREP 
Parkinson disease 6 (PARK6) [MIM:605909] PINK1 Q9BXM7_P196L GLLPGRGPGTSAPGE 
Neurodegeneration with brain iron 
accumulation 2B (NBIA2B) [MIM:610217] 
PLA2G6 O60733_R632W PSDQLVWRAARSSGA 
Boucher-Neuhauser syndrome (BNHS) 
[MIM:215470] 
PNPLA6 Q8IY17_R1350W EEEKSILRQRRCLPQ 
Progressive external ophthalmoplegia with 
mitochondrial DNA deletions, autosomal 
dominant, 1 (PEOA1) [MIM:157640] 
POLG P54098_S511N KKEPATASKLPIEGA 
Mitochondrial DNA depletion syndrome 4B 
(MTDPS4B) [MIM:613662] 
POLG P54098_T251I LIPLEVPTGASSPTQ 
Sensory ataxic neuropathy dysarthria and 
ophthalmoparesis (SANDO) [MIM:607459] 
POLG P54098_G517V ASKLPIEGAGAPGDP 
Gerstmann-Straussler disease (GSD) 
[MIM:137440] 
PRNP P04156_P102L THSQWNKPSKPKTNM 
Noonan syndrome 1 (NS1) [MIM:163950] PTPN11 Q06124_Y279C ENKNKNRYKNILPFD 
Noonan syndrome 1 (NS1) [MIM:163950] PTPN11 Q06124_E139D HGSFLVRESQSHPGD 
Noonan syndrome 1 (NS1) [MIM:163950] PTPN11 Q06124_L564F TSGDQSPLPPCTPTP 
Noonan syndrome 5 (NS5) [MIM:611553] RAF1 P04049_R256S GSLSQRQRSTSTPNV 
Coffin-Lowry syndrome (CLS) [MIM:303600] RPS6KA3 P51812_R729Q GRSTLAQRRGIKKIT 
Epileptic encephalopathy, early infantile, 6 
(EIEE6) [MIM:607208] 
SCN1A P35498_L1514S YYNAMKKLGSKKPQK 
Generalized epilepsy with febrile seizures plus 
2 (GEFS+2) [MIM:604403] 
SCN1A P35498_R27T ESLAAIERRIAEEKA 
Epileptic encephalopathy, early infantile, 6 
(EIEE6) [MIM:607208] 
SCN1A P35498_F63L EAGKNLPFIYGDIPP 
Schinzel-Giedion midface retraction syndrome 
(SGMFS) [MIM:269150] 
SETBP1 Q9Y6X0_G870S ETIPSDSGIGTDNNS 
Schinzel-Giedion midface retraction syndrome 
(SGMFS) [MIM:269150] 
SETBP1 Q9Y6X0_I871T TIPSDSGIGTDNNST 
Schinzel-Giedion midface retraction syndrome 
(SGMFS) [MIM:269150] 
SETBP1 Q9Y6X0_D868N SEETIPSDSGIGTDN 
Spinocerebellar ataxia, autosomal recessive, 
1 (SCAR1) [MIM:606002] 
SETX Q7Z333_Q653K SKEPMKVQDSVLIKA 
Spinocerebellar ataxia, autosomal recessive, 
1 (SCAR1) [MIM:606002] 
SETX Q7Z333_R1294C LGLKKGPRKAYELSQ 
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GLUT1 deficiency syndrome 1 (GLUT1DS1) 
[MIM:606777] 
SLC2A1 P11166_P485L TPEELFHPLGADSQV 
Niemann-Pick disease B (NPDB) 
[MIM:607616] 
SMPD1 P17405_A196P PSPPAPGAPVSRILF 
Amyotrophic lateral sclerosis 1 (ALS1) 
[MIM:105400] 
SOD1 P00441_D77Y RKHGGPKDEERHVGD 
Amyotrophic lateral sclerosis 1 (ALS1) 
[MIM:105400] 
SOD1 P00441_I152T NAGSRLACGVIGIAQ 
Amyotrophic lateral sclerosis 1 (ALS1) 
[MIM:105400] 
SOD1 P00441_G86R ERHVGDLGNVTADKD 
Spastic paraplegia 4, autosomal dominant 
(SPG4) [MIM:182601] 
SPAST Q9UBP0_P293L PTTHKGTPKTNRTNK 
Opitz GBBB syndrome 2 (GBBB2) 
[MIM:145410] 
SPECC1L Q69YQ0_T397P EVSVACLTERIHQME 
Microcephaly-capillary malformation 
syndrome (MICCAP) [MIM:614261] 
STAMBP O95630_R14P VSLPPEDRVRALSQL 
Spinocerebellar ataxia, autosomal recessive, 
16 (SCAR16) [MIM:615768] 
STUB1 Q9UNE7_E28K EKSPSAQELKEQGNR 
Isolated sulfite oxidase deficiency (ISOD) 
[MIM:272300] 
SUOX P51687_S427Y IQELPVQSAITEPRD 
Amyotrophic lateral sclerosis 10 (ALS10) 
[MIM:612069] 
TARDBP Q13148_G295S GFGNSRGGGAGLGNN 
Amyotrophic lateral sclerosis 10 (ALS10) 
[MIM:612069] 
TARDBP Q13148_G348C ASQQNQSGPSGNNQN 
Amyotrophic lateral sclerosis 10 (ALS10) 
[MIM:612069] 
TARDBP Q13148_G290A FGNQGGFGNSRGGGA 
Pitt-Hopkins syndrome (PTHS) [MIM:610954] TCF4 P15884_R565W KAEREKERRMANNAR 
Pitt-Hopkins syndrome (PTHS) [MIM:610954] TCF4 P15884_D535G SSEDKKLDDDKKDIK 
Pitt-Hopkins syndrome (PTHS) [MIM:610954] TCF4 P15884_G358V SPPSLSAGTAVWSRN 
Hereditary motor and sensory neuropathy, 
proximal type (HMSNP) [MIM:604484] 
TFG Q92734_P285L QQTGPQQPQQFQGYG 
Dyskeratosis congenita, autosomal dominant, 
3 (DKCA3) [MIM:613990] 
TINF2 Q9BSI4_K280E ASTRGGHKERPTVML 
Spinocerebellar ataxia 21 (SCA21) 
[MIM:607454] 
TMEM240 Q5SV17_P170L KQKLYHNGHPSPRHL 
Charcot-Marie-Tooth disease 2C (CMT2C) 
[MIM:606071] 
TRPV4 Q9HBA0_R315W PHKKADMRRQDSRGN 
Mitochondrial DNA depletion syndrome 1, 
MNGIE type (MTDPS1) [MIM:603041] 
TYMP P19971_R44Q PELIRMKRDGGRLSE 
Spinal muscular atrophy X-linked 2 (SMAX2) 
[MIM:301830] 
UBA1 P22314_S547G NPHIRVTSHQNRVGP 
Amyotrophic lateral sclerosis 15, with or 
without frontotemporal dementia (ALS15) 
[MIM:300857] 
UBQLN2 Q9UHD9_A283T QEPMLNAAQEQFGGN 
Amyotrophic lateral sclerosis 15, with or 
without frontotemporal dementia (ALS15) 
[MIM:300857] 
UBQLN2 Q9UHD9_P525S PTGPAAPPGSTGSGG 
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Combined oxidative phosphorylation 
deficiency 20 (COXPD20) [MIM:615917] 
VARS2 Q5ST30_A349T LPGDVAVAVHPDDSR 
Wolfram syndrome 1 (WFS1) [MIM:222300] WFS1 O76024_A58V GPGVRDAAAPAEPQA 
Spinocerebellar ataxia, autosomal recessive, 
12 (SCAR12) [MIM:614322] 
WWOX Q9NZC7_P47T EKTQWEHPKTGKRKR 
Wieacker-Wolf syndrome (WRWF) 
[MIM:314580] 
ZC4H2 Q9NQZ6_R213W CKAKSRSRNPKKPKR 
Mowat-Wilson syndrome (MOWS) 
[MIM:235730] 
ZEB2 O60315_Q1119R YLQSITPQGYSDSEE 
 
Table 5 Mutations in cytoplasmic regions of transmembrane proteins that lead to gain 
of dileucine motifs 
dbSNP Uniprot 
Accession 
Gene 
name 
Mutation Flanking 
sequence 
Disease 
- O95180 CACNA1H P648L PGTGGHGPLSLNSPD Epilepsy, childhood absence 6 
(ECA6) [MIM:611942] 
rs60734921 O95180 CACNA1H P618L MNYPTILPSGVGSGK Epilepsy, idiopathic 
generalized 6 (EIG6) 
[MIM:611942] 
rs193922501 P13569 CFTR P5L MQRSPLEKASVV Cystic fibrosis 
rs140455771 P13569 CFTR P750L EQGEAILPRISVIST Cystic fibrosis 
- Q14643 ITPR1 P1059L GGSEENTPLDLDDH
G 
Spinocerebellar ataxia 15 
(SCA15) [MIM:606658] 
rs145229963 P51787 KCNQ1 R452L CDPPEERRLDHFSVD not provided 
rs199472814 P51787 KCNQ1 R591L GSNTIGARLNRVEDK not provided 
rs137852522 P32004 L1CAM S1194L AFGSSQPSLNGDIKP Hydrocephalus due to 
stenosis of the aqueduct of 
Sylvius (HSAS) [MIM:307000] 
rs79853121 P07949 RET P1039L GLSEEETPLVDCNNA Congenital central 
hypoventilation syndrome 
(CCHS) [MIM:209880] 
rs387907130 Q6PJF5 RHBDF2 P189L KMPKIVDPLARGRAF Tylosis with esophageal 
cancer (TOC) [MIM:148500] 
- P11166 SLC2A1 P485L TPEELFHPLGADSQV GLUT1 deficiency syndrome 1 
(GLUT1DS1) [MIM:606777] 
 
See Meyer et al. 2018 for additional tables. 
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Key resources table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-FLAG Sigma-Aldrich Cat# F3165; 
RRID:AB_259529 
Rabbit polyclonal anti-GLUT1 Merck Millipore Cat# 07-1401; 
RRID:AB_1587074 
Rat monoclonal anti-ICAM2 BD Biosciences Cat# 553326; 
RRID:AB_394784 
Isolectin GS-IB4 Alexa Fluor 488 
conjugate (IB4) 
Thermo Fisher 
Scientific 
Cat# I21411; 
RRID:AB_2314662 
Mouse monoclonal anti-Vti1a BD Biosciences Cat# 611220; 
RRID:AB_398752 
Mouse monoclonal anti-Vti1b BD Biosciences Cat# 611405; 
RRID:AB_398927 
Rabbit polyclonal anti-EEA1 Cell Signaling 
Technology 
Cat# 2411S; 
RRID:AB_2096814 
Rabbit monoclonal anti-Rab4 Abcam Cat# ab13252; 
RRID:AB_2269374 
Rabbit monoclonal anti-Rab9 Cell Signaling 
Technology 
Cat# 5118S; 
RRID:AB_10621426 
Rabbit monoclonal anti-LAMP1 Cell Signaling 
Technology 
Cat# 9091; 
RRID:AB_2687579 
Mouse monoclonal anti-gamma 
Adaptin (AP-1 γ) 
BD Biosciences Cat# 610385; 
RRID:AB_397768 
Mouse monoclonal anti-AP50 (AP-2 µ) BD Biosciences Cat# 611351; 
RRID:AB_398873 
Mouse monoclonal anti- alpha Adaptin 
(AP-2 α) 
Thermo Fisher 
Scientific 
Cat# MA3-061; 
RRID:AB_2056321 
Mouse monoclonal anti-alpha Adaptin 
(AP-2 α) 
Abcam Cat# ab2730; 
RRID:AB_303255 
Mouse monoclonal anti - IL-2 R alpha 
(TAC) 
Santa Cruz 
Biotechnology 
Cat# sc-65258, 
RRID:AB_631112 
Chemicals, Peptides, and Recombinant Proteins 
 Deoxy-D-glucose, 2-[1,2-3H (N)]-, 
Specific Activity: 5-10 Ci (185-370 
GBq)/mmol, 250 µCi (9.25 MBq) 
Perkin Elmer  NET328250UC 
L-arginine-HCl (Arg0) Sigma-Aldrich A6969; CAS: 1119-34-2  
L-arginine-HCl(13C6) (Arg6) Sigma-Aldrich 643440; CAS: 201740-91-
2 
L-arginine-HCl(13C6,15N4) (Arg10) Sigma-Aldrich 608033; CAS: 202468-25-
5 
L-lysine-HCl (Lys0) Sigma-Aldrich L8662; CAS: 657-27-2 
L-lysine-2HCl(4,4,5,5-D4) (Lys4) Cambridge Isotope 
Laboratories 
DLM-2640-PK; CAS: 657-
26-1 
L-lysine-HCl(13C6,15N2) (Lys8) Silantes 211604102 
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Cytochalasin B Sigma-Aldrich C2743; CAS: 14930-96-2 
Deposited Data 
Peptide-protein interaction screen 
dataset 
Meyer et al. 2018  PXD010027 
PRM dataset Meyer et al. 2018  PXD010005 
BioID Meyer et al. 2018  PXD010061 
Experimental Models: Cell Lines 
Flp-In T-Rex GLUT1 Meyer et al. 2018 N/A 
Flp-In T-Rex GLUT1_P485L Meyer et al. 2018 N/A 
Human: Patient-derived iPSCs Meyer et al. 2018 https://hpscreg.eu/: 
BIHi037-(A-E) 
Experimental Models: Organisms 
Mouse: C57BL/6N: GLUT1_P485L   N/A 
Oligonucleotides 
ON-TARGETplus Human AP2M1 (1173) 
siRNA - SMARTpool 
Dharmacon Cat# L-008170-00-0005 
ON-TARGETplus Non-targeting Pool Dharmacon Cat# D-001810-10-05 
Recombinant DNA 
SLC2A1 (GLUT1) Harvard Plasmid 
Repository 
 HsCD00378964 
Software and Algorithms 
Imaris v8.4.1  Bitplane N/A 
MaxQuant v1.5.2.8 http://www.biochem.
mpg.de/5111795/max
quant 
Cox and Mann 2008 
  
94 
 
 
  
 95 
 
 
Acknowledgments 
I want to start with thanking Matthias Selbach for having been such an inspiring 
leader, scientist, and person, throughout the entire time of my Ph.D. The positive 
and supportive work environment he has created is unique and I am eternally 
grateful to have had the opportunity to carry out my Ph.D studies in his lab. This 
positive vibe has been wonderfully filled with life by all current and past 
members of the lab: Amir, Boris, Carlos, Christian, Christopher, Damir, Djordje, 
Erik, Florian, Fritz, Henrik, Jimmy, Joao, Kamila, Katrin, Koshi, Marie, Martha, 
Michal, Mirjam, Teresa and Tommaso. 
I would also like to thank all members of my Ph.D committee: Prof. Andreas 
Herrmann, Prof. Markus Landthaler, Prof. Matthias Selbach, Prof. Thomas 
Sommer and Dr. Bora Uyar for taking the time to read my dissertation and for 
participating in my defense. 
I was blessed with a very diligent and scientifically curious master student, Jing-
Yuan, who help me pushing the GLUT1 part of the project further. I want to 
especially thank Marie for starting off the project with me and being a great 
example on how to get things done; Martha, who always has always lent a 
helping hand and was the keeper of the cool in the most stressful situations; 
Christian, without whom the lab falls into pieces and who keeps everything (and 
everyone as Flying Ion Circus) running; Katrin, who took all the time in the 
world to introduce me to the lab and made my start in the lab really pleasant. 
She had to leave us way too early; Boris, who always had an open ear and the 
willingness to dive deep into projects to help out with new ideas.  
It was a pleasure to work together with all collaboration partners on this project 
and so overwhelming to see with how much energy and enthusiasm they 
contributed. I am also grateful to the patient and her family. Seeing that our 
work reaches real people is priceless. So many different people from other labs 
at the MDC offered their help simply out of kindness: Ouidad and Nouhad from 
Markus Landthaler’s lab generated stable cell lines. Jane Reznick spent a whole 
afternoon with me in the isotope lab to introduce me to radioactive glucose 
uptake. Many others helped out with reagents or borrowed their machines. 
96 
 
 
Koshi was so kind to host me in Japan for 2 months and provided me with an 
unforgettable experience at the end of my Ph.D. 
In general, this work would not have been possible without MDC’s great scientific 
infrastructure and experts for everything just next door. 
 
It’s not only help with the daily scientific tasks, but also mental support during 
a Ph.D’s ups and downs that make a real difference: Kamila, I would have never 
been able to do this without your hugs. Kamila and Michal, you are both my 
favorite conference/retreat roommates. Sharing experiences and talking with 
you and Erik about everything and anything made some big problems all of a 
sudden become small. 
The “Wednesday’s lunch” was a steady institution during the whole time of my 
Ph.D. Thank you, Anna, Giulia, Ina, and Julia. Sharing the dessert and the latest 
news with you was always a joy. 
Ale, you are my life- and work-illustrator of choice. Thank you for always being 
there for me. The biggest thanks go to my family, a constant source of support, 
even if they sometimes wonder what in the world happened so I would end up 
in a white coat. 
  
 97 
 
 
Selbständigkeitserklärung 
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig und nur unter 
Verwendung der angegebenen Hilfen und Hilfsmittel angefertigt habe. 
  
98 
 
 
  
 99 
 
 
References 
Alexa, A., and Rahnenfuhrer, J. 2016. “topGO: Enrichment Analysis for Gene Ontology. 
R package version 2.24.0. CRAN. 
Babu, M. Madan, Robin van der Lee, Natalia Sanchez de Groot, and Jörg Gsponer. 2011. 
“Intrinsically Disordered Proteins: Regulation and Disease.” Current Opinion in 
Structural Biology 21 (3): 432–40. 
Bantscheff, Marcus, Simone Lemeer, Mikhail M. Savitski, and Bernhard Kuster. 2012. 
“Quantitative Mass Spectrometry in Proteomics: Critical Review Update from 
2007 to the Present.” Analytical and Bioanalytical Chemistry 404 (4): 939–65. 
Bartke, Till, Michiel Vermeulen, Blerta Xhemalce, Samuel C. Robson, Matthias Mann, 
and Tony Kouzarides. 2010. “Nucleosome-Interacting Proteins Regulated by DNA 
and Histone Methylation.” Cell 143 (3): 470–84. 
Becerra, Andrés, Victor A. Bucheli, and Pedro A. Moreno. 2017. “Prediction of Virus-Host 
Protein-Protein Interactions Mediated by Short Linear Motifs.” BMC 
Bioinformatics 18 (1): 163. 
Belotti, Edwige, Jolanta Polanowska, Avais M. Daulat, Stéphane Audebert, Virginie Thomé, 
Jean-Claude Lissitzky, Frédérique Lembo, et al. 2013. “The Human PDZome: A 
Gateway to PSD95-Disc Large-Zonula Occludens (PDZ)-Mediated Functions.” 
Molecular & Cellular Proteomics: MCP 12 (9): 2587–2603. 
Bezprozvanny, Ilya. 2011. “Role of Inositol 1,4,5-Trishosphate Receptors in Pathogenesis 
of Huntington’s Disease and Spinocerebellar Ataxias.” Neurochemical Research 
36 (7): 1186–97. 
Blaydon, Diana C., Sarah L. Etheridge, Janet M. Risk, Hans-Christian Hennies, Laura J. 
Gay, Rebecca Carroll, Vincent Plagnol, et al. 2012. “RHBDF2 Mutations Are 
Associated with Tylosis, a Familial Esophageal Cancer Syndrome.” American 
Journal of Human Genetics 90 (2): 340–46. 
Boehr, David D., Ruth Nussinov, and Peter E. Wright. 2009. “The Role of Dynamic 
Conformational Ensembles in Biomolecular Recognition.” Nature Chemical 
Biology 5 (11): 789–96. 
Bonifacino, Juan S., and Raul Rojas. 2006. “Retrograde Transport from Endosomes to 
the Trans-Golgi Network.” Nature Reviews. Molecular Cell Biology 7 (8): 568–79. 
Boothby, Thomas C., Hugo Tapia, Alexandra H. Brozena, Samantha Piszkiewicz, Austin E. 
Smith, Ilaria Giovannini, Lorena Rebecchi, Gary J. Pielak, Doug Koshland, and Bob 
Goldstein. 2017. “Tardigrades Use Intrinsically Disordered Proteins to Survive 
Desiccation.” Molecular Cell 65 (6): 975–84.e5. 
Borgia, Alessandro, Madeleine B. Borgia, Katrine Bugge, Vera M. Kissling, Pétur O. 
Heidarsson, Catarina B. Fernandes, Andrea Sottini, et al. 2018. “Extreme 
Disorder in an Ultrahigh-Affinity Protein Complex.” Nature 555 (7694): 61–66. 
Buljan, Marija, Guilhem Chalancon, Sebastian Eustermann, Gunter P. Wagner, Monika 
Fuxreiter, Alex Bateman, and M. Madan Babu. 2012. “Tissue-Specific Splicing of 
Disordered Segments That Embed Binding Motifs Rewires Protein Interaction 
Networks.” Molecular Cell 46 (6): 871–83. 
Castro, Anna, Cyril Bernis, Suzanne Vigneron, Jean-Claude Labbé, and Thierry Lorca. 
2005. “The Anaphase-Promoting Complex: A Key Factor in the Regulation of Cell 
Cycle.” Oncogene 24 (3): 314–25. 
100 
 
 
Chen, Yucai, Jianjun Lu, Hong Pan, Yuehua Zhang, Husheng Wu, Keming Xu, Xiaoyan Liu, 
et al. 2003. “Association between Genetic Variation ofCACNA1H and Childhood 
Absence Epilepsy.” Annals of Neurology 54 (2): 239–43. 
Coderre, P. E., E. K. Cloherty, R. J. Zottola, and A. Carruthers. 1995. “Rapid Substrate 
Translocation by the Multisubunit, Erythroid Glucose Transporter Requires 
Subunit Associations but Not Cooperative Ligand Binding.” Biochemistry 34 (30): 
9762–73. 
Collins, Mark O., Lu Yu, Iain Campuzano, Seth G. N. Grant, and Jyoti S. Choudhary. 2008. 
“Phosphoproteomic Analysis of the Mouse Brain Cytosol Reveals a Predominance 
of Protein Phosphorylation in Regions of Intrinsic Sequence Disorder.” Molecular & 
Cellular Proteomics: MCP 7 (7): 1331–48. 
Cooper, Gregory M., and Jay Shendure. 2011. “Needles in Stacks of Needles: Finding 
Disease-Causal Variants in a Wealth of Genomic Data.” Nature Reviews. Genetics 
12 (9): 628–40. 
Costes, Sylvain V., Dirk Daelemans, Edward H. Cho, Zachary Dobbin, George Pavlakis, and 
Stephen Lockett. 2004. “Automatic and Quantitative Measurement of Protein-
Protein Colocalization in Live Cells.” Biophysical Journal 86 (6): 3993–4003. 
Couzens, Amber L., James D. R. Knight, Michelle J. Kean, Guoci Teo, Alexander Weiss, 
Wade H. Dunham, Zhen-Yuan Lin, et al. 2013. “Protein Interaction Network of 
the Mammalian Hippo Pathway Reveals Mechanisms of Kinase-Phosphatase 
Interactions.” Science Signaling 6 (302): rs15. 
Cox, Guy, and Colin J. R. Sheppard. 2004. “Practical Limits of Resolution in Confocal and 
Non-Linear Microscopy.” Microscopy Research and Technique 63 (1): 18–22. 
Cox, Jürgen, Marco Y. Hein, Christian A. Luber, Igor Paron, Nagarjuna Nagaraj, and Matthias 
Mann. 2014. “Accurate Proteome-Wide Label-Free Quantification by Delayed 
Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ.” Molecular & 
Cellular Proteomics: MCP 13 (9): 2513–26. 
Cox, Jürgen, and Matthias Mann. 2008. “MaxQuant Enables High Peptide Identification Rates, 
Individualized P.p.b.-Range Mass Accuracies and Proteome-Wide Protein 
Quantification.” Nature Biotechnology 26 (12): 1367–72. 
Cox, Jürgen, and Matthias Mann. 2011. “Quantitative, High-Resolution Proteomics for 
Data-Driven Systems Biology.” Annual Review of Biochemistry 80: 273–99. 
Craig, N. L. 1988. “The Mechanism of Conservative Site-Specific Recombination.” Annual 
Review of Genetics 22: 77–105. 
Davey, Norman E., Gilles Travé, and Toby J. Gibson. 2011. “How Viruses Hijack Cell 
Regulation.” Trends in Biochemical Sciences 36 (3): 159–69. 
Davey, Norman E., Kim Van Roey, Robert J. Weatheritt, Grischa Toedt, Bora Uyar, Brigitte 
Altenberg, Aidan Budd, Francesca Diella, Holger Dinkel, and Toby J. Gibson. 
2012. “Attributes of Short Linear Motifs.” Molecular bioSystems 8 (1): 268–81. 
Dellis, Olivier, Skarlatos G. Dedos, Stephen C. Tovey, Taufiq-Ur-Rahman, Stefan J. 
Dubel, and Colin W. Taylor. 2006. “Ca2+ Entry through Plasma Membrane IP3 
Receptors.” Science 313 (5784): 229–33. 
Deng, Hao, Kai Gao, and Joseph Jankovic. 2014. “The Role of FUS Gene Variants in 
Neurodegenerative Diseases.” Nature Reviews. Neurology 10 (6): 337–48. 
De Vivo, Darryl C., Rosario R. Trifiletti, Ronald I. Jacobson, Gabriel M. Ronen, Ramin A. 
Behmand, and Sami I. Harik. 1991. “Defective Glucose Transport across the 
Blood-Brain Barrier as a Cause of Persistent Hypoglycorrhachia, Seizures, and 
Developmental Delay.” The New England Journal of Medicine 325 (10): 703–9. 
 101 
 
 
Diella, Francesca, Niall Haslam, Claudia Chica, Aidan Budd, Sushama Michael, Nigel P. 
Brown, Gilles Trave, and Toby J. Gibson. 2008. “Understanding Eukaryotic Linear 
Motifs and Their Role in Cell Signaling and Regulation.” Frontiers in Bioscience: A 
Journal and Virtual Library 13 (May): 6580–6603. 
Dinkel, Holger, Kim Van Roey, Sushama Michael, Norman E. Davey, Robert J. Weatheritt, 
Diana Born, Tobias Speck, et al. 2014. “The Eukaryotic Linear Motif Resource 
ELM: 10 Years and Counting.” Nucleic Acids Research 42 (Database issue): 
D259–66. 
Dinkel, Holger, Kim Van Roey, Sushama Michael, Manjeet Kumar, Bora Uyar, Brigitte 
Altenberg, Vladislava Milchevskaya, et al. 2016. “ELM 2016--Data Update and 
New Functionality of the Eukaryotic Linear Motif Resource.” Nucleic Acids 
Research 44 (D1): D294–300. 
Diril, Muhammed Kasim, Stefan Schmidt, Michael Krauss, Verena Gawlik, Hans-Georg 
Joost, Annette Schürmann, Volker Haucke, and Robert Augustin. 2009. 
“Lysosomal Localization of GLUT8 in the Testis--the EXXXLL Motif of GLUT8 Is 
Sufficient for Its Intracellular Sorting via AP1- and AP2-Mediated Interaction.” 
The FEBS Journal 276 (14): 3729–43. 
Dittmar, Gunnar, Daniel Perez-Hernandez, Elisabeth Kowenz-Leutz, Marieluise Kirchner, 
Guenther Kahlert, Radoslaw Wesolowski, Katharina Baum, et al. 2017. “Protein 
Interaction Screen on Peptide Matrix (PRISMA) Reveals Interaction Footprints 
and the PTM-Dependent Interactome of Intrinsically Disordered C/EBPβ.” 
https://doi.org/10.1101/238709. 
Dormann, Dorothee, Ramona Rodde, Dieter Edbauer, Eva Bentmann, Ingeborg Fischer, 
Alexander Hruscha, Manuel E. Than, et al. 2010. “ALS-Associated Fused in 
Sarcoma (FUS) Mutations Disrupt Transportin-Mediated Nuclear Import.” The 
EMBO Journal 29 (16): 2841–57. 
Dosztanyi, Z., B. Meszaros, and I. Simon. 2009. “Bioinformatical Approaches to 
Characterize Intrinsically Disordered/unstructured Proteins.” Briefings in 
Bioinformatics 11 (2): 225–43. 
Dosztányi, Zsuzsanna. 2018. “Prediction of Protein Disorder Based on IUPred.” Protein 
Science: A Publication of the Protein Society 27 (1): 331–40. 
Dosztányi, Zsuzsanna, Veronika Csizmok, Peter Tompa, and István Simon. 2005. “IUPred: 
Web Server for the Prediction of Intrinsically Unstructured Regions of Proteins 
Based on Estimated Energy Content.” Bioinformatics  21 (16): 3433–34. 
Duncan, Bruce K., and Jeffrey H. Miller. 1980. “Mutagenic Deamination of Cytosine 
Residues in DNA.” Nature 287 (5782): 560–61. 
Dyson, H. Jane, and Peter E. Wright. 2002. “Coupling of Folding and Binding for 
Unstructured Proteins.” Current Opinion in Structural Biology 12 (1): 54–60. 
Dyson, H. Jane, and Peter E. Wright. 2005. “Intrinsically Unstructured Proteins and Their 
Functions.” Nature Reviews. Molecular Cell Biology 6 (3): 197–208. 
Eyster, Craig A., Jason D. Higginson, Robert Huebner, Natalie Porat-Shliom, Roberto 
Weigert, Wells W. Wu, Rong-Fong Shen, and Julie G. Donaldson. 2009. 
“Discovery of New Cargo Proteins That Enter Cells through Clathrin-Independent 
Endocytosis.” Traffic  10 (5): 590–99. 
Fabbro, Megan, and Beric R. Henderson. 2003. “Regulation of Tumor Suppressors by 
Nuclear-Cytoplasmic Shuttling.” Experimental Cell Research 282 (2): 59–69. 
Famiglietti, Maria Livia, Anne Estreicher, Arnaud Gos, Jerven Bolleman, Sébastien 
Géhant, Lionel Breuza, Alan Bridge, et al. 2014. “Genetic Variations and Diseases 
102 
 
 
in UniProtKB/Swiss-Prot: The Ins and Outs of Expert Manual Curation.” Human 
Mutation 35 (8): 927–35. 
Fields, S., and O. Song. 1989. “A Novel Genetic System to Detect Protein-Protein 
Interactions.” Nature 340 (6230): 245–46. 
Foskett, J. Kevin, J. Kevin Foskett, Carl White, King-Ho Cheung, and Don-On Daniel Mak. 
2007. “Inositol Trisphosphate Receptor Ca2 Release Channels.” Physiological 
Reviews 87 (2): 593–658. 
Foskett, J. Kevin, Carl White, King-Ho Cheung, and Don-On Daniel Mak. 2007. “Inositol 
Trisphosphate Receptor Ca2+ Release Channels.” Physiological Reviews 87 (2): 
593–658. 
Francavilla, Chiara, Kristoffer T. G. Rigbolt, Kristina B. Emdal, Gianni Carraro, Erik 
Vernet, Dorte B. Bekker-Jensen, Werner Streicher, et al. 2013. “Functional 
Proteomics Defines the Molecular Switch Underlying FGF Receptor Trafficking and 
Cellular Outputs.” Molecular Cell 51 (6): 707–22. 
Frank, Ronald. 1992. “Spot-Synthesis: An Easy Technique for the Positionally 
Addressable, Parallel Chemical Synthesis on a Membrane Support.” Tetrahedron 
48 (42): 9217–32. 
Frank, Ronald. 2002. “The SPOT-Synthesis Technique. Synthetic Peptide Arrays on 
Membrane Supports--Principles and Applications.” Journal of Immunological 
Methods 267 (1): 13–26. 
Fuchs, Serge Y., Vladimir S. Spiegelman, and K. G. Suresh Kumar. 2004. “The Many 
Faces of Beta-TrCP E3 Ubiquitin Ligases: Reflections in the Magic Mirror of 
Cancer.” Oncogene 23 (11): 2028–36. 
Fuxreiter, Monika, Peter Tompa, and István Simon. 2007. “Local Structural Disorder Imparts 
Plasticity on Linear Motifs.” Bioinformatics  23 (8): 950–56. 
Gandhi, T. K. B., Jun Zhong, Suresh Mathivanan, L. Karthick, K. N. Chandrika, S. Sujatha 
Mohan, Salil Sharma, et al. 2006. “Analysis of the Human Protein Interactome 
and Comparison with Yeast, Worm and Fly Interaction Datasets.” Nature Genetics 
38 (3): 285–93. 
Gardner, Mckinlay, Melanie Knight, Kenju Hara, Shoji Tsuji, Susan Forrest, and Elsdon Storey. 
2005. “Spinocerebellar Ataxia Type 15.” Cerebellum  4 (1): 47–50. 
Gibson, Toby J., Holger Dinkel, Kim Van Roey, and Francesca Diella. 2015. “Experimental 
Detection of Short Regulatory Motifs in Eukaryotic Proteins: Tips for Good 
Practice as Well as for Bad.” Cell Communication and Signaling: CCS 13 
(November): 42. 
Gingras, Anne-Claude, Matthias Gstaiger, Brian Raught, and Ruedi Aebersold. 2007. 
“Analysis of Protein Complexes Using Mass Spectrometry.” Nature Reviews. 
Molecular Cell Biology 8 (8): 645–54. 
Gould, Cathryn M., Francesca Diella, Allegra Via, Pål Puntervoll, Christine Gemünd, 
Sophie Chabanis-Davidson, Sushama Michael, et al. 2010. “ELM: The Status of 
the 2010 Eukaryotic Linear Motif Resource.” Nucleic Acids Research 38 (Database 
issue): D167–80. 
Gsponer, Jörg, Matthias E. Futschik, Sarah A. Teichmann, and M. Madan Babu. 2008. 
“Tight Regulation of Unstructured Proteins: From Transcript Synthesis to Protein 
Degradation.” Science 322 (5906): 1365–68. 
Gstaiger, Matthias, and Ruedi Aebersold. 2009. “Applying Mass Spectrometry-Based 
Proteomics to Genetics, Genomics and Network Biology.” Nature Reviews. 
Genetics 10 (9): 617–27. 
 103 
 
 
Guettler, Sebastian, Jose LaRose, Evangelia Petsalaki, Gerald Gish, Andy Scotter, Tony 
Pawson, Robert Rottapel, and Frank Sicheri. 2011. “Structural Basis and 
Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for 
Cherubism Disease.” Cell 147 (6): 1340–54. 
Hara, K., A. Shiga, H. Nozaki, J. Mitsui, Y. Takahashi, H. Ishiguro, H. Yomono, et al. 
2008. “Total Deletion and a Missense Mutation of ITPR1 in Japanese SCA15 
Families.” Neurology 71 (8): 547–51. 
He, Bo, Kejun Wang, Yunlong Liu, Bin Xue, Vladimir N. Uversky, and A. Keith Dunker. 
2009. “Predicting Intrinsic Disorder in Proteins: An Overview.” Cell Research 19 
(8): 929–49. 
Hernández-Miranda, Luis R., Anna Cariboni, Clare Faux, Christiana Ruhrberg, Jin Hyung 
Cho, Jean-François Cloutier, Britta J. Eickholt, John G. Parnavelas, and William D. 
Andrews. 2011. “Robo1 Regulates Semaphorin Signaling to Guide the Migration of 
Cortical Interneurons through the Ventral Forebrain.” The Journal of Neuroscience: 
The Official Journal of the Society for Neuroscience 31 (16): 6174–87. 
Heron, Sarah E., Hilary A. Phillips, John C. Mulley, Aziz Mazarib, Miriam Y. Neufeld, 
Samuel F. Berkovic, and Ingrid E. Scheffer. 2004. “Genetic Variation of CACNA1H 
in Idiopathic Generalized Epilepsy.” Annals of Neurology 55 (4): 595–96. 
Higo, Takayasu, Kozo Hamada, Chihiro Hisatsune, Nobuyuki Nukina, Tsutomu 
Hashikawa, Mitsuharu Hattori, Takeshi Nakamura, and Katsuhiko Mikoshiba. 
2010. “Mechanism of ER Stress-Induced Brain Damage by IP(3) Receptor.” 
Neuron 68 (5): 865–78. 
Hilpert, Kai, Dirk F. H. Winkler, and Robert E. W. Hancock. 2007. “Peptide Arrays on 
Cellulose Support: SPOT Synthesis, a Time and Cost Efficient Method for 
Synthesis of Large Numbers of Peptides in a Parallel and Addressable Fashion.” 
Nature Protocols 2 (6): 1333–49. 
Hirst, Jennifer, Georg H. H. Borner, Robin Antrobus, Andrew A. Peden, Nicola A. Hodson, 
Daniela A. Sahlender, and Margaret S. Robinson. 2012. “Distinct and Overlapping 
Roles for AP-1 and GGAs Revealed by the ‘Knocksideways’ System.” Current 
Biology: CB 22 (18): 1711–16. 
Holt, Liam J., Brian B. Tuch, Judit Villén, Alexander D. Johnson, Steven P. Gygi, and 
David O. Morgan. 2009. “Global Analysis of Cdk1 Substrate Phosphorylation Sites 
Provides Insights into Evolution.” Science 325 (5948): 1682–86. 
Hosp, Fabian, Hannes Vossfeldt, Matthias Heinig, Djordje Vasiljevic, Anup Arumughan, 
Emanuel Wyler, Genetic and Environmental Risk for Alzheimer’s Disease GERAD1 
Consortium, et al. 2015. “Quantitative Interaction Proteomics of 
Neurodegenerative Disease Proteins.” Cell Reports 11 (7): 1134–46. 
Hunt T. 1990 Protein sequence motifs involved in recognition and targeting: a new 
series. Trends Biochem. Sci.15:305. 
Iakoucheva, L. M., P. Radivojac, C. J. Brown, T. R. O’Connor, J. G. Sikes, Z. Obradovic, 
and A. K. Dunker. 2004. “The Importance of Intrinsic Disorder for Protein 
Phosphorylation.” Nucleic Acids Research 32 (3): 1037–49. 
Ingram, V. M. 1957. “Gene Mutations in Human Hæmoglobin: The Chemical Difference 
Between Normal and Sickle Cell Hæmoglobin.” Nature 180 (4581): 326–28. 
Ittner, Lars M., and Jürgen Götz. 2007. “Pronuclear Injection for the Production of 
Transgenic Mice.” Nature Protocols 2 (5): 1206–15. 
Kaake, Robyn M., Xiaorong Wang, Anthony Burke, Clinton Yu, Wynne Kandur, Yingying 
Yang, Eric J. Novtisky, et al. 2014. “A New in Vivo Cross-Linking Mass 
104 
 
 
Spectrometry Platform to Define Protein-Protein Interactions in Living Cells.” 
Molecular & Cellular Proteomics: MCP 13 (12): 3533–43. 
Kadaveru, Krishna, Jay Vyas, and Martin R. Schiller. 2008. “Viral Infection and Human 
Disease--Insights from Minimotifs.” Frontiers in Bioscience: A Journal and Virtual 
Library 13 (May): 6455–71. 
Keane, Harriet, Brent J. Ryan, Brendan Jackson, Alan Whitmore, and Richard Wade-
Martins. 2015. “Protein-Protein Interaction Networks Identify Targets Which 
Rescue the MPP+ Cellular Model of Parkinson’s Disease.” Scientific Reports 5 
(November): 17004. 
Keilhauer, Eva C., Marco Y. Hein, and Matthias Mann. 2015. “Accurate Protein Complex 
Retrieval by Affinity Enrichment Mass Spectrometry (AE-MS) rather than Affinity 
Purification Mass Spectrometry (AP-MS).” Molecular & Cellular Proteomics: MCP 
14 (1): 120–35. 
Kelly, Bernard T., and David J. Owen. 2011. “Endocytic Sorting of Transmembrane Protein 
Cargo.” Current Opinion in Cell Biology 23 (4): 404–12. 
Kenworthy, A. K. 2001. “Imaging Protein-Protein Interactions Using Fluorescence 
Resonance Energy Transfer Microscopy.” Methods  24 (3): 289–96. 
Khosravani, Houman, Christophe Altier, Brett Simms, Kevin S. Hamming, Terrance P. 
Snutch, Janette Mezeyova, John E. McRory, and Gerald W. Zamponi. 2004. 
“Gating Effects of Mutations in the Cav3.2 T-Type Calcium Channel Associated 
with Childhood Absence Epilepsy.” The Journal of Biological Chemistry 279 (11): 
9681–84. 
Köhler, Sebastian, Nicole A. Vasilevsky, Mark Engelstad, Erin Foster, Julie McMurry, 
Ségolène Aymé, Gareth Baynam, et al. 2017. “The Human Phenotype Ontology 
in 2017.” Nucleic Acids Research 45 (D1): D865–76. 
Kononenko, Natalia L., Dmytro Puchkov, Gala A. Classen, Alexander M. Walter, Arndt 
Pechstein, Linda Sawade, Natalie Kaempf, et al. 2014. “Clathrin/AP-2 Mediate 
Synaptic Vesicle Reformation from Endosome-like Vacuoles but Are Not Essential 
for Membrane Retrieval at Central Synapses.” Neuron 82 (5): 981–88. 
Kozik, Patrycja, Richard W. Francis, Matthew N. J. Seaman, and Margaret S. Robinson. 
2010. “A Screen for Endocytic Motifs.” Traffic  11 (6): 843–55. 
Landrum, Melissa J., Jennifer M. Lee, Mark Benson, Garth Brown, Chen Chao, Shanmuga 
Chitipiralla, Baoshan Gu, et al. 2016. “ClinVar: Public Archive of Interpretations 
of Clinically Relevant Variants.” Nucleic Acids Research 44 (D1): D862–68. 
Landry, Christian R., Emmanuel D. Levy, Diala Abd Rabbo, Kirill Tarassov, and Stephen 
W. Michnick. 2013. “Extracting Insight from Noisy Cellular Networks.” Cell 155 
(5): 983–89. 
Lau, Ho-Tak, Hyong Won Suh, Martin Golkowski, and Shao-En Ong. 2014. “Comparing 
SILAC- and Stable Isotope Dimethyl-Labeling Approaches for Quantitative 
Proteomics.” Journal of Proteome Research 13 (9): 4164–74. 
Lee, Eunice E., Jing Ma, Anastasia Sacharidou, Wentao Mi, Valerie K. Salato, Nam 
Nguyen, Youxing Jiang, et al. 2015. “A Protein Kinase C Phosphorylation Motif in 
GLUT1 Affects Glucose Transport and Is Mutated in GLUT1 Deficiency Syndrome.” 
Molecular Cell 58 (5): 845–53. 
Leen, Wilhelmina G., Joerg Klepper, Marcel M. Verbeek, Maike Leferink, Tom Hofste, 
Baziel G. van Engelen, Ron A. Wevers, et al. 2010. “Glucose Transporter-1 
Deficiency Syndrome: The Expanding Clinical and Genetic Spectrum of a 
Treatable Disorder.” Brain: A Journal of Neurology 133 (Pt 3): 655–70. 
 105 
 
 
Lee, Robin van der, Marija Buljan, Benjamin Lang, Robert J. Weatheritt, Gary W. 
Daughdrill, A. Keith Dunker, Monika Fuxreiter, et al. 2014. “Classification of 
Intrinsically Disordered Regions and Proteins.” Chemical Reviews 114 (13): 
6589–6631. 
Levy, Emmanuel D., Christian R. Landry, and Stephen W. Michnick. 2009. “How Perfect 
Can Protein Interactomes Be?” Science Signaling 2 (60): e11. 
Lippmann, Ethan S., Samira M. Azarin, Jennifer E. Kay, Randy A. Nessler, Hannah K. 
Wilson, Abraham Al-Ahmad, Sean P. Palecek, and Eric V. Shusta. 2012. 
“Derivation of Blood-Brain Barrier Endothelial Cells from Human Pluripotent Stem 
Cells.” Nature Biotechnology 30 (8): 783–91. 
Liu, Bernard A., Brett W. Engelmann, and Piers D. Nash. 2012. “High-Throughput 
Analysis of Peptide-Binding Modules.” Proteomics 12 (10): 1527–46. 
Liu, Xiaonan, Kari Salokas, Fitsum Tamene, Yaming Jiu, Rigbe G. Weldatsadik, Tiina Öhman, 
and Markku Varjosalo. 2018. “An AP-MS- and BioID-Compatible MAC-Tag Enables 
Comprehensive Mapping of Protein Interactions and Subcellular Localizations.” 
Nature Communications 9 (1): 1188. 
Lyon, Kenneth F., Xingyu Cai, Richard J. Young, Abdullah-Al Mamun, Sanguthevar 
Rajasekaran, and Martin R. Schiller. 2018. “Minimotif Miner 4: A Million Peptide 
Minimotifs and Counting.” Nucleic Acids Research 46 (D1): D465–70. 
Maldonado-Báez, Lymarie, Chad Williamson, and Julie G. Donaldson. 2013. “Clathrin-
Independent Endocytosis: A Cargo-Centric View.” Experimental Cell Research 
319 (18): 2759–69. 
Malty, Ramy H., Hiroyuki Aoki, Ashwani Kumar, Sadhna Phanse, Shahreen Amin, 
Qingzhou Zhang, Zoran Minic, et al. 2017. “A Map of Human Mitochondrial 
Protein Interactions Linked to Neurodegeneration Reveals New Mechanisms of 
Redox Homeostasis and NF-κB Signaling.” Cell Systems 5 (6): 564–77.e12. 
Mann, Matthias. 2006. “Functional and Quantitative Proteomics Using SILAC.” Nature 
Reviews. Molecular Cell Biology 7 (12): 952–58. 
McLaren, William, Laurent Gil, Sarah E. Hunt, Harpreet Singh Riat, Graham R. S. Ritchie, 
Anja Thormann, Paul Flicek, and Fiona Cunningham. 2016. “The Ensembl Variant 
Effect Predictor.” Genome Biology 17 (1): 122. 
Meier, Florian, Andreas-David Brunner, Scarlet Koch, Heiner Koch, Markus Lubeck, 
Michael Krause, Niels Goedecke, et al. 2018. “Online Parallel Accumulation − 
Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass 
Spectrometer.” https://doi.org/10.1101/336743. 
Meyer, Katrina, Marieluise Kirchner, Bora Uyar, Jing-Yuan Cheng, Giulia Russo, Luis R. 
Hernandez-Miranda, Anna Szymborska, et al. 2018. “Mutations in Disordered 
Regions Can Cause Disease by Creating Dileucine Motifs.” Cell, August. 
https://doi.org/10.1016/j.cell.2018.08.019. 
Mitsunari, Takashi, Fubito Nakatsu, Noriko Shioda, Paul E. Love, Alexander Grinberg, 
Juan S. Bonifacino, and Hiroshi Ohno. 2005. “Clathrin Adaptor AP-2 Is Essential 
for Early Embryonal Development.” Molecular and Cellular Biology 25 (21): 
9318–23. 
Motley, Alison, Nicholas A. Bright, Matthew N. J. Seaman, and Margaret S. Robinson. 
2003. “Clathrin-Mediated Endocytosis in AP-2–depleted Cells.” The Journal of Cell 
Biology 162 (5): 909–18. 
Narayan, Soumil, Gary D. Bader, and Jüri Reimand. 2016. “Frequent Mutations in 
Acetylation and Ubiquitination Sites Suggest Novel Driver Mechanisms of 
Cancer.” Genome Medicine 8 (1): 55. 
106 
 
 
Neduva, Victor, Rune Linding, Isabelle Su-Angrand, Alexander Stark, Federico de Masi, 
Toby J. Gibson, Joe Lewis, Luis Serrano, and Robert B. Russell. 2005. “Systematic 
Discovery of New Recognition Peptides Mediating Protein Interaction Networks.” 
PLoS Biology 3 (12): e405. 
Neduva, Victor, and Robert B. Russell. 2006. “Peptides Mediating Interaction Networks: 
New Leads at Last.” Current Opinion in Biotechnology 17 (5): 465–71. 
Okada, Hirokazu, Akiyoshi Uezu, Erik J. Soderblom, M. Arthur Moseley 3rd, Frank B. Gertler, 
and Scott H. Soderling. 2012. “Peptide Array X-Linking (PAX): A New Peptide-Protein 
Identification Approach.” PloS One 7 (5): e37035. 
Owen, David J., Brett M. Collins, and Philip R. Evans. 2004. “ADAPTORS FOR CLATHRIN 
COATS: Structure and Function.” Annual Review of Cell and Developmental 
Biology 20 (1): 153–91. 
Pajkos, Mátyás, Bálint Mészáros, István Simon, and Zsuzsanna Dosztányi. 2012. “Is 
There a Biological Cost of Protein Disorder? Analysis of Cancer-Associated 
Mutations.” Molecular bioSystems 8 (1): 296–307. 
Pandey, Kailash N. 2009. “Functional Roles of Short Sequence Motifs in the Endocytosis 
of Membrane Receptors.” Frontiers in Bioscience  14 (June): 5339–60. 
Park, Sang Yoon, and Xiaoli Guo. 2014. “Adaptor Protein Complexes and Intracellular 
Transport.” Bioscience Reports 34 (4): 381–90. 
Pascual, Juan M., Dong Wang, Ru Yang, Lei Shi, Hong Yang, and Darryl C. De Vivo. 2008. 
“Structural Signatures and Membrane Helix 4 in GLUT1.” The Journal of Biological 
Chemistry 283 (24): 16732–42. 
Pasternak, Jack J. 2005. An Introduction to Human Molecular Genetics: Mechanisms of 
Inherited Diseases. John Wiley & Sons. 
Paul, Florian E., Fabian Hosp, and Matthias Selbach. 2011. “Analyzing Protein-Protein 
Interactions by Quantitative Mass Spectrometry.” Methods  54 (4): 387–95. 
Peden, Andrew A., Viola Oorschot, Boris A. Hesser, Cary D. Austin, Richard H. Scheller, 
and Judith Klumperman. 2004. “Localization of the AP-3 Adaptor Complex 
Defines a Novel Endosomal Exit Site for Lysosomal Membrane Proteins.” The 
Journal of Cell Biology 164 (7): 1065–76. 
Pierce, M. M., C. S. Raman, and B. T. Nall. 1999. “Isothermal Titration Calorimetry of 
Protein-Protein Interactions.” Methods  19 (2): 213–21. 
Puig, O., F. Caspary, G. Rigaut, B. Rutz, E. Bouveret, E. Bragado-Nilsson, M. Wilm, and 
B. Séraphin. 2001. “The Tandem Affinity Purification (TAP) Method: A General 
Procedure of Protein Complex Purification.” Methods  24 (3): 218–29. 
Puntervoll, P. 2003. “ELM Server: A New Resource for Investigating Short Functional 
Sites in Modular Eukaryotic Proteins.” Nucleic Acids Research 31 (13): 3625–30. 
Radivojac, P., P. H. Baenziger, M. G. Kann, M. E. Mort, M. W. Hahn, and S. D. Mooney. 
2008. “Gain and Loss of Phosphorylation Sites in Human Cancer.” Bioinformatics  
24 (16): i241–47. 
Raiborg, Camilla, and Harald Stenmark. 2009. “The ESCRT Machinery in Endosomal 
Sorting of Ubiquitylated Membrane Proteins.” Nature 458 (7237): 445–52. 
Rappsilber, Juri, Yasushi Ishihama, and Matthias Mann. 2003. “Stop and Go Extraction 
Tips for Matrix-Assisted Laser Desorption/ionization, Nanoelectrospray, and LC/MS 
Sample Pretreatment in Proteomics.” Analytical Chemistry 75 (3): 663–70. 
Reimand, Jüri, and Gary D. Bader. 2013. “Systematic Analysis of Somatic Mutations in 
Phosphorylation Signaling Predicts Novel Cancer Drivers.” Molecular Systems 
Biology 9: 637. 
 107 
 
 
Rhee, Hyun-Woo, Peng Zou, Namrata D. Udeshi, Jeffrey D. Martell, Vamsi K. Mootha, 
Steven A. Carr, and Alice Y. Ting. 2013. “Proteomic Mapping of Mitochondria in 
Living Cells via Spatially Restricted Enzymatic Tagging.” Science 339 (6125): 
1328–31. 
Romero, Pedro R., Saima Zaidi, Ya Yin Fang, Vladimir N. Uversky, Predrag Radivojac, 
Christopher J. Oldfield, Marc S. Cortese, et al. 2006. “Alternative Splicing in Concert 
with Protein Intrinsic Disorder Enables Increased Functional Diversity in Multicellular 
Organisms.” Proceedings of the National Academy of Sciences of the United States 
of America 103 (22): 8390–95. 
Romero, P., Z. Obradovic, X. Li, E. C. Garner, C. J. Brown, and A. K. Dunker. 2001. 
“Sequence Complexity of Disordered Protein.” Proteins 42 (1): 38–48. 
Ross, Christopher A., Jacopo Meldolesi, Teresa A. Milner, Tomohide Satoh, Surachai 
Supattapone, and Solomon H. Snyder. 1989. “Inositol 1,4,5-Trisphosphate 
Receptor Localized to Endoplasmic Reticulum in Cerebellar Purkinje Neurons.” 
Nature 339 (6224): 468–70. 
Roux, Kyle J., Dae In Kim, Brian Burke, and Danielle G. May. 2018. “BioID: A Screen for 
Protein-Protein Interactions.” Current Protocols in Protein Science / Editorial 
Board, John E. Coligan ... [et Al.] 91 (February): 19.23.1–19.23.15. 
Roux, Kyle J., Dae In Kim, Manfred Raida, and Brian Burke. 2012. “A Promiscuous Biotin 
Ligase Fusion Protein Identifies Proximal and Interacting Proteins in Mammalian 
Cells.” The Journal of Cell Biology 196 (6): 801–10. 
Sahni, Nidhi, Song Yi, Mikko Taipale, Juan I. Fuxman Bass, Jasmin Coulombe-
Huntington, Fan Yang, Jian Peng, et al. 2015. “Widespread Macromolecular 
Interaction Perturbations in Human Genetic Disorders.” Cell 161 (3): 647 60. 
Sarkar, Debasree, Tanmoy Jana, and Sudipto Saha. 2015. “LMPID: A Manually Curated 
Database of Linear Motifs Mediating Protein–protein Interactions.” Database 
2015. https://doi.org/10.1093/database/bav014. 
Sauer, B. 1994. “Site-Specific Recombination: Developments and Applications.” Current 
Opinion in Biotechnology 5 (5): 521–27. 
Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark 
Longair, Tobias Pietzsch, Stephan Preibisch, et al. 2012. “Fiji: An Open-Source 
Platform for Biological-Image Analysis.” Nature Methods 9 (7): 676–82. 
Schorge, Stephanie, Joyce van de Leemput, Andrew Singleton, Henry Houlden, and John 
Hardy. 2010. “Human Ataxias: A Genetic Dissection of Inositol Triphosphate 
Receptor (ITPR1)-Dependent Signaling.” Trends in Neurosciences 33 (5): 211–19. 
Schulze, Waltraud X., and Matthias Mann. 2004. “A Novel Proteomic Screen for Peptide-
Protein Interactions.” The Journal of Biological Chemistry 279 (11): 10756–64. 
Schuster-Böckler, Benjamin, and Alex Bateman. 2008. “Protein Interactions in Human 
Genetic Diseases.” Genome Biology 9 (1): R9. 
Schwanhäusser, Björn, Dorothea Busse, Na Li, Gunnar Dittmar, Johannes Schuchhardt, 
Jana Wolf, Wei Chen, and Matthias Selbach. 2011. “Global Quantification of 
Mammalian Gene Expression Control.” Nature 473 (7347): 337–42. 
Seet, Bruce T., and Tony Pawson. 2004. “MAPK Signaling: Sho Business.” Current 
Biology: CB 14 (17): R708–10. 
Seidner, G., M. G. Alvarez, J. I. Yeh, K. R. O’Driscoll, J. Klepper, T. S. Stump, D. Wang, 
N. B. Spinner, M. J. Birnbaum, and D. C. De Vivo. 1998. “GLUT-1 Deficiency 
Syndrome Caused by Haploinsufficiency of the Blood-Brain Barrier Hexose 
Carrier.” Nature Genetics 18 (2): 188–91. 
108 
 
 
Selbach, Matthias, Florian Ernst Paul, Sabine Brandt, Patrick Guye, Oliver Daumke, 
Steffen Backert, Christoph Dehio, and Matthias Mann. 2009. “Host Cell 
Interactome of Tyrosine-Phosphorylated Bacterial Proteins.” Cell Host & Microbe 
5 (4): 397–403. 
Seo, Moon-Hyeong, and Philip M. Kim. 2018. “The Present and the Future of Motif-
Mediated Protein–protein Interactions.” Current Opinion in Structural Biology 50: 
162–70. 
Shannon, Paul, Andrew Markiel, Owen Ozier, Nitin S. Baliga, Jonathan T. Wang, Daniel 
Ramage, Nada Amin, Benno Schwikowski, and Trey Ideker. 2003. “Cytoscape: A 
Software Environment for Integrated Models of Biomolecular Interaction Networks.” 
Genome Research 13 (11): 2498–2504. 
Sharma, Aarti, Alexander K. Lyashchenko, Lei Lu, Sara Ebrahimi Nasrabady, Margot 
Elmaleh, Monica Mendelsohn, Adriana Nemes, Juan Carlos Tapia, George Z. 
Mentis, and Neil A. Shneider. 2016. “ALS-Associated Mutant FUS Induces 
Selective Motor Neuron Degeneration through Toxic Gain of Function.” Nature 
Communications 7 (February): 10465. 
Shi, Jun, and Konstantin V. Kandror. 2008. “Study of Glucose Uptake in Adipose Cells.” 
Methods in Molecular Biology  456: 307–15. 
Sickmeier, M., J. A. Hamilton, T. LeGall, V. Vacic, M. S. Cortese, A. Tantos, B. Szabo, et 
al. 2007. “DisProt: The Database of Disordered Proteins.” Nucleic Acids Research 
35 (Database): D786–93. 
Silvis, Mark R., John A. Picciano, Carol Bertrand, Kelly Weixel, Robert J. Bridges, and 
Neil A. Bradbury. 2003. “A Mutation in the Cystic Fibrosis Transmembrane 
Conductance Regulator Generates a Novel Internalization Sequence and 
Enhances Endocytic Rates.” The Journal of Biological Chemistry 278 (13): 
11554–60. 
Slaughter, Laurel, George Vartzelis, and Todd Arthur. 2009. “New GLUT-1 Mutation in a 
Child with Treatment-Resistant Epilepsy.” Epilepsy Research 84 (2-3): 254–56. 
Staudt, Catherine, Emeline Puissant, and Marielle Boonen. 2016. “Subcellular Trafficking 
of Mammalian Lysosomal Proteins: An Extended View.” International Journal of 
Molecular Sciences 18 (1). https://doi.org/10.3390/ijms18010047. 
Stein, Amelie, Roberto Mosca, and Patrick Aloy. 2011. “Three-Dimensional Modeling of 
Protein Interactions and Complexes Is Going ’Omics.” Current Opinion in 
Structural Biology 21 (2): 200–208. 
Storey, E., R. J.M. Gardner, M. A. Knight, M. L. Kennerson, R. R. Tuck, S. M. Forrest, and 
G. A. Nicholson. 2001. “A New Autosomal Dominant Pure Cerebellar Ataxia.” 
Neurology 57 (10): 1913–15. 
Subramanian, Sankar, and Sudhir Kumar. 2006. “Evolutionary Anatomies of Positions 
and Types of Disease-Associated and Neutral Amino Acid Mutations in the Human 
Genome.” BMC Genomics 7 (December): 306. 
Sury, Matthias D., Jia-Xuan Chen, and Matthias Selbach. 2010. “The SILAC Fly Allows 
for Accurate Protein Quantification in Vivo.” Molecular & Cellular Proteomics: MCP 
9 (10): 2173–83. 
Szklarczyk, Damian, Andrea Franceschini, Stefan Wyder, Kristoffer Forslund, Davide 
Heller, Jaime Huerta-Cepas, Milan Simonovic, et al. 2015. “STRING v10: Protein-
Protein Interaction Networks, Integrated over the Tree of Life.” Nucleic Acids 
Research 43 (Database issue): D447–52. 
 109 
 
 
Tanimura, A., Y. Tojyo, and R. J. Turner. 2000. “Evidence That Type I, II, and III Inositol 
1,4,5-Trisphosphate Receptors Can Occur as Integral Plasma Membrane 
Proteins.” The Journal of Biological Chemistry 275 (35): 27488–93. 
Theillet, Francois-Xavier, Lajos Kalmar, Peter Tompa, Kyou-Hoon Han, Philipp Selenko, 
A. Keith Dunker, Gary W. Daughdrill, and Vladimir N. Uversky. 2013. “The 
Alphabet of Intrinsic Disorder: I. Act like a Pro: On the Abundance and Roles of 
Proline Residues in Intrinsically Disordered Proteins.” Intrinsically Disordered 
Proteins 1 (1): e24360. 
Theos, Alexander C., Danièle Tenza, José A. Martina, Ilse Hurbain, Andrew A. Peden, 
Elena V. Sviderskaya, Abigail Stewart, et al. 2005. “Functions of Adaptor Protein 
(AP)-3 and AP-1 in Tyrosinase Sorting from Endosomes to Melanosomes.” 
Molecular Biology of the Cell 16 (11): 5356–72. 
Tompa, Peter. 2002. “Intrinsically Unstructured Proteins.” Trends in Biochemical 
Sciences 27 (10): 527–33. 
Tompa, Peter. 2011. “Unstructural Biology Coming of Age.” Current Opinion in Structural 
Biology 21 (3): 419–25. 
Tompa, Peter, Norman E. Davey, Toby J. Gibson, and M. Madan Babu. 2014. “A Million 
Peptide Motifs for the Molecular Biologist.” Molecular Cell 55 (2): 161–69. 
Tonikian, Raffi, Xiaofeng Xin, Christopher P. Toret, David Gfeller, Christiane Landgraf, 
Simona Panni, Serena Paoluzi, et al. 2009. “Bayesian Modeling of the Yeast SH3 
Domain Interactome Predicts Spatiotemporal Dynamics of Endocytosis Proteins.” 
PLoS Biology 7 (10): e1000218. 
Toprak, Umut H., Ludovic C. Gillet, Alessio Maiolica, Pedro Navarro, Alexander Leitner, 
and Ruedi Aebersold. 2014. “Conserved Peptide Fragmentation as a 
Benchmarking Tool for Mass Spectrometers and a Discriminating Feature for 
Targeted Proteomics.” Molecular & Cellular Proteomics: MCP 13 (8): 2056–71. 
Traub, Linton M. 2009. “Tickets to Ride: Selecting Cargo for Clathrin-Regulated 
Internalization.” Nature Reviews. Molecular Cell Biology 10 (9): 583–96. 
Traub, Linton M., and Juan S. Bonifacino. 2013. “Cargo Recognition in Clathrin-Mediated 
Endocytosis.” Cold Spring Harbor Perspectives in Biology 5 (11): a016790. 
Tripathi, Shashank, Marie O. Pohl, Yingyao Zhou, Ariel Rodriguez-Frandsen, Guojun 
Wang, David A. Stein, Hong M. Moulton, et al. 2015. “Meta- and Orthogonal 
Integration of Influenza ‘OMICs’ Data Defines a Role for UBR4 in Virus Budding.” 
Cell Host & Microbe 18 (6): 723–35. 
UniProt Consortium. 2012. “Reorganizing the Protein Space at the Universal Protein 
Resource (UniProt).” Nucleic Acids Research 40 (Database issue): D71–75. 
Uversky, Vladimir N. 2015. “Intrinsically Disordered Proteins and Their (disordered) 
Proteomes in Neurodegenerative Disorders.” Frontiers in Aging Neuroscience 7 
(March): 18. 
Uversky, V. N., J. R. Gillespie, and A. L. Fink. 2000. “Why Are ‘Natively Unfolded’ Proteins 
Unstructured under Physiologic Conditions?” Proteins 41 (3): 415–27. 
Uyar, Bora, Robert J. Weatheritt, Holger Dinkel, Norman E. Davey, and Toby J. Gibson. 
2014. “Proteome-Wide Analysis of Human Disease Mutations in Short Linear 
Motifs: Neglected Players in Cancer?” Molecular bioSystems 10 (10): 2626–42. 
Vacic, Vladimir, and Lilia M. Iakoucheva. 2012. “Disease Mutations in Disordered 
Regions--Exception to the Rule?” Molecular bioSystems 8 (1): 27–32. 
Vacic, Vladimir, Phineus R. L. Markwick, Christopher J. Oldfield, Xiaoyue Zhao, Chad Haynes, 
Vladimir N. Uversky, and Lilia M. Iakoucheva. 2012. “Disease-Associated Mutations 
110 
 
 
Disrupt Functionally Important Regions of Intrinsic Protein Disorder.” PLoS 
Computational Biology 8 (10): e1002709. 
Van Roey, Kim, Holger Dinkel, Robert J. Weatheritt, Toby J. Gibson, and Norman E. Davey. 
2013. “The switches.ELM Resource: A Compendium of Conditional Regulatory 
Interaction Interfaces.” Science Signaling 6 (269): rs7. 
Van Roey, Kim, Toby J. Gibson, and Norman E. Davey. 2012. “Motif Switches: Decision-
Making in Cell Regulation.” Current Opinion in Structural Biology 22 (3): 378–
85. 
Van Roey, Kim, Sandra Orchard, Samuel Kerrien, Marine Dumousseau, Sylvie Ricard-
Blum, Henning Hermjakob, and Toby J. Gibson. 2013. “Capturing Cooperative 
Interactions with the PSI-MI Format.” Database: The Journal of Biological 
Databases and Curation 2013 (September): bat066. 
Vavouri, Tanya, Jennifer I. Semple, Rosa Garcia-Verdugo, and Ben Lehner. 2009. 
“Intrinsic Protein Disorder and Interaction Promiscuity Are Widely Associated 
with Dosage Sensitivity.” Cell 138 (1): 198–208. 
Veltman, Joris A., and Han G. Brunner. 2012. “De Novo Mutations in Human Genetic 
Disease.” Nature Reviews. Genetics 13 (8): 565–75. 
Venter, J. C. 2001. “The Sequence of the Human Genome.” Science 291 (5507): 1304–
51. 
Vermeulen, Michiel, Nina C. Hubner, and Matthias Mann. 2008. “High Confidence 
Determination of Specific Protein-Protein Interactions Using Quantitative Mass 
Spectrometry.” Current Opinion in Biotechnology 19 (4): 331–37. 
Vidal, Marc, Michael E. Cusick, and Albert-László Barabási. 2011. “Interactome Networks 
and Human Disease.” Cell 144 (6): 986–98. 
Vidal, M., J. L. Montiel, D. Cussac, F. Cornille, M. Duchesne, F. Parker, B. Tocqué, B. P. 
Roques, and C. Garbay. 1998. “Differential Interactions of the Growth Factor 
Receptor-Bound Protein 2 N-SH3 Domain with Son of Sevenless and Dynamin. 
Potential Role in the Ras-Dependent Signaling Pathway.” The Journal of Biological 
Chemistry 273 (9): 5343–48. 
Wald, Tomas, Frantisek Spoutil, Adriana Osickova, Michaela Prochazkova, Oldrich 
Benada, Petr Kasparek, Ladislav Bumba, et al. 2017. “Intrinsically Disordered 
Proteins Drive Enamel Formation via an Evolutionarily Conserved Self-Assembly 
Motif.” Proceedings of the National Academy of Sciences of the United States of 
America 114 (9): E1641–50. 
Wang, Xiujuan, Xiaomu Wei, Bram Thijssen, Jishnu Das, Steven M. Lipkin, and Haiyuan 
Yu. 2012. “Three-Dimensional Reconstruction of Protein Networks Provides 
Insight into Human Genetic Disease.” Nature Biotechnology 30 (2): 159–64. 
Weatheritt, Robert J., and Toby J. Gibson. 2012. “Linear Motifs: Lost in (pre)translation.” 
Trends in Biochemical Sciences 37 (8): 333–41. 
Wefers, Benedikt, Sanum Bashir, Jana Rossius, Wolfgang Wurst, and Ralf Kühn. 2017. 
“Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System.” Methods  121-
122 (May): 55–67. 
Wong, Andrew D., Mao Ye, Amanda F. Levy, Jeffrey D. Rothstein, Dwight E. Bergles, and 
Peter C. Searson. 2013. “The Blood-Brain Barrier: An Engineering Perspective.” 
Frontiers in Neuroengineering 6 (August): 7. 
Woodsmith, Jonathan, and Ulrich Stelzl. 2017. “Understanding Disease Variants through 
the Lens of Protein Interactions.” Cell Systems 5 (6): 544–46. 
 111 
 
 
Wright, Peter E., and H. Jane Dyson. 2015. “Intrinsically Disordered Proteins in Cellular 
Signalling and Regulation.” Nature Reviews. Molecular Cell Biology 16 (1): 18–
29. 
Wright, Peter E., and H. Jane Dyson. 2009. “Linking Folding and Binding.” Current 
Opinion in Structural Biology 19 (1): 31–38. 
Wu, Ning, Bin Zheng, Adam Shaywitz, Yossi Dagon, Christine Tower, Gary Bellinger, Che-
Hung Shen, et al. 2013. “AMPK-Dependent Degradation of TXNIP upon Energy 
Stress Leads to Enhanced Glucose Uptake via GLUT1.” Molecular Cell 49 (6): 
1167–75. 
Xie, Q., G. E. Arnold, P. Romero, Z. Obradovic, E. Garner, and A. K. Dunker. 1998. “The 
Sequence Attribute Method for Determining Relationships Between Sequence 
and Protein Disorder.” Genome Informatics. Workshop on Genome Informatics 
9: 193–200. 
Xue, Bin, A. Keith Dunker, and Vladimir N. Uversky. 2012. “Orderly Order in Protein 
Intrinsic Disorder Distribution: Disorder in 3500 Proteomes from Viruses and the 
Three Domains of Life.” Journal of Biomolecular Structure & Dynamics 30 (2): 
137–49. 
Yamazaki, Haruka, Hiroaki Nozaki, Osamu Onodera, Takayuki Michikawa, Masatoyo 
Nishizawa, and Katsuhiko Mikoshiba. 2011. “Functional Characterization of the 
P1059L Mutation in the Inositol 1,4,5-Trisphosphate Receptor Type 1 Identified 
in a Japanese SCA15 Family.” Biochemical and Biophysical Research 
Communications 410 (4): 754–58. 
Yang, L., L. J. Embree, S. Tsai, and D. D. Hickstein. 1998. “Oncoprotein TLS Interacts 
with Serine-Arginine Proteins Involved in RNA Splicing.” The Journal of Biological 
Chemistry 273 (43): 27761–64. 
Yue, Peng, Zhaolong Li, and John Moult. 2005. “Loss of Protein Structure Stability as a 
Major Causative Factor in Monogenic Disease.” Journal of Molecular Biology 353 
(2): 459–73. 
Zakaryan, Rouzanna P., and Heinz Gehring. 2006. “Identification and Characterization 
of the Nuclear Localization/Retention Signal in the EWS Proto-Oncoprotein.” 
Journal of Molecular Biology 363 (1): 27–38. 
Zauber, Henrik, Marieluise Kirchner, and Matthias Selbach. 2018. “Picky: A Simple Online 
PRM and SRM Method Designer for Targeted Proteomics.” Nature Methods 15 
(3): 156–57. 
Zhong, Quan, Nicolas Simonis, Qian-Ru Li, Benoit Charloteaux, Fabien Heuze, Niels Klitgord, 
Stanley Tam, et al. 2009. “Edgetic Perturbation Models of Human Inherited 
Disorders.” Molecular Systems Biology 5 (November): 321. 
  
  
112 
 
 
 
 
 
 
